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Abstract 
 
The etiology of anxiety disorders remains incompletely understood.  Clear evidence for a 
genetic component has been proposed; however, there is also an increasing focus on 
environmental factors and the interaction between these and the genetic components that may 
mediate (anxiety) disorder pathogenesis.  
No single gene or genetic component has been explicitly identified as being involved in the 
development of anxiety disorders.  This is most likely due to a number of reasons, which 
include, for example, the heterogeneity of anxiety disorders, the contribution of 
environmental factors and methodological limitations (e.g. small sample size) of research 
studies.  Until now, genetic association studies usually focused on one particular psychiatric 
disorder at a time. However, with the difficulty in identifying susceptibility genes and/or loci 
in heterogeneous disorders like obsessive-compulsive disorder and other conditions in the 
anxiety spectrum, it is perhaps timely to consider multivariate genetics and epidemiological 
studies in a number of disorders sharing a core characteristic – such as anxiety. In addition to 
genetic underpinnings, a number of environmental variables have also been identified as risk 
factors for pathological anxiety, including adverse life events like childhood physical and 
sexual abuse.   
The hypothesis for this project is that a pre-existing genetic vulnerability (or genetic risk) 
interacts with the impact of adverse life events to result in the development of one or more 
anxiety disorder(s).  Considering phenotypic overlap amongst the anxiety disorders, it is 
likely that diverse networks of genes and/ or interacting pathways are responsible for the 
phenotypic manifestations observed.  Sprague Dawley rats exhibiting behaviours indicative 
of anxiety in the context of environmental stressors (maternal separation and restraint stress) 
were used as model for the identification of novel susceptibility genes for anxiety disorders in 
humans.  The striatum has previously been implicated as a candidate in the brain architecture 
of anxiety pathogenicity, and is also a site exhibiting a high degree of synaptic plasticity.  The 
synaptic plasticity pathway was investigated using the dorsal striatum of the rat brain and 
several genes were identified to be aberrantly expressed in “anxious” rats relative to controls 
(Mmp9, Bdnf, Ntf4, Egr2, Egr4, Grm2 and Arc).  
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In humans, it was found that the severity of early adversity was significantly and positively 
associated with the presence of an anxiety disorder in adulthood.  When the human 
homologues of the susceptibility candidate genes that were identified using the animal model 
were screened in a human cohort of patients with obsessive-compulsive disorder (OCD), 
panic disorder (PD) or social anxiety disorder (SAD) (relative to controls), five single 
nucleotide polymorphisms (SNPs) were found to be significantly associated with these 
conditions.  Four of these SNPs were also found to significantly interact with the severity of 
childhood trauma.  Haplotype analysis of variants within the identified susceptibility 
candidates revealed novel haplotype associations, four of which are located in the MMP9 
gene.  Notably, this the first study to link these particular mutations in the MMP9 gene with 
anxiety disorders and this finding is consistent with previous work suggesting that MMP9 is 
involved in conditions like cardiovascular disease and cancer which have been associated 
with increased prevalence of anxiety disorders.  
In conclusion, this project yielded important findings pertaining to the etiology of anxiety 
disorders.  The use of a combined anxiety disorders cohort (OCD, PD and SAD) may suggest 
that the associations found here may hold true for anxiety disorders in general and not only 
for a particular clinically delineated condition.  Childhood trauma was confirmed as an 
increased susceptibility risk for anxiety disorders. Also, this research contributed several 
novel susceptibility genes (MMP9, EGR2, EGR4, NTF4, and ARC), five significant SNP 
associations, four significant SNP-environment interactions and five haplotype associations 
(within MMP9 and BDNF) as candidates for anxiety pathogenicity.  The identified 
polymorphisms and haplotypes were demonstrated to be associated with susceptibility to 
anxiety disorders in a gene-environment correlation and gene-environment interaction.   
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Opsomming 
 
Die oorsake van angssteurings word steeds nie volledig verstaan nie. Daar is duidelike 
bewyse vir 'n genetiese komponent, maar daar is ook toenemende fokus op 
omgewingsfaktore en die interaksie tussen hierdie omgewingsfaktore en genetiese 
komponente by angssteurings. 
 
Geen enkele geen of genetiese komponent is al geïdentifiseer as diè wat betrokke is by die 
ontwikkeling van angssteurings nie. Dit is waarskynlik weens 'n aantal redes, wat 
byvoorbeeld, die heterogeneïteit van angssteurings, die bydrae van omgewingsfaktore en 
metodologiese beperkings (bv. klein steekproef) van die navorsingstudies, insluit. Verder het 
genetiese assosiasiestudies tot nou toe gewoonlik net op een spesifieke psigiatriese 
versteuring op 'n slag gefokus.  Maar, gegewe die uitdaging om vatbaarheidsgene en / of loci 
in heterogene steurings soos obsessief – kompulsiewe steuring (OKV) en ander toestande op 
die angsspektrum te identifiseer, is dit tyd om genetiese en kliniese studies in ‘n aantal 
steurings - met ‘n oorvleuende kern-element soos angs -, gesamentlik te oorweeg. Bykomend 
tot die genetiese boustene, is ‘n aantal omgewingsveranderlikes soos traumatiese 
lewenservarings tydens die kinderjare as risikofaktore vir patologiese angs geidentifiseer.  
 
Die hipotese vir hierdie projek is dat daar 'n interaksie tussen genetiese kwesbaarheid (of 
genetiese risiko) en traumatiese lewensevarings is en dat dit tot die ontwikkeling van 'n / 
veelvoudige angssteuring(s) kan lei. Inaggenome die fenotipiese oorvleueling tussen die 
angssteurings, is dit waarskynlik dat diverse netwerke van gene en / of interaktiewe geen-
paaie vir die manifestasie van hierdie toestande verantwoordelik is. Sprague Dawley-rotte 
met gedragswyses aanduidend van angs, in die konteks van omgewingstressore (d.i. skeiding 
van die ma-rot en bedwang-stres [restraint stress]), is as model gebruik vir die identifisering 
van nuwe vatbaarheidsgene vir angssteurings in mense.  Die striatum is voorheen as ‘n 
kandidaat in die brein-argitektuur van patologiese angs voorgehou, en is ook ‘n plek met ‘n 
hoë mate van sinaptiese plastisiteit.  Die sinaptiese plastisiteit is ondersoek deur te fokus op 
die dorsale striatum van die rotbrein en daar is verskeie gene gevind wat anders is in 
“angstige” rotte in vergelyking met kontroles (Mmp9, Bdnf, Ntf4, Egr2, Egr4, Grm2 en Arc).  
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In mense is daar gevind dat die ernstigheidsgraad van vroeë trauma beduidend en positief met 
die teenwoordigheid van ‘n angssteuring tydens volwassenheid verband hou.  Toe die 
menslike ekwivalente van die vatbaarheidsgene wat met die dieremodel geïdentifiseer is in ‘n 
mens-kohort met obsessief-kompulsiewe steuring (OKS), panieksteuring (PS) en sosiale 
angssteuring (SAS) ondersoek is, is gevind dat daar 5 enkele nukleotied polimorfismes 
(ENPs) is wat met die toestande verband hou.  Daar is ook gevind dat vier van hierdie ENPs 
beduidend verband hou met die ernstigheidsgraad van trauma tydens die kinderjare.  
Haplotipe analise van variante binne die geïdentifiseerde vatbaarheidsgene het op nuwe 
haplotipe assosiasies – waarvan 4 op die MMP9-geen geleë is – gedui.  Hierdie is dus die 
eerste studie wat gevind het dat dié spesifieke mutasies van die MMP9-geen met 
angssteurings verband hou.  Hierdie bevinding strook met vorige werk wat daarop dui dat die 
MMP9-geen by toestande soos kardiovaskulêre siekte en kanker wat ook met verhoogde 
voorkoms van angssteurings verband hou, betrokke is.  
 
Ter afsluiting kan ons sê dat hierdie projek belangrike bevindinge oor die oorsake van 
angssteurings gemaak het.  Die gebruik van ‘n gekombineerde angssteurings-kohort (OKS. 
PS en SAS) kan moontlik suggereer dat die assosiasies wat ons hier gevind het, waar is vir 
alle angssteurings en nie net vir ‘n spesifieke afgebakende toestand nie.  Traumatiese 
ervarings tydens die kinderjare is ook bevestig as ‘n risiko vir die ontwikkeling van 
angssteurings.  Hierdie navorsing het ook verskeie nuwe vatbaarheidsgene (MMP9, EGR2, 
EGR4, NTF4, en ARC), 5 beduidende ENP assosiasies, 4 beduidende ENP-omgewings-
interaksies en 5 haplotipe assosiasies (by MMP9 en BDNF) geïdentifiseer as moontlike 
kandidate wat ‘n rol speel by die ontstaan van patologiese angs.  Daar is ook gevind dat die 
geïdentifiseerde polimorfismes en haplotipes met vatbaarheid vir angssteurings in ‘n geen-
omgewing- korrelasie en geen-omgewing- interaksie verband hou.    
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“Worrying is carrying tomorrow's load with today's strength- carrying two days at once. It is 
moving into tomorrow ahead of time. Worrying doesn't empty tomorrow of its sorrow, it 
empties today of its strength.” 
Corrie ten Boom
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Overview 
 
Anxiety disorders are now recognized as being of the world’s most debilitating conditions, 
associated with substantial morbidity and impaired quality of life.  Twenty years ago it was 
estimated that around 2 – 3 % of the world’s population may be affected by one or more of 
these conditions (Weissman et al., 1994).  More recent statistics put the life-time prevalence 
for any anxiety disorder at 18.1% (United States) for adults and even higher at 25.1% for 
adolescents (13 – 18 years) (United States) (Kessler, 2005).  Two years later a meta-analysis 
suggested an increased prevalence of 31% in the United States (Kessler et al., 2007).  In 
South Africa the estimated prevalence for any anxiety disorder is 15.8% with a life-time 
prevalence of 30.1%, which are of the highest globally (Kessler et al., 2007). Understanding 
the pathophysiology of these conditions is therefore paramount.  Major advances have 
recently been made in terms of the molecular etiology of these disorders, largely within the 
serotonin, corticotrophin and dopamine pathways.  These strides emphasize the complex 
nature of these conditions.  Although there is a clear genetic component, no single gene or 
genetic abnormality has been exclusively identified as being involved in the development 
and/ or progression of anxiety disorders (Hettema et al., 2005).  Literature has also routed a 
large seating in the contribution of environmental stress and the interaction that genes and the 
environment (specifically trauma in anxiety disorders) may play in disorder pathogenesis 
(Hettema et al., 2005; Van Grootheest et al., 2007; Hovens et al., 2012; Norman et al., 2013). 
 
This dissertation focused on identifying novel susceptibility genes in anxiety disorders, 
arguing that the use of an animal model of behaviours suggestive of anxiety could point to 
susceptibility candidates for anxiety disorders in humans.  The overall objective of this study 
was to determine whether rats subjected to early-developmental stress and exhibiting anxiety-
like behaviours would show differential gene expressions in a particular pathway, and then if 
these differentially expressed genes would hold true as candidates in humans using a case-
control association study.  This investigation may support use of an animal model of anxiety-
like behaviours after early-developmental stress as an effective model for the identification of 
novel candidate genes in humans with anxiety disorders and with a history of severe 
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childhood trauma.  Literature has previously implicated synaptic plasticity and the ability of 
the body to modify neuronal circuitry in response to an event, in the pathogenesis of anxiety 
(Citri and Malenka, 2008; McEwen et al., 2012).  This was therefore the focal pathway 
chosen for this dissertation, and since the striatum (comprising the caudate nucleus, putamen 
and nucleus accumbens) is a major site of synaptic plasticity in the basal ganglia (Bolam et 
al., 2000; Gerfen, 2000; Gerdeman et al., 2003; Sturm et al., 2003; Haji et al., 2012), this was 
chosen as the focal brain region.   
 
Chapter 2 focuses on the methodology employed to assess the aforementioned objectives of 
this study and the results are presented in Chapter 3. The findings and the conclusions in 
addition to study limitations can be found in Chapter 4. 
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1. Literature Review 
 
The central aim of Chapter 1 is to review the existing literature on the molecular standing of 
anxiety disorders, as well as environmental contributions in the form of trauma, providing an 
introduction to and motivation for subsequent chapters.  Each anxiety disorder focused on in 
this dissertation will be briefly discussed in terms of neurobiology and pathogenicity and then 
the contribution of trauma to the pathogenesis of these disorders will be jointly evaluated.  
The use of animal models in elucidating the etiology of anxiety disorders in humans will also 
be addressed. 
 
1.1. An introduction to anxiety disorders 
 
Conditions characterized by pathological anxiety were initially classified under a broad term 
namely, anxiety neurosis (First et al., 1998), and were only separated into a number of 
conditions categorized as anxiety disorders much later on.  This division was beneficial as it 
allowed for a more specific diagnosis, and ultimately more specific treatment.  This disorder 
sub-categorization facilitated more homogenous research cohorts which are necessary for 
predicting clinical features associated with psychobiological mediating factors (Stein, 2004).  
A strong seating in literature supports the notion of genetic contributions to susceptibility for 
anxiety disorders (van Grootheest et al., 2005; Nugent et al., 2011; Papaleo et al., 2011; 
Schumacher et al., 2011; Sokolowska, 2013).  In trying to identify possible common genetic 
traits associated with pathological anxiety, the grouping of patients with different anxiety 
disorders into a single cohort for comparison on a genetic level might provide better insight 
into common underlying causes of these conditions.  
Large scale studies performed in the 1990s and early 2000s have shown that anxiety disorders 
are more common than originally thought and are debilitating and costly in both the 
developed and developing world (reviewed in Stein, 2004).  Estimates by Kessler et al., in 
2007 showed substantial increases in country specific prevalence compared to earlier work 
(Kessler, 2005; Kessler et al., 2007)   Even with high prevalence, however, many cases still 
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go under-diagnosed or are mistreated, further contributing to suffering and the cost associated 
with the disorders.  Studies have also shown that anxiety disorders precede the development 
of a variety of other disorders (e.g. depression and mood syndromes (Goes, 2012; Penninx 
and Comijs, 2012) and have a chronic course (Stein, 2004; Yonkers et al., 2000).   
The etiology of anxiety disorders remains incompletely understood.  A number of 
neurochemical systems and neurocircuitry have been implicated to date (reviewed by Stein, 
2004 and Sokolowska, 2013).  Initial work involved focus on the noradrenergic system, but 
with the advent of serotonin reuptake inhibitor efficacy in the treatment of anxiety disorders, 
focus was shifted to serotonin receptors and sub-receptors (Stein, 2004).  Further 
consideration focusing on benzodiazepines highlighted the role of glutamate and GABA 
neurosystems  in the development and progression of anxiety disorders (Kendell et al., 2005; 
Möhler, 2012).  Molecular (such as that pertaining to serotonergic and dopaminergic systems) 
research provides promise regarding the elucidation of the roles these and other systems may 
play in the etiology of anxiety disorders.  Molecular focus, however, should by no means 
negate any environment aspects that may be involved in disorder pathogenesis (Sánchez et 
al., 2001); for example, childhood trauma has been associated with the development of 
anxiety disorders in later life (Stein et al., 2008; Simon et al., 2009; Nugent et al., 2011).   
 
1.2. Anxiety Disorders 
 
The following is a brief discussion on the current literature pertaining to the neurobiology and 
pathogenicity of three anxiety disorders (Obsessive-Compulsive Disorder (OCD), Panic 
Disorder (PD) and Social Anxiety Disorder (SAD) – according to DSM-IV diagnostic 
criteria).  A dataset with data from patients with a primary disorder of OCD, PD or SAD were 
available to us and these disorders were thus used as focal disorders in this study. 
The DSM-IV categorizes several disorders together under the anxiety spectrum, namely 
generalized anxiety disorder (GAD), SAD, specific phobia (SP), post-traumatic stress 
disorder (PTSD) and OCD.  Table 1.1 below gives a brief summary and characterization of 
each of the disorders mentioned and the three that will serve as focal point for this 
dissertation. The nature of each of these disorders and that which makes them distinct, 
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however, allows for significant comorbidity amongst the anxiety disorders as well as 
comorbidity for other mental illnesses such as depression and substance abuse (Egan et al., 
2010).  Anxiety and fear can be considered natural responses to possibly threatening 
situations.  In anxiety disorders, however, these responses are either exaggerated or 
prolonged and in being so inhibit or disturb the daily life of an affected individual.  Current 
treatment strategies involve behavioural (e.g. cognitive behavioural therapy) and/ or 
pharmacotherapy (e.g. benzodiazepines or serotonin reuptake inhibitors) options, but these 
present with addictive, tolerance build-up or inadequate efficacy in some individuals 
(Sokolowska, 2013).  That said it is important to investigate and understand the molecular 
mechanisms underlying anxiety disorders, in order to contribute to the development of wider 
acting and more effective anxiolytics.  Genetic studies offer an ideal target for considering 
molecular background as the identification of gene candidates can point directly to protein 
function and pathway. 
 
Table 1.1: DSM-IV classifications of disorders under the anxiety spectrum  
Disorder Characterization Treatment 
OCD Recurrent, intrusive obsessions and 
distressing thoughts, images or feelings 
CBT, SSRIs 
PD Unexpected panic attacks of brief, sudden, 
intense periods of anxiety 
CBT, SSRIs, TCAs, 
MAOIs, Benzodiazepines 
SAD Excessive fear of negative evaluation by 
others 
 
CBT, SSRIs, MAOIs, 
benzodiazepines 
PTSD Subsequent to experiencing a traumatic 
event: afflicted individuals re-experience the 
trauma, avoidance behaviour, numbing of 
emotions 
CBT, SSRIs, MAOIs, TCAs 
GAD Excessive and uncontrollable worries about 
life events 
Benzodiazepines, 
antidepressants  
*OCD: obsessive-compulsive disorder; PD: panic disorder; SAD: social anxiety disorder; 
PTSD: post-traumatic stress disorder; GAD: generalized anxiety disorder; CBT: cognitive 
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behavioural therapy; SSRIs: selective serotonin reuptake inhibitors; MAOIs: monoamine 
oxidase inhibitors; TCAs: tricyclics 
 
Anxiety disorders are complex and caused by a combination of both environment and genetic 
factors.  Recent Genome Wide Association Studies (GWAS)  into anxiety-related personality 
trait neuroticism and panic disorder have identified a large number of small effect-size 
common and rare variation in anxiety predisposition (Shifman et al., 2007; Otowa et al., 
2009; Calboli et al., 2010; Terracciano et al., 2010).  This infers that sample sizes of several 
thousand would be required to identify variation predisposing to anxiety disorder.  
Considering the practicality and feasibility of this, the consideration of gene-environment 
interaction and strict population stratification may be prudent in studies in which these 
sample numbers are not possible to reach (Sokolowska, 2013).   
 
The neurobiology of anxiety disorders 
The genetic basis for anxiety disorders has been explored within the literature and there are 
many proposals with regards to neuropathophysiology.  Proposals for fear arousal and 
anxiety being organized in the locus coeruleus have been proposed.  Neurons in this area may 
project to the paraventricular nucleus in the hypothalamus allowing for the activation of the 
HPA axis, triggering an anxiety response (Steimer, 2002; Egan et al., 2010).  The locus 
coeruleus may also project into the amygdala, striatum, prefrontal cortex, bed nucleus of stria 
terminalis, hippocampus, periaqueductal gray, hypothalamus, and nucleus solitaries based on 
assumptions regarding differences found within the serotonergic, GABAergic, neurosteriod 
and HPA hormone axis systems (reviewed by Steimer, 2002; Meaney, 2010; Egan et al., 
2010; Maschi et al., 2013). 
With regards to the anxiety disorders included in this project: OCD is characterized by 
recurrent obsessions and compulsions in both an individual’s personal and psychological life.  
They can result in severe distress and increasing risk for comorbidity, such as major 
depression (Stein, 2004; Hemmings et al., 2008; Egan et al., 2010).  Obsessions may manifest 
as repetitive thoughts, ideas, and images which result in anxiety.  Compulsions or urges 
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follow and are repetitive mental or motor activities that occur in order to neutralize anxiety 
(Stein, 2004; Abramowitz, 2012).  Literature supports a familial link to OCD progression 
and/ or development; for example studies by Pauls et al., 1995, 1986 showed that first-degree 
relatives of probands with OCD had higher risk for clinical and subclinical OCD 
manifestation.  Medical conditions such as Sydenham’s chorea and the obsessive-compulsive 
symptoms observed have implicated the basal ganglia in OCD neuroanatomy.  Cortical-
striatal-thalamic-cortical pathway (Figure 1.1) has been implicated based on imaging studies 
investigating the clinical manifestations of OCD (Milad and Rauch, 2012).  The orbitofrontal 
cortex, anterior cingulate cortex and the caudate nucleus have demonstrated hyperactivity in 
resting-state and this has been shown to be attenuated with exposure/ response prevention and 
serotonergic treatment therapies (Baxter et al., 1996).  The aforementioned, amongst others, 
have led to a popularity for cortico-striatal models of the pathophysiology of OCD (Stein et 
al., 2010; Milad and Rauch, 2012). 
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PD is characterized by the tendency of a patient to misinterpret their own bodily sensations as 
signs of imminent physical or mental harm.  In PD, individuals experience recurrent and 
unexpected panic attacks (Association, 2000; Stein, 2004; Egan et al., 2010).  PD, as with 
OCD, can be quite debilitating and has major impact on the sufferer’s quality of life.  It has 
been shown to be associated with a decrease in physical and mental functioning and can be 
compounded with co-morbid chronic medical conditions and depression (Stein, 2004).  The 
Figure 1.1: Schematic representation of the different components of the cortico -
striato-thalamic-cortical pathways implicated in OCD psycopathology and the 
cortico-strial loops involved (Milad and Rauch, 2012).  ACC: anterior cingulate 
cortex, vmPFC: ventromedial prefrontal cortex, diPFC: dorsolateral prefrontal 
cortex, NAC: nucleus accumbens, OFC: orbitofrontal cortex  
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disorder is often under-diagnosed (Sartorius et al., 1993; Steimer, 2002; Schumacher et al., 
2011) and this may be attributed to its typical presentation as predominantly somatic 
symptoms such as chest pain or dizziness as oppose to psychologically based observations.  
Literature revolving specifically around PD, as with the other anxiety disorders, has 
implicated a number of systems to be involved in the pathogenesis of PD; namely, the brain 
monoaminergic systems (noradrenergic and serotonin systems), the GABA (γ-aminobutyric 
acid) system and respiratory and cardiovascular functions (Gorman, 2000; Stein, 2004; 
Schumacher et al., 2011). Neuroanatomical investigations into the pathogenesis of panic 
disorder have implicated several brain areas, similar to the aforementioned OCD 
neurobiology.  The locus coeruleus, principal nucleus of noradrenergic systems within the 
brain, has also been implicated in the development of fear and anxiety in PD affliction 
(Redmond et al., 1976; Stein, 2004; Reif et al., 2013).  Other repeat structures (structures also 
included in other anxiety disorders) of the central nervous system (CNS) that have been 
implicated include the striatum, thalamus, hypothalamus, hippocampus, anterior cingulated 
gyrus, peri-aqueductal gray area and the frontal cortex (Gorman, 2000; Stein, 2004).   
SAD can be defined as a marked and persistent fear of one or more social or performance 
situations in which a person is exposed to unfamiliar people or to scrutiny by others 
(Association, 2000; Egan et al., 2010).  The individual in question fears a behavioural 
manifestation that will result in humiliation or embarrassment and experiences anxiety as a 
result.  This anxiety may manifest in the form of a panic attack.  Despite this, the affected 
individual understands that this behaviour is excessive or unreasonable and therefore avoids 
these kinds of situations.  The fear experienced in social situations can result in severe 
anxiety or marked distress and functional impairment (Stein, 2004).  As with the other 
anxiety disorders, most SAD sufferers have one or more comorbidities such as depression, 
PD, agoraphobia, generalized anxiety disorder or substance abuse disorders (Schneier et al., 
1992; Stein, 2004; Egan et al., 2010; Shirayama et al., 2013).  Similar to some of the other 
anxiety disorders (e.g. OCD above), the first-degree relatives of patients with SAD have 
shown increased rates of SAD (Fyer AJ, 1993; Goes, 2012), suggesting a significant genetic 
(and environmental) contribution.  Initial theories regarding the pathogenesis of SAD 
involved the presence of an overactive autonomic nervous system considering autonomic 
arousal when in social settings (Levin et al., 1993).  However, when blood pressure and heart 
rate were monitored in SAD patients relative to controls no significant differences were 
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found, suggesting that SAD in this instance was limited to performance anxiety associated 
with increase autonomic reactivity.  Literature then continues to implicate, as with OCD and 
PD, similar neurobiological systems such as dopaminergic transmission where patients with 
SAD showed a preferential response to monoamine oxidase inhibitors (MAOIs), and also 
decreased striatal dopamine D2 receptor and dopamine transporter binding (Sidhu, Laruelle, 
& Vernier, 2003; D. J. Stein, 2004).  Several other systems have also been implicated in SAD 
pathogenicity including serotonin and growth hormone abnormalities, as well as amygdala 
function in fear conditioning (Stein, 2004; Morreale et al., 2009), as with OCD and PD and 
anxiety disorders pathogenesis in general. 
 
The striatum, plasticity and anxiety disorders 
Considering the literature on the striatal involvement in anxiety disorders, the striatum has 
been used as a target source for real-time investigation into aberrant gene expression.  The 
striatum is a prime area of high synaptic plasticity (Shin and Liberzon, 2009; Schilman et al., 
2010; Guyer et al., 2012).  Plasticity refers to the ability of the neural activity generated by an 
experience to modify neural circuit function which could ultimately modify thoughts, feelings 
and behaviour (Citri and Malenka, 2008).  Synaptic plasticity refers to the ability of the brain 
to create persistent memory traces by the activity-dependent modification of the efficacy of a 
synaptic transmission at pre-existing synapses.  Synaptic plasticity is believed to play a key 
role during early neural circuitry development and that major events (e.g. trauma) altering the 
regular plasticity mechanisms may contribute to neuropsychiatric disorders (Citri and 
Malenka, 2008).  Identifying the mechanisms and genes responsible for changes at neuronal 
synapses could prove crucial to the understanding and/ or progression of anxiety disorders, 
and possibly other neurological disorders involving synaptic circuitry considering the cortico-
striato-thalamic-cortical pathway seating for anxiety psychopathology (Milad and Rauch, 
2012). 
The striatum comprises dorsal (caudate nucleus and putamen) and ventral (nucleus 
accumbens and ventral portions of caudate and putamen) brain structures and is the primary 
input nucleus receiving excitatory impulses from the cortex and thalamus (Figure 1.1).  It also 
receives innervations from midbrain dopamine neurons, and represents a major site of 
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synaptic plasticity in the basal ganglia (Bolam et al., 2000; Gerfen, 2000; Gerdeman et al., 
2003; Milad and Rauch, 2012).  The striatum is involved in basal ganglia circuitry by two 
parallel cortex-basal ganglia-thalamus-cortex loops diverging within the striatum, 
differentially modulated by dopamine.  Considering these pathways, the high level of 
synaptic plasticity occurring in the striatum as well as the association of the striatum in the 
pathophysiology of OCD, SAD and PD mentioned above (Shin and Liberzon, 2009; Guyer et 
al., 2012; Milad and Rauch, 2012) the striatal brain region is a prime candidate for 
investigating the effects of gene-environment interactions in the development and/ or 
progression of anxiety disorders. 
 
Pharmacotherapy and psychotherapy 
A number of pharmacotherapies are available for the treatment of SAD which include, but 
are not limited to, SSRIs, benzodiazepines, MAOIs, β-adrenergic blockers and buspirone 
(Bouwer and Stein, 1998; Stein MB, 1998; Roy-Byrne et al., 2010).  Current drug therapies, 
however, only work on a subset of those affected and it is estimated that approximately half 
of those affected by one or more anxiety disorders respond effectively to drug therapies.  The 
goal in treatment is to reduce or completely eliminate avoidance, anticipatory anxiety, panic 
attacks etc. (depending on the anxiety disorder(s) in question) and to treat any co-morbidity 
which may be present.  Psychotherapy schedules include exposure, cognitive restructuring, 
relaxation timing and social skills training; which are all facets of cognitive behavioural 
therapy (CBT).  CBT is the most extensively researched and empirically supported of the 
psychotherapies utilized in the treatment of anxiety disorders (Stein, 2004; Olatunji et al., 
2010).  Clinical studies have shown efficacy for both cognitive-behavioural as well as 
pharmacological therapies; especially when implemented together (Heimberg, 2001; Olatunji 
et al., 2010).  
Anxiety disorders are challenging conditions, not only for patients and their families, but also 
for clinicians.  As mentioned above, there is clear overlap in the neurobiological pathways for 
independent disorder diagnoses as well as response to pharmacotherapeutic agents.  Their 
possible early onset and chronic course make it all the more important to find more effective 
treatments and treatment strategies that benefit the patient and his/her significant others.  
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More recent treatments, such as serotonergic agents, have significantly contributed to the 
alleviation, if only partially, of symptoms improving a patient’s quality of life.  There is still, 
however, much research that needs to be done regarding further elucidation into the 
pathophysiology of anxiety disorders.  The identification of novel pathways, genes or gene-
environment interactions underpinning the development and/ or progression of the anxiety 
disorders are crucial to a better understanding of these disorders, and may ultimately lead to 
better treatment strategies and outcomes. 
 
1.3. Etiology of Anxiety disorders: a gene-environment interaction 
 
Trauma as a risk factor for developing an anxiety disorder has been well depicted within the 
literature.  An example of environmental influence is the development of OCD after sexual 
assault, personal violence or road accident incidents (de Silva and Marks, 1999; Pitman, 
1993; Sasson et al., 2005).  These clinical and neurobiological observations are further 
backed by community studies indicating that exposure to a situation in which a person fears a 
serious injury or death is associated with increased susceptibility to PTSD, agoraphobia, SAD 
and OCD (Boudreaux et al., 1998; Jordan et al., 1991; Maes et al., 2000).   
Early life stress (such as childhood trauma) is an established predictor of adverse outcome 
across the lifespan and can encompass psychiatric, behavioural and neurocognitive spheres 
(Gunnar and Quevedo, 2007; Danese et al., 2009; Irish et al., 2010; Nugent et al., 2011).  
Literature has also specified an elevated risk for internalizing disorders (such as anxiety) in 
individuals who have suffered early life stress (Meaney, 2010; Nugent et al., 2011; Maschi et 
al., 2013).  Although early life stress and childhood trauma are well established risk factors 
for several psychiatric disorders (e.g. the anxiety disorders), they do not always result in 
dysfunction or impairment or the development of a psychiatric condition.  This divergent 
outcome can be best explained by an interaction between the environment (the early life 
stress or childhood trauma) and genetic predisposition (Caspi et al., 2002; Lochner et al., 
2002; Caspi and Moffitt, 2006; Nugent et al., 2011; Maschi et al., 2013).  Gene-environment 
interaction can therefore be defined as the ability of genetic variables to interact with the 
environment (early-life trauma) and result in an anxiety disorder(s) psychopathology.   
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Figure 1.2 graphically depicts the gene-environment interaction. Under low environmental 
stress, functioning is considered normal; however, normal function can be impaired under 
conditions of high environmental stress (curved line).  A high level of environmental stress 
alone (e.g. trauma) could impair functioning (solid line), however, the gene-environment 
interaction implies a genetically determined increase in susceptibility to the environmental 
influence and therefore a non-linear decline in normal functioning is expected (Nugent et al., 
2011).  Genetically determined resilience (grey dashed line) or impairment (black dashed 
line) can be associated with normal functioning or impairment, respectively, independent of 
environmental contributions (Figure 1.2) and these also need to be considered within the 
gene-environment interplay. 
A number of case studies have demonstrated how trauma may contribute to the development 
of anxiety disorders.  Gene-environment interaction in early life stress has been characterized 
extensively for a number of promising target candidate genes and/ or pathways that are 
involved in the development and/ or progression of anxiety including the serotonin system, 
the HPA axis, neurotrophins, dopaminergic and GABA genes (Nugent et al., 2011).  A 
summary of these studies focusing on those that include anxiety disorders can be found in 
Table 1.2.    
Figure 1.2: A depiction of gene-environment 
interaction (Nugent et al., 2011) *level of functioning 
may refer to gene, social, cognitive etc.  
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Childhood trauma can have persistent or intermittent mental effects including, but not limited 
to, psychiatric disorders (such as anxiety and depression), cognitive impairment, and 
maladaptive stress responses (Stesssman et al., 2008; Gagnon and Hersen, 2000; Maschi et 
al., 2013).  Other stressful life events may occur later on at different points during the life 
course and this could exacerbate existing subjective symptoms (Maschi, 2006).  Research 
regarding the temporal effects of childhood trauma, especially concerning later life 
functioning, point to increased occurrence of minor psychological distress which often leads 
to more severe mental health problems like anxiety disorders and depression (Neal et al., 
1995; Shmotkin and Litwin, 2009; Hovens et al., 2012; Maschi et al., 2013).   
Studies exist which focus on epidemiological data regarding childhood trauma/ maltreatment 
and have shown increased risk for SAD in such cases (Nelson et al., 2002; Kuo et al., 2011).  
Further evidence regarding the association of childhood trauma with SAD looked at the 
generalized subtype (GSAD) for the prevalence of childhood trauma in a clinical population 
who are at sufficient severity to seek treatment (Simon et al., 2009).  Trauma can be 
expanded beyond that of physical and sexual criteria and include emotional abuse and neglect 
as well (Mancini et al., 1995; Hovens et al., 2012; Maschi et al., 2013).  When including 
emotional abuse and neglect as well as physical and sexual abuse, significant findings were 
identified for childhood trauma history in a GSAD cohort with a greater SAD symptom 
severity and poorer associated function (Simon et al., 2009).  Simon and associates (2009) 
found that emotional neglect and abuse amongst their GSAD cohort was associated with an 
observed symptom severity and that multiple types of childhood maltreatment in a single 
individual had an additive effect.  This is an important finding considering evidence for 
childhood maltreatment contributing to increased risk of anxiety, especially when coupled to 
genetic risk factors (Stein et al., 2008).  Stein and associates (2008) demonstrated a classic 
example of genetic risk factors (specifically the serotonin transporter gene polymorphism) for 
anxiety in conjunction with childhood maltreatment where it can amplify anxiety phenomena 
such as anxiety sensitivity. The serotonergic involvement in anxiety disorder pathogenesis 
and exacerbation in the presence of childhood trauma was addressed in a review by Meaney 
(2010).   
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Table 1.2: Studies highlighting candidate genes and GxE interaction in early life stress (adapted from Nugent et al., 2011) 
Author 
Sample 
Gender(M, F); 
Ethnicity 
Age of ELS 
Age at 
outcome M 
(SD) or range 
Type of ELS 
ELS 
assessment 
Outcome 
 
Outcome 
Assessment 
Major 
Findings 
5-HTTLPR: studies supporting increased risk associated with s/s’ 
Cicchetti et 
al., 2007 
184, 155 
 
 
 
 
 
 
 
 
209 AA, 79 
EA, 43 H, 
8 other 
Childhood and 
adolescence 
17 (1) Neglect, physical or 
sexual abuse, emotional 
abuse 
DHS records Depressive 
symptoms: 
anxious, 
depressed and 
somatic 
symptoms 
Clinical 
interview, self-
report 
Significant of 
sexual abuse x 
5-HTTLPR: 
sexually abused 
s/s genotype 
predicted 
increased 
depression/ 
anxiety 
Significant 
sexual abuse x 
5-HTTLPR x 
MAOA: 
sexually abused 
low MAOA 
activity, s 
carriers at 
greatest 
depression 
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Nobile et al., 
2009 
315, 292 
 
 
 
E 592 
 
Childhood and 
adolescence 
12 (1) “Family structure” (i.e., 
single vs. two-parent 
families) 
Parent report Affective 
problems 
Parent-report 
questionnaire 
rGE trend: 
excess s/s in 
single parent 
families 
Significant 
ELS x 5-
HTTLPR: 
single-parent s’ 
carriers greatest 
affective 
problems 
Stein et al., 
2008 
76, 171 Childhood and 
adolescence 
19 (2) Emotional or physical 
abuse 
Retrospective 
self-report 
questionnaire 
Anxiety 
sensitivity 
Self-report 
questionnaire 
Significant 
ELS x 5-
HTTLPR: 
greatest anxiety 
sensitivity 
(especially 
physical 
sensitivity) in 
s/s or s’/s’ with 
emotional or 
physical abuse 
history 
Xie et al., 656, 596 Before age 13 40 (10) Violent crime, sexual Retrospective PTSD Semi-structured Significant 
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2009 582 EA, 670 
AA 
abuse, physical abuse, 
neglect 
semi-structured 
interview 
diagnosis interview ELS x 5-
HTTLPR: s’ 
carriers more 
likely to 
develop PTSD 
Studies supporting increased risk associated with l/l’ alleles 
Laucht et al., 
2009 
142, 167 
309 E 
Childhood 19 Family adversity (low 
parent education, 
unwanted pregnancy, 
overcrowding, etc.) 
Parent 
interview at 3 
months post-
partum 
Depressive 
symptoms & 
diagnosis: 
anxiety 
diagnosis 
Clinical 
interview; self-
report 
questionnaire 
Significant 
ELS x 5-
HTTLPR: 
increased 
anxiety or 
depression 
diagnosis in 
youth with ELS 
and l’/l’ (or l/l) 
genotype 
Studies reporting no G x E effects 
Araya et al., 
2009 
2,306,2,028 
4,170 E 
5 - 7 7 Maternal postnatal 
depression; 17 adverse 
life events 
Maternal report Emotionality 
symptoms 
Parent-report 
questionnaire 
No significant 
ELS x 5-
HTTLPR 
predicting 
emotional 
symptoms 
Additional serotonin system candidate genes investigations of early life stress (ELS) 
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Nobile et al., 
2009 
315, 292 
E 592 
Childhood and 
adolescence 
12 (1) “Family structure” (i.e. 
single- vs. two-parent 
families) 
Parent report Affective 
problems 
Parent-report 
questionnaire 
Significant 
ELS x TPH2 
G-703T: 
single-parent G 
carriers greatest 
affective 
problems 
Cicchetti et 
al., 2007 
184, 155 
 
 
 
 
 
 
 
 
 
209 AA, 79 
EA, 
43 H, 8 other 
Childhood and 
adolescence 
17 (1) Neglect, physical or 
sexual abuse, emotional 
abuse 
DHS records Depressive 
symptoms; 
anxious/ 
depressed 
symptoms 
Clinical 
interview, self-
report 
Significant 
MAOA x 
number of 
maltreatment 
subtypes: low 
activity variant 
at greatest risk 
for depression 
in 3 – 4 
subtypes 
Significant 
sexual abuse x 
5-HTTLPR x 
MAOA: 
sexually abused 
low MAOA 
activity, s 
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carriers at 
greatest 
depression 
Chipman et 
al., 2010 
3,177, 3,294 
6,471 AC 
Childhood and 
adolescence 
20 – 24; 40 – 
44; 60 - 64 
17 adversities ranging 
from maternal mental 
health concerns to abuse 
Self-report 
questionnaire 
Depression and 
anxiety 
symptoms 
Self-report 
questionnaire 
No significant 
interaction or 
main effects 
HPA axis candidate gene investigations of early life stress (ELS) 
Heim et al., 
2009 
424, 639 
 
 
 
 
 
 
 
 
 
 
 
1,063 AA 
 
 
 
 
Childhood 18 – 77 
 
 
 
 
 
 
 
 
 
 
 
18 - 45 
Physical, sexual, 
emotional abuse 
Retrospective 
self-report 
questionnaire 
Depressive and 
PTSD 
symptoms; 
cortisol 
response 
Self-report 
questionnaire 
Significant 
ELS x CRHR1 
on depressive 
symptoms in 
men: male 
abused 
rs110402 G 
carriers 
reported 
increased 
depressive 
symptoms 
Significant 
physical abuse 
x CRHR1 on 
depressive 
symptoms: G/G 
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25, 53 
NR 
genotype 
associated with 
depressive 
symptoms 
Significant 
ELS x CRHR1 
in men: male 
abused 
rs110402 G 
evidenced 
increased 
cortisol 
response 
Tyrka et al., 
2009 
51, 78 
129 EA 
Childhood  18 - 61 Emotional/ physical/ 
sexual abuse; physical/ 
emotional neglect 
Retrospective 
self-report 
questionnaire 
Cortisol 
response 
Dexamethasone/ 
corticotrophin-
releasing 
(DEX/CRH) 
hormone test 
Significant 
ELS x CRHR1: 
rs110402 & 
rs242924 G/G 
genotypes 
associated with 
increased 
cortisol 
response only if 
reporting 
moderate to 
Stellenbosch University  http://scholar.sun.ac.za
Stellenbosch University  http://scholar.sun.ac.za
Chapter 1: Literature Review 
23 
 
severe 
childhood 
maltreatment 
Binder et al., 
2008 
384, 516 
855 AA, 20 
EA, 1 AsianA, 
8 BiR, 9 other, 
2 NR 
Childhood 
 
41 (14) Physical/ sexual/ 
emotional abuse 
Retrospective 
self-report 
PTSD 
symptoms 
Self-report 
questionnaire 
Significant 
ELS severity x 
FKBP5 SNPs 
predicting 
PTSD 
Xie et al., 
2009 
1,320, 1,107 
1,284 AA, 
1,143 EA 
Prior to 13 39 (11) Violent crime, sexual 
abuse, physical abuse 
Retrospective 
self-report 
PTSD 
diagnosis 
Clinical 
interview 
Significant 
ELS x FKBP5 
in AA 
Neurotrophic and other candidate gene investigations of early life stress (ELS) 
Gatt el al., 
2009 
184, 190 
 
 
 
 
 
 
 
374 EA 
Childhood and 
adolescent 
36 (13) Abuse, neglect, family 
conflict, illness/ death, 
natural disasters 
Retrospective 
self-report 
questionnaire 
Severity of 
depressive and 
anxiety 
symptoms 
 
 
 
 
Heart rate 
Brain gray 
matter 
Self-report 
questionnaire 
Significant 
ELS x BNDF: 
ELS exposed 
Met carriers 
had smaller 
hippocampal 
and amygdala 
volume 
Structural 
Modeling: ELS 
exposure and 
Met carrier 
Stellenbosch University  http://scholar.sun.ac.za
Stellenbosch University  http://scholar.sun.ac.za
Chapter 1: Literature Review 
24 
 
predict smaller 
gray matter in 
hippocampus 
and lateral 
prefrontal 
cortex which in 
turn predicts 
depressive 
symptoms 
Haeffel et al., 
2010 
251, 222 3 years of age 
or younger 
3 Parenting practices and 
interaction styles 
Ratings of 
parent 
supportiveness/ 
intrusiveness 
during 
standardized 
interaction task 
Diagnoses of 
depression, 
anxiety, ODD; 
symptoms of 
internalizing, 
externalizing, 
anxious/ 
depressed 
Diagnostic 
interview 
completed with 
parents; parent 
report 
questionnaire 
Significant rGE 
between child 
DRD2 and 
parent 
behaviour 
during task 
Marginally 
significant 
intrusiveness x 
DRD2 Taq1A: 
A2 
homozygotes 
showed 
positive 
association 
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between parent 
intrusiveness 
and symptoms 
while A1 
carriers showed 
a negative 
association 
Evans et al., 
2009 
3,016, 
5,838 
5 - 7 7 Maternal postnatal 
depression, 17 adverse 
life events 
Maternal report Emotionality 
symptoms 
Parent report No significant 
ELS x COMT 
Nelson et al., 
2009 
259 
NR 
Childhood “Adult” Sexual abuse, physical 
abuse, emotional/physical 
partner maltreatment 
Retrospective 
self-report 
PTSD Interview Significant 
ELS x 
GABRAA2 
predicting 
PTSD 
*M: Male; F: Female; AA: African American; AsianA: Asian American; AC: Australian White/ Caucasian; BiR: Biracial; EA: European 
American/White/Caucasian; E: European; H: Hispanic; NZC: New Zealand White Caucasian; NR: not reported; rGE: gene-environment 
correlation
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Although childhood trauma from an emotional abuse and neglect aspect has not been well 
characterized to date, sexual and physical abuse can be found more readily amongst literature 
(Bryer et al., 1987; Mancini et al., 1995; Mulder et al., 1998; Nelson et al., 2002; Hovens et 
al., 2012; Maschi et al., 2013).  Nelson and associates (2002) demonstrated an increased risk 
for many a disorder, including SAD and depression, using twin studies (childhood sexual 
abuse versus those without).  Increased risk for SAD amongst sexual abuse cases, although 
specifically in women, was also reported in an Australian study (Dinwiddie et al., 2000).  
Simon and associates (2009) reported an incidence of 17% of childhood sexual abuse in their 
clinical GSAD sample cohort and found it was associated with a higher risk for disability 
when data was adjusted for age and gender.  Simon and co-workers (2009) found a similar 
trend for increased risk in women over men in their GSAD childhood sexual abuse cases.  
Overall, data obtained using the Liebowitz Social Anxiety Scale (LSAS) and Childhood 
Trauma Questionnaire (CTQ) suggested increased illness severity in both men and women 
with childhood maltreatment (Simon et al., 2009) and this theory seems to hold true for other 
anxiety conditions (OCD and PD) and childhood adversities (Kessler et al., 1997).   
Using the revised CTQ (Bernstein et al., 1994, 1997) OCD patients were found to have 
significantly higher incidence of childhood maltreatment compared to controls (Lochner et 
al., 2002).  The OCD patients were found to score highly concerning emotional neglect 
implicating a possible common childhood trauma marker amongst the two disorders 
(trichotillomania and OCD).  Although the use of an all-female cohort as well as the need to 
consider other environmental factors (such as socio-economic status, comorbidity and age) 
can be considered limitations, Lochner and colleagues (2002) have confirmed an association 
between childhood trauma and OCD.  A higher prevalence of childhood trauma in patients 
with PD compared to healthy controls has also been reported (Stein, 2004; Lochner et al., 
2010).  Previous studies have specifically associated emotional abuse during childhood with 
increased risk for PD later in life (David et al., 1995; Young et al., 1997). 
In summary, there is a strong association between early trauma and anxiety disorders.  This 
literature has specifically highlighted early developmental stress and trauma in the 
development of OCD, SAD and PD.  Furthermore, the literature indicates links between the 
molecular underpinnings and gene-environment interaction in the development and or 
progression of anxiety disorders (Maschi, 2006; Lochner et al., 2010; Meaney, 2010; Hovens 
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et al., 2012; Maschi et al., 2013).  Specific types of trauma exposure have been associated 
with the development or exacerbation of specific anxiety disorders (Lochner et al., 2010; 
Hovens et al., 2012).  Taking all of this into account, it is crucial that when considering the 
molecular underpinnings of anxiety disorders, one must also consider trauma history.  The 
gene-environment interaction can therefore not be negated when investigating the molecular 
etiology of anxiety disorders. 
 
1.4. The use of animal models in anxiety disorders research 
 
It has been argued that animal models represent useful tools for investigating the 
pathophysiology of psychiatric conditions, particularly those that “mimic” the behavioural 
aspects of the disorders.  Tests are often assessed based on face (looks like it would be a good 
test), test (accurately measures the desired trait, usually based on evidence to support the 
interpretations of test scores in psychological testing) and construct (the degree to which the 
test measures what it claims) validity.  However, for an animal model to be effective, it needs 
to more or less mimic the condition of interest with regards to etiology and symptomatology 
(amongst other things) (Bloom and Kupfer, 1995).  Anxiety is an evolutionary conserved 
response and can be measured in animal models (Stein and Bouwer, 1997; Nesse, 1998).  At 
the same time animal models allow for the harvesting of brain tissue at any time-point.  The 
key question to be answered, however, is, ‘Can we use an animal (rat or mouse specifically) 
to model aspects of human anxiety disorders?’  In complex psychiatric conditions, like the 
anxiety disorders, many of the cardinal features are based on subjective verbal report making 
the ‘ideal’ animal model completely unfeasible. This means that when looking at an animal 
model for anxiety disorders it is important to redefine the usual requirements and focus on 
approaches relying on the mimicking of specific signs, symptoms, behaviours or responses as 
oppose to trying to replicate the entire condition (Müller and Holsboer, 2006; Schmidt and 
Müller, 2006).   
From a behavioural state anxiety is a response to signals of danger, however, physiologically 
it involves the activation of the hypothalamus-pituitary-adrenal (HPA) axis allowing for 
steroid secretion (Korte, 2001; Boyce and Ellis, 2005).  The genes that code for the steroid 
hormones associated with the stress response are highly conserved across diverse species 
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including primates, rodents, reptiles and amphibians (Lovejoy and Balment, 1999; Lovejoy 
and Jahan, 2006).  It has also been shown that the neural structure and functioning underlying 
a fear or anxiety response are similar across species (Elliot, 2008).  In rodents, the approach-
avoidance paradigm is what is monitored in order to assess for anxiety-like behaviours 
(Dell’Osso et al., 2003; Stein and Paulus, 2009) and these have been evaluated and validated 
with drugs that have been used to treat human variations of these disorders (Gordon and Hen, 
2004).  The most popular and well validated testing paradigms used to evaluate approach-
avoidance behaviour include the open-field test (OFT) and elevated-plus maze (EPM) 
(Pellow et al., 1985; Lau et al., 2008; Chadman et al., 2009).  As mentioned, although animal 
models prove useful in studying complex disorders such as anxiety disorders, they do only 
mimic certain aspects of disease and one cannot ignore the cognitive differences between 
rodent and humans.  Nevertheless, the behavioural differences between stressed and 
unstressed rats may still point to potential candidate susceptibility genes in humans.  A 
diagrammatic outline of the general approach for using an animal model to identify 
susceptibility candidate genes can be found in Figure 1.3 below.   
Quantitative trait loci (QTL) mapping  has been used to identify susceptibility candidates in 
rodents (Ramos et al., 1999; Zhu et al., 2012), with underlying notion that genes in the human 
homologue loci could be considered susceptibility genes for human phenotypes - in this case, 
anxiety disorders.  Initially, QTL mapping was based on genome-wide marker usage within 
the F2 rodent generation, relative to anxiety-like behavioural assessment; but this showed 
relatively poor resolution.  Present day models include, but are not limited to, genetic 
manipulation (when a specific gene target has been selected for and incorporated/ knocked-
out), strain selection (capitalizing on the inherent ability of a particular strain to be high- or 
low-anxiety), bidirectional breeding (using inherent strains for comparison independent of an 
outside stimulus), and environmental innervations (the application of an external stimulus 
like a stressor to produce a behavioural response that may be monitored) (Mott and Flint, 
2002; Yalcin et al., 2005; Valdar et al., 2006; Zhu et al., 2012).  These may all be combined 
with pathway specific screening and/ or tissue specific expression for increased resolution or 
candidacy identification. 
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Rodents represent a good model system for evaluating human anxiety disorders as 1) the 
central nervous system is sufficiently developed enough to mimic aspects of human anxiety 
2) there are multiple strains available and the full genomic sequence for most of these are 
easily accessible 3) there are well established techniques allowing for transgenic 
manipulation within rodents and 4) maintenance of the model is relatively cost-effective 
(Keane et al., 2011; Sokolowska, 2013).   
 
Maternal separation (MS) is the most widely accepted model in rats for investigating the 
effects of early-life trauma and many studies have indicated its validity in humans (Andersen, 
2003; Lehmann and Feldon, 2000; Roman, 2004; McEwen et al., 2012).  Separating rat pups 
from their mothers during the postnatal period results in a range of physiological changes, the 
nature of which depend of the duration of separation, the specifics of the separation act itself 
as well as the environmental conditions under which the separation takes place (Lehmann and 
Feldon, 2000).  The behavioural changes associated with MS has been known for past 50 
years (Levine, 1957; Denenberg and Morton, 1964) where it was initially found that the 
Figure 1.3: A strategy for cross-species (rodent-human) 
identification of susceptibility genes for anxiety disorders 
(Sokolowska, 2013) 
Stellenbosch University  http://scholar.sun.ac.za
Chapter 1: Literature Review 
30 
 
handling and or stroking of pups allowed them to develop differently to those not handled.  
Furthermore these short periods of MS were found to have profound long-term effects on 
certain hormones, resulting in alterations in corticosterone response, enhanced learning, 
enhanced attention abilities and decreased emotional activity (Arnold et al., 2009).  
Prolonged periods of MS then led to the development of animal models better mimicking 
behaviours useful for extrapolation to human depression and anxiety studies (Hall, 1998; 
Kuhn and Schanberg, 1998).  Post-natal (PND) days 4 – 14 are found to be the most sensitive 
period (hypo-responsive period) for MS applications (Roman, 2004).  Rats do not respond to 
mild-stressors during this time due to low levels of circulating glucocorticoids (Sapolsky and 
Meaney, 1986; Schmidt et al., 2005).  The MS model can be performed with single occasion 
for a specific duration, or at multiple time periods during the hypo-responsive period.  
Common protocol for anxiety models dictate minimum separation periods of between 3 and 
15 min all showing to be effective in producing anxiety-like behaviours during adulthood.  
Prolonged periods of separation (> 1hr) can also be applied.  Shorter MS application periods 
have been shown to result in neurochemical, behavioural and hormonal changes that 
culminate in the rodent’s ability to cope with and adapt to more stressful situations as adults, 
whereas interestingly the longer periods of application appear to result in contradictory 
behavioural observations  (Anisman et al., 1998; Ladd et al., 1999; Anand and Scalzo, 2000; 
Lehmann and Feldon, 2000; Pryce and Feldon, 2003; Roman, 2004; Eiland and McEwen, 
2012).  Contradictory results regarding prolonged MS application has been painted 
predominantly as variation in experimental protocol between research facilities (individual or 
litter separation, temperature conditions, lighting, or handling periods) (Lehmann and Feldon, 
2000; Pryce and Feldon, 2003); however literature supports the results from studies on early-
life experiences modifying behaviour under shorter MS application times with replications in 
rats, mice and primates (Clausing et al., 2000; Romeo et al., 2003; Levine and Mody, 2003; 
Schmidt et al., 2004; Roman, 2004; O’Mahony et al., 2009; George et al., 2010; Eiland and 
McEwen, 2012). 
Restraint stress (RS) is considered to be an acceptable model to be used to mimic a human 
adult stressor (Doremus-Fitzwater et al., 2009; Spear, 2000).  During RS, rodents are placed 
in a clear plexi-glass container with a narrowing tailgate.  This impedes their locomotive 
ability without hindering blood flow or inflicting pain.  This particular stress is either applied 
to adolescence rodents (PND 28 – 42) or during adulthood (PND 42 +) (Doremus-Fitzwater 
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et al., 2009). Restraint stress can also be applied prenatally in the same fashion as above, but 
then applied to the pregnant mother rats during different stages of fetal development (Maccari 
and Morley-Fletcher, 2007; Morley-Fletcher et al., 2013).  Repeated exposure to RS has been 
shown to increase anxiety-like behaviours in rodents (Gehlert et al., 2005; Sajdyk et al., 2006; 
Sevgi et al., 2006; Doremus-Fitzwater et al., 2009) pre- or postnatally, evaluated by validated 
testing [pharmacological testing with anxiolytic and anxiogenic compounds (Cooper and 
Hendrie, 1995; File and Seth, 2003)] paradigms, namely EPM, OFT and also social 
interaction (SI) testing.  The use of RS in an animal model to mimic mild adulthood stress in 
humans has received some paucity amongst the literature.  For example, although the EPM 
test is an established test for anxiety levels in rodents exposed to a postnatal stress 
application, it doesn’t always show significant differences between cases and controls in 
application (Albonetti and Farabollini, 1992; Chadda and Devaud, 2005; Doremus-Fitzwater 
et al., 2009); however when the same rats are evaluated using an alternative testing paradigm 
(e.g. SI) RS rats show significantly higher anxiety compared to controls (Doremus-Fitzwater 
et al., 2009).  These contradictions have been attributed, as with MS, to inter-laboratory 
protocol deviations; however the over-all accreditation on restraint stress is that it results in 
an increased level of anxiety-like behaviour when applied prenatally (Maccari and Morley-
Fletcher, 2007; Morley-Fletcher et al., 2013) or postnatally (Doremus-Fitzwater et al., 2009; 
Wang et al., 2012).   
Rats exposed to environmental stressors can, therefore, subsequently be assessed for anxiety-
like behaviours using various well-established behaviour assessment paradigms (EPM, OFT, 
SI etc.).  The use of short-term MS during early developmental stages has been repeatedly 
shown to allow for long-term behavioural, neurochemical and hormonal changes in rodents, 
and also that short application time MS better prepares for adulthood stressors (Roman, 2004; 
Eiland and McEwen, 2012).  Literature indicates RS application to mimic adult human 
neurobehavioral anxiety features, and in conjunction with MS (relative to RS only 
independent controls) could provide insight into the mechanisms involved in the pathogenesis 
of anxiety disorders in humans with a trauma history, and subsequent trauma exposure.   In 
this study the use of an inherently ‘calm’ rat strain (Sprague Dawley) was subjected to 
environmental interventions of MS and RS, separately and in combination, to investigate this 
for use as an effective model for anxiety for candidate susceptibility gene identification.  
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Arguably these findings may assist in the search for novel candidate genes and/ or pathways 
involved in anxiety disorders in humans. 
 
In conclusion, there are genetic component(s) to the pathogenesis of anxiety disorders; 
however, this is not independent of interaction with environmental variables, such as early life 
trauma.  Investigating genes that are differentially expressed in trauma-exposed animals with 
subsequent anxiety-like behaviours, could point to novel susceptibility genes for anxiety 
disorders in humans.  It is hoped that this would ultimately allow for a better understanding of 
the molecular etiology of anxiety disorders.  This dissertation therefore aims to use trauma-
exposed rats exhibiting anxiety-like behaviour to identify target genes for anxiety pathology 
and that may also be subject to interaction with early-developmental trauma.  Investigating 
childhood trauma in the human cohort as a variable possibly interacting with the genetic 
components could elucidate on gene-environment interactions that may be present.  By doing 
so, it is hoped to significantly enhance the understanding of the molecular basis of anxiety 
disorders and provide researchers with novel anxiety susceptibility genes to test for association 
in populations. In a clinical context, the identification of novel susceptibility candidates for 
anxiety pathology could lead to better treatment strategies by yielding novel drug targets.  
Treatment strategies may also be better designed or altered with a clearer understanding of 
the gene-environment interaction concerning these gene targets.  This knowledge is pivotal 
considering the literature content indicating childhood trauma to be a susceptibility risk factor 
in developing anxiety disorders. 
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Study objectives 
 
This project aims to evaluate whether the expression of certain genes encoding proteins 
involved in synaptic plasticity would be altered in maternally separated and restraint stressed 
rats compared to non-stressed controls.  Genes identified to be differentially expressed in 
stressed rats expressing anxiety-like behaviours may be considered plausible candidate genes 
(novel and/ or previously described) for increased susceptibility to anxiety disorders in 
humans.  
 
The objectives of this study were as follows:- 
1. To determine the effect of stress (maternal separation and restraint stress) on gene 
expression in the rat striatum, i.e. to see if there are differentially expressed genes in 
rats with a trauma history vs. those without. 
2. To determine whether the identified differentially expressed genes are potential 
susceptibility genes for anxiety-related disorders using case-control association 
studies. 
3. To determine whether genes that are differentially expressed in rats with a trauma 
history and with consequent anxiety-like behaviours point to susceptibility genes for 
anxiety disorders in humans for which trauma severity scores are known. 
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2. Materials and Methods 
 
The central aim of Chapter 2 is to discuss the methodology employed.  Chapter 2 will cover 
all methodologies, including clinical assessment, animal paradigms and the extrapolation 
onto a human cohort.  
 
Role of the incumbent  
Clinical interviews, data collection, sampling and human DNA extractions were performed 
by trained clinicians and a laboratory technician.  The animal work was performed by experts 
in the field at the University of Cape Town.  The role of the incumbent of this study was 
therefore to analyze the behavioural data obtained, to perform the RNA extractions and to do 
the cDNA conversions for expression analyses.  In addition, he executed these assays and 
analyzed the data obtained to subsequently identify susceptibility genes in accordance with 
the aims and objectives of this study.  The incumbent tested for carry-over significance 
within a human cohort of anxiety disorders patients and controls by implementing targeted 
next generation sequencing, and analyzed extended genotyping data obtained for the human 
cohort.  Gene-environment correlation, gene-environment interaction and haplotype analyses 
were performed and conclusions were subsequently drawn and discussed within this 
dissertation. 
 
2.1. Ethics 
 
The study has been approved by Health Research Ethics Committee of the Faculty of 
Medicine and Health Sciences, University of Stellenbosch (Project number: 99/013). The 
work with humans is conducted in accordance with the guidelines of the International 
Conference on Harmonization Good Clinical Practice Guidelines (ICH/GCP, 1996), The 
Declaration of Helsinki (Edinburgh 2000) and The Medical Research Council of South 
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Africa’s guidelines (2002) on the ethical conduct of research studies in humans.  All 
participants provided written and informed consent for the study.  If under the age of 18 
years, participants provided assent and their parents or guardians consent for their 
participation.   
The work with the animals is part of a larger study for which ethics approval has been 
obtained from the University of Cape Town, Department of Human Biology. (None of the 
animal work for this project was performed at Stellenbosch University, but completed in its 
entirety under the supervision of Dr. Jacqueline Dimatelis and Prof Vivienne Russell.) (UCT 
ethics approval Rec Ref: 010/030) 
 
2.2. Animal work 
 
A total of 51 male Sprague Dawley rats were used.  Sprague Dawley rats are an outbred 
breed of albino rats that have been used extensively in medical research for close to 100 
years.  Their particular use within this study can be attributed to their calmness and ease of 
handling (Rodeheaver et al., 1996).  Male rats were used to minimalize any gender bias that 
may be associated with X-linked traits. 
The rats were divided into a set of four experimental groups and all testing paradigms were 
carried out in the Department of Human Biology at the University of Cape Town: 
 Maternal Separation (MS) group:  rats were subjected to MS from post-natal day 
(PND) 2-14 (i.e. days 2 – 14 after birth), after which they were kept under controlled 
conditions until they reached PND75, when they were sacrificed (decapitation). 
 Restraint Stress (RS) group: rats were subjected to RS for five consecutive days 
during adulthood (PND65) and left to reach PND75 before decapitation. 
 MS+RS group: MS rats underwent RS for 5 consecutive days during adulthood 
(PND65) and left to reach PND75 before decapitation. 
 Control group: rats were not subjected to MS or RS and were kept under controlled 
conditions until PND75 when they were decapitated and used as a control group for 
comparison to the above trials. 
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2.2.1. Maternal Separation 
 
On PND2, rat pups were removed from their home cages (to separate them from their 
mothers) for a period of 3 h/day for 14 days, between 09h00 and 12h00. During the 
separation period, the pups were housed under infrared lights at a constant temperature of  
31 – 33 ˚C inside the cage, to prevent hypothermia.  During the separation procedure, the 
dam was housed in a separate room under controlled conditions.  After 3 hours, the pups were 
reunited with their mothers and normal housing was not disrupted until the pups were weaned 
at PND21.  Control animals were not separated from their mothers.  
 
2.2.2. Restraint stress 
 
The RS rat group was repeatedly stressed from PND 65 for 5 consecutive days using restraint 
stress.  Male rats are considered adults from PND 60 (Spear, 2000), and this is therefore 
considered indicative of a mild adulthood stress.   Rats were placed in a Plexiglas restrainer 
with the tailgate adjusted to keep the rat well contained, but without impairing circulation to 
the limbs.  This was performed for each rat in the group for 4h per day for 5 consecutive 
days.  
 
2.2.3. Behavioural tests 
 
Behavioural tests were carried out by Dr Jacqueline Dimatelis and Prof Vivienne Russell in 
the Department of Human Biology at the University of Cape Town.  These were performed in 
order to assess, relative to a control group, whether the environmental interventions of MS, 
RS and MS-RS lead to increased anxiety-like behaviour by the different rat experimental 
groups.  Data were made available to me in Excel format.   
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The Open Field Test involves exposing individual rats to an open 1 m
2
 arena enclosed by 50 
cm high walls to measure anxiety levels (time spent in middle zone) and locomotor activity 
(distance travelled).  The distance travelled is indicative of a level of exploration within the 
arena.  Longer distance-travelled values are associated with increased time spent around the 
periphery of the arena and considered indicative of increased levels of anxiety.  Rats tend to 
stay along the peripheral walls where it’s ‘guarded’ in higher anxiolytic states (Lau et al., 
2008).  Distances were measured by Dr Jacqueline Dimatelis using EthoVision video 
tracking software (in cm) at UCT. 
The Elevated-Plus Maze (EPM) is a plus-shaped maze that is elevated 50 cm above the 
ground. The ends of the four arms are open, two of the arms have short 2 cm walls (open-
arms) and two of the arms have high 50 cm walls (closed-arms). Individual rats were placed 
in the maze for 5 minute intervals for a singular occurrence per rat.  Time spent in the open 
arms suggests decreased anxiety-like behaviour and time spent in closed arms suggests 
increased anxiety-like behaviour (Pellow et al., 1985; Schmidt and Müller, 2006).  Times 
were again measured by Dr Jacqueline Dimatelis using EthoVision video tracking software 
(in seconds) at UCT. 
The Forced Swimming test (FST) makes use of a transparent cylinder (19 cm in diameter and 
40 cm in height), containing tap water (25°C, depth = 19 cm).  Rats are habituated in water 
for 15 minutes and tests are carried out 24hrs after habituation.  Rats are subjected to 5 min 
swim test periods within the cylinder.  After the test (as well as after habituation), rats are 
dried under a lamp to prevent hypothermia.  Tests were evaluated using an over-head camera, 
where higher immobility times are associated with increased levels of anxiety.  Although FST 
is usually used as a measure of depression, this is often a comorbid condition in anxiety 
disorders and can be associated with increased levels of anxiety as well (Ramboz et al., 1998; 
Dulawa et al., 2004; Suvrathan et al., 2010).  Data were recorded by Dr Jacqueline Dimatelis 
at UCT. 
After the behavioural assessments, rats were decapitated and the striatum surgically excised 
for further analysis.  Decapitation occurred on PND 75 and the dorsal and ventral striatal 
regions were surgically removed by a skilled technician in the Department of Human Biology 
at the UCT.  Striatal regions were subsequently housed at the Division of Biomedical 
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Sciences in 1.5 ml cryotubes (ThermoScientific - Johannesburg, South Africa) containing 
RNAlater (Qiagen) and stored immediately at -80°C until needed. 
 
2.2.4. Behavioural data analysis 
 
Time-bin and movement data was collected and assessed using the automated EthoVision 
video tracking software platform.  Locomotive information was measured in time-bins in 
order to control for the initial minute of handling and acclimatization of the rat to the testing 
arena.  The final (6
th
) minute was also controlled for regarding retrieval of the rat from the 
testing arena.  Statistical analyses were performed using Statistica 10 (StatSoft Inc., 2011).  
MS, RS and MS-RS and control groups were compared in order to assess deviation in 
behaviours as a result of the stressor(s) used.  Statistical correlation of groups with regards to 
a time effect (the comparison of individual time-bin minutes with each other to control for 
animal handling and acclimatization factors) were evaluated by means of mixed model 
repeated measures ANOVA and group assessment by one-way ANOVA.  In all cases, Fisher 
LSD post-hoc tests were performed.   
 
2.3. Human work 
 
Assessments were conducted and recorded by a clinician with expertise within the field.  
Blood was collected by a nurse and DNA extracted by a qualified laboratory technician using 
the methodology described in section 2.4 below.  
 
2.3.1. Participants 
 
The study cohort comprised 149 patients (89 OCD, 33 PD, and 29 SAD) and 181 control 
individuals of South African Caucasian descent.  Patients of various ages (between 9 and 82 
years; 34.8 ± 13.2) were recruited countrywide, with the majority being from the Western 
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Cape Province.  Patient recruitment was implemented via media advertisements and 
recruitment calls to psychiatrists and psychologists, primary care practitioners, and advocacy 
groups.  Patients had to meet the Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition (DSM-IV) (First et al., 1998) criteria for a primary diagnosis of their 
respective illnesses (OCD, PD or SAD) for study inclusion. Patients were included 
irrespective of baseline (not receiving treatment for primary psychiatric disorder) or receiving 
treatment for primary diagnosis.  Patients with comorbidities for any of the primary disorders 
in question (e.g. PD with comorbid SAD) were excluded.  
The controls were recruited countrywide from both university and non-university settings 
(e.g. from organizations like the SA National Blood Services [SANBS], Metropolitan, Old 
Mutual etc.).  Possible participants were approached either directly (the case of people 
attending SANBS clinics) or indirectly, i.e. with notices and advertisements sent out by their 
respective Human Resources departments.  Most controls did not undergo comprehensive 
diagnostic interviews, and can be taken as representative of the local general population.   
 
2.3.2. Participant Interviews 
 
Data, including age at interview, age of onset of their primary disorder, highest level of 
education, current employment status, and population group were obtained from all 
participants. The clinical diagnoses were made based on the Structured Clinical Interview for 
Diagnostics and Statistical Manual of Mental Disorders, Fourth Edition, Axis I Disorders-
Patient Version (First et al., 1998; First and Gibbon, 2004). 
 
2.3.3. Self-report questionnaires 
 
The Childhood Trauma Questionnaire (CTQ) (Bernstein et al. 1994), a scale proven to be a 
valid and reliable measure of past traumatic experiences (Bernstein et al. 1997), was used as a 
self-report questionnaire to assess the nature and severity of childhood trauma.  Notably, a 
subset of the total sample of patients (n = 92) and controls (n = 194) for whom we obtained a 
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blood sample for DNA extraction completed this self-report questionnaire. The CTQ items 
are divided into 5 subscales: emotional abuse, physical abuse, sexual abuse, emotional 
neglect and physical neglect.  The CTQ also includes a 3-item minimization/denial (MD) 
scale, which is indicative of potential underreporting of maltreatment or idealizing the family 
of origin.  The scoring of responses on the 3 items comprising the MD scale were 
dichotomized (“very often true” = 1, all other responses = 0) and summed.  A total of 1 or 
greater suggests the possible underreporting of maltreatment (false negatives) (Bernstein and 
Fink 1998) whereas a score of 3 indicates extreme minimization or denial of maltreatment 
during childhood. MD-scores of 3 were taken into consideration as possible confounders in 
the analyses.    
All controls were also required to complete a questionnaire pertaining to his/her personal 
demographic data.   
 
2.4. DNA/ RNA Extraction 
 
2.4.1. DNA/RNA extraction from rat striatal tissue 
 
Simultaneous DNA/ RNA extraction was performed using the Qiagen AllPrep 
DNA/RNA/Protein extraction kit.  Rat striatal samples stored in RNALater (Qiagen - Hilden, 
Germany) stabilizing reagent prior to extraction, were then removed and transferred to 2 ml 
FastPrep-24 lysing matrix tubes (MP Biomedicals), containing 600 µl of RLT PLUS buffer,  
for homogenization.  Samples were homogenized at full speed for 20 sec in the FastPrep 
FP120 (Savant), cooled on ice for 1 min and then re-homogenized at full speed for a further 
20 sec.  The matrix tube was subsequently centrifuged for 3 min at 10 000 rpm, and the 
supernatant removed and transferred to an AllPrep DNA spin column placed in a 2 ml 
collection tube.  DNA/RNA extraction was then carried out according the manufacturers’ 
instructions.  Post extraction DNA and RNA were stored at -80°C until needed. 
 
2.4.2. DNA extraction from human whole blood 
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Genomic DNA was extracted from whole-blood using venipuncture and a chloroform/ 
isopropanol extraction method previously described (Meulenbelt et al., 1995).  Blood samples 
(between 5 and 10 ml) were collected in spray-coated K2EDTA BD Vacutainer
®
 Venous 
Blood Collection tubes (New Jersey, USA), and stored at 4°C until extraction and extractions 
were performed within 5 days of collection. 
   
2.5. DNA/ RNA quantification and qualification 
 
DNA and RNA quantification and qualification was assessed using the Nanodrop (Delaware, 
USA).  Concentrations were assessed at a maximum absorbance 260 nm (A260) for DNA and 
230 nm A230 for RNA. DNA sample purity was assessed using the A260/A280 ratio, with a ratio 
> 1.8 showing adequate purity and minimal protein contamination. 
RNA quality and quantity was further assessed using the Experion RNA StdSens RNA 
Analysis kit and Experion automated electrophoresis system (BioRad – Johannesburg, South 
Africa) running Experion Software System Operation and Data Analysis Tools V3.0.226.0.  
The analysis kit and RNA StdSens chips were used according to the manufacturers’ protocol 
(BioRad) and digital RNA gel images, concentrations and RNA quality indicator (RQI) 
values assessed for RNA quality. 
 
2.6. Gene expression analysis using the RT2 ProfilerTM PCR Array 
 
The RT
2
 Profiler
TM
 Array (SABiosciences, a Qiagen Company), in question is a 384-well 
plate based system capable of assessing tissue-specific expression for 84 genes in the 
synaptic plasticity pathway for 4 independent samples.  The plate also houses a series of 
internal controls including a genomic DNA control (to assess for genomic DNA 
contamination), non-template control (to assess for plate contamination in general) and 
positive controls (to assess for plate integrity). 
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2.6.1. cDNA synthesis 
 
Complementary DNA (cDNA) synthesis was performed using the RT
2
 First Strand Kit 
(Qiagen) to ensure optimal results for detection of reverse transcription controls contained in 
the RT
2
 Profiler PCR Array.  cDNA was prepared for use with the RT
2
 Profiler PCR Array 
format E 384 (96 x 4) option and therefore the recommended 400 ng input RNA was used for 
cDNA conversion.  cDNA conversion was performed according to the manufacturers’ 
protocol.   
 
2.6.2. QC Array 
 
The RT
2
 QC PCR Array is designed to assess the quality of RNA samples before gene 
expression analysis using any of the RT
2
 Profiler PCR Array systems available.  The QC 
Array was used according to the manufacturer’s instructions.  Twenty-four individual PCR 
component mixes were prepared containing 2.4 µl of the prepared cDNA for each respective 
rat striatal sample as well as 27.6 µl of RNase-free water.   Dilutions (1/100) were prepared 
for the same twenty-four samples using the extracted RNA and not cDNA conversions to use 
in the genomic contamination control wells of the QC array plate.  Samples and master mixes 
were aliquoted into the wells of the QC Array using the EpMotion 5070 automated liquid 
handler (Eppendorf – Hamburg, Germany) and the plate subsequently run on the 7900HT 
Fast Real-Time PCR Machine (Applied Biosystems – Carlsbad, California) according to the 
following protocol: 95°C for 10mins, followed by 40 cycles of 95°C for 15 sec and 60°C for 
1 min. Analysis of PCR amplification was done using SDS software Version 2.4 (Applied 
Biosystems – Carlsbad, California). 
 
2.6.3. Rat Synaptic Plasticity RT2 Profiler PCR Array 
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The Rat Synaptic Plasticity PCR Array, PARN – 126Z (SABiosciences - Hilden, Germany) 
was used to assess differential expression in the synaptic plasticity pathway genes between 
the aforementioned four (MS, RS, MS-RS and Control) rat groups (Section 2.1).  The genes 
included in the PCR array include, but are not limited to the following groupings: immediate-
early response genes (IEGs), late response genes, long-term potentiation (LTP), long-term 
depression (LTP), cell adhesion, extracellular matrix and proteolytic processing, cAMP 
response element binding (CREB) factors, neuronal receptors and post-synaptic density.  A 
detailed list of the genes included within these groupings can be found in Appendix II.  Five 
housekeeping genes (Rplp1, Hprt1, Rpl13A, Ldha and Actb) were included for normalization 
of the expression data, and a rat genomic template control to determine whether the extracted 
RNA samples were contaminated with genomic contamination. Reverse transcription and 
positive amplification controls were also included.  cDNA representative of a single rat 
specimen from each of the aforementioned groups was analyzed on a single array to address 
grouping-bias that may be introduced when running all control and all patient samples in a 
single run.  Mastermixes were prepared according to the manufacturer’s protocol using RT2 
SYBR Green ROX qPCR Mastermix (Qiagen - Hilden, Germany) and mastermixes were 
aliquoted into the wells of the QC Array using the EpMotion 5070 automated liquid handler 
(Eppendorf – Hamburg, Germany).  Real-time PCR was performed using the 7900HT Fast 
Real-Time PCR Machine (Applied Biosystems – Carlsbad, California) running SDS software 
Version 2.4 (Carlsbad, California).  Cycling conditions were as follows: 95ºC for 1 min to 
allow for HotStart Taq Polymerase activation, followed by 40 cycles of 95ºC for 15 sec and 
60ºC for 1 min for which fluorescence data capture was performed.  A dissociation curve 
(machine default) was employed post amplification to verify PCR specificity. 
 
2.6.4. RT2 Expression Profile Analysis 
 
Expression data obtained using the RT
2 
Profiler PCR Array (SABiosciences, a Qiagen 
Company) were analyzed online at http://www.sabiosciences.com/pcrarraydataanalysis.php 
using the prescribed data analysis software.  The software employs a 2
-∆∆Ct
 approach using all 
five of the included housekeeping genes in the analyses to provide fold-changes as well as P-
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values relative to the control group.  The software also analyses the internal genomic, reverse 
transcriptase and positive amplification controls for quality assessment. 
 
2.7. Candidate susceptibility gene characterization 
 
Characterization of candidate genes was done using a combination of a TagSNP approach 
using the online databases and MAFs, as well as the identification of inter-species (rat, mouse 
and human) DNA conservation.  Next generation sequencing (NGS) was employed in cases 
where the current databases lacked sufficient information for informative SNP selection for 
the population group used in this study.  
 
2.7.1. TagSNP identification 
 
The susceptibility genes identified using the RT
2
 Profiler
TM
 array were used as input into the 
International HapMap Project database (www.hapmap.org), HapMap genome browser 
release #27 (Phase II & III – merged genotypes and frequencies) on Feb09, on NCBI B36 
assembly, dbSNP b126.  TagSNPs were identified by searching the susceptibility gene of 
interest in the aforementioned data source to find informative SNPs spread across the gene.  
The HapMap TagSNP data file was downloaded and TagSNPs confirmed using the 
Haploview software analysis program (www.broadinstitute.org/haploview/haploview).  
Minor allele frequencies (MAFs) of ≥ 0.2 and R2 ≥ 0.8 were used at cut-offs for SNP 
inclusion. 
 
2.7.2. Core-domain region identification 
 
Simple Modular Architecture Research Tool (SMART) software (http://smart.embl-
heidelberg.de/), Swiss-Prot, SP-TrEMBL (http://www.ebi.ac.uk/uniprot), and Esembl 
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(www.esembl.org) databases were used to determine the domain structure of the proteins 
encoded by the identified candidate genes.  
 
2.7.3. Inter-species conservation analysis 
 
 rVISTA software analysis tool (http://rvista.dcode.org/) and ECR Browser 
(http://ecrbrowser.dcode.org/) were used to search for conserved genomic DNA regions of 
candidate genes between human and rat species.   
 
2.7.4. Targeted next generation sequencing (NGS) 
 
Targeted NGS was performed using a combination of whole-genome amplification (as 
opposed to a tagged-fragment approach).  Successfully amplified genes were normalized 
(SeqTarget Normalization, Qiagen) to ensure even coverage during reading, then tagged and 
fragmented (NexteraXT, Qiagen) for use with Illumina’s MiSeq platform.  The NGS cohort 
comprised 12 patients (even numbers of OCD, PD and SAD) and 19 controls, in accordance 
with the run requirements for kit usage on the MiSeq Illumina experimental setup.  CTQ total 
score means were calculated using Graphpad Prism 5.0 (student’s t-test) and confirmed using 
the descriptive statistics add-on package for Excel (Microsoft Office 2010).  Cases for 
inclusion were selected by choosing those with higher CTQ total scores in OCD, SAD and 
PD sub-populations so as to allow for even numbers of OCD, PD and SAD participants 
(mean CTQtot: 51.16).  Controls were selected choosing those that were the same or closely 
related mean CTQ total score (mean CTQtot: 26.66) of the control group to represent the 
general population. Selected individuals were controlled for gender and age. An underlying 
genetic component associated with anxiety disorders in general is the target focus of this 
study, not a specific disorder.  The small number of individuals able to be screened using 
NGS considering cost also required the merging of this individual disorders into one group to 
maximize statistical power. 
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2.7.4.1  Whole-Gene amplification 
 
Whole gene amplification was carried out on ARC, EGR2, EGR4, NTF4 and GRM2, 
considering the absence of sufficient HapMap database data to perform a TagSNP analyses.  
A total of 31 individuals (12 patients and 19 controls) were selected (criteria described in 
2.7.4 above) for whole-gene amplification.  DNA quality was assessed using the Nanodrop 
(Delaware, USA) as well as agarose gel electrophoresis to assess integrity. Age- and sex-
matched patients and control individuals above the age of 18 years were selected for whole-
gene PCR amplification.   
The aforementioned genes were amplified using the primer sets specified in Table 2.1 in 
conjunction with QIAGEN LongRange PCR kit.  Primers were designed using Integrated 
DNA Technologies (www.idtdna.com) and in silico specificity testing performed using 
Primer-BLAST (www.ncbi.nlm.nih.gov/tools/primer-blast/). PCR conditions were carried out 
according the manufacturer’ instructions using either cycling conditions A or B with the 
annealing temperatures specified in Table 2.2. 
 
Cycling Condition A 
Initial denaturation at 93°C for 3 min, followed by 35 cycles of denaturation at 93°C for 15 
sec, annealing at the specified annealing temperature for 30 sec, and extension at 68°C for 8 
min. The reaction was then set to cool to 4°C until removed from the PCR machine for 
further use. 
 
Cycling Condition B 
Initial denaturation at 93°C for 3 min, followed by 10 cycles of denaturation at 93°C for 15 
sec, annealing at the specified annealing temperature for 30 sec, and extension at 68°C for 10 
min. This was followed by 28 cycles of 93°C for 15 sec, annealing at the specified annealing 
temperature for 30 sec, and extension at 68°C for 10 min + 20sec with every cycle. The 
reaction was then set to cool to 4°C until removed from the PCR machine for further use. 
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Table 2.1: Whole gene amplification primer specifications 
Gene Primer (5’ – 3’) Ta (°C) 
Product size 
(bp) 
Cycling 
condition 
EGR2 
CGCGAGCGAGAAACTTTCCCAAAT 
58 8156 A 
CGTGCAAGAAGCACCCTGAACATT 
EGR4 
TTTGGTGACTTGGACCCTTGTCCT 
58 6752 A 
TCAGGTGGCCCATGCCTAATAAGT 
NTF4 
AAATAACTGGAGCGGCCTTGTGTG 
62 7936 A 
AATCCTGCTTTGCAGTCGGAGGTA 
ARC 
AGTTTGCTGAGCCAGCTCTCACAT 
58 3269 A 
AAATGACAGCTTTCAGGCAGCACC 
GRM2 
TTTGTGGCATGTCCTTGTGTGAGC 
62 7222 A/B 
ACAGCTAGCAGGTCTTGGTGTCAA 
TGTGGACACTTGACACCAAGACCT 
62 8328 A/B 
ATTCACCATGATGAGTGGCTCCCT 
Abbreviations: bp: base-pair, Ta: annealing temperature 
 
Successful amplifications were tested using horizontal agarose gel electrophoresis on a 1% 
(w/v) agarose gel in 1X sodium tetraborate decahydrate (SB) buffer.  Samples were 
electrophoresed for 1 hr at 120 V along with Hyperladder I (1 Kb ladder; Bioline – Cape 
Town, South Africa) for size comparison, and subsequently visualized using ultraviolet light 
transillumination using GeneSnap V 6.07 (SynGene).  Successful amplifications were 
confirmed using semi-automated bi-directional sequencing analysis.  Sequencing results were 
analyzed using ClustalW and BioEdit Sequence Alignment Editor software (Hall, 1999; 
Thompson et al., 1997).   
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Due to the sporadic GC-rich regions contained within the ARC gene, whole-gene 
optimization could not be successfully achieved.  The QIAGEN SeqTarget Primer Select kit 
(Cat. 122001-ST00745787) was used in conjunction with QIAGEN LongRange PCR kit 
according to the manufacturers’ protocol using PCR cycling condition B for amplification of 
the ARC gene.  Successful amplification was assessed using horizontal gel electrophoresis as 
described above. 
 
2.7.4.2  SeqTarget normalization 
 
Long-range PCR products were purified by size exclusion and adsorbed onto a silica 
membrane for elution using the SeqTarget Normalization kit (Qiagen).  Purification and 
normalization was performed according to the manufacturer’s instructions for microtiter-plate 
centrifuge and vacuum manifold utilization.   
 
2.7.4.3  Sample and library preparation 
 
Sample and library preparation was performed using the Nextera XT DNA Sample 
preparation kit (Qiagen).  Tagmentation (fragmenting and tagging) of normalized DNA was 
simultaneously performed by the Nextera XT transposome according to the manufacturer’s 
recommendations.   
PCR amplification and the incorporation of indexes (i7 and i5) and sequences required for 
cluster formation was performed by initially selecting the necessary indexes to insure sample 
distinction post run.  Indexing i7 1 – 12 were selected and combined with i5 1 – 3 to ensure 
unique tags for all individual samples to be processed (Table 2.2).  Samples were centrifuged 
at 280 x g for 1 min and subsequently amplified in a thermocycler under the following 
conditions: 72°C for 3 mins, 95°C for 30s, followed by 12 cycles of 95°C for 10s, 55°C for 
30s and 72°C for 30s.  A final incubation step at 72°C for 5 min was then followed by 
immediate hold at 10°C until further processing. 
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Table 2.2: Indexing (i7 and i5) combinations added to each sample as unique identifiers 
  
           
i5 
S501 
i7 
N701 
i7 
N702 
i7 
N703 
i7 
N704 
i7 
N705 
i7 
N706 
i7 
N707 
i7 
N708 
i7 
N709 
i7 
N710 
i7 
N711 
i7 
N712 
i5 
S502 
i7 
N701 
i7 
N702 
i7 
N703 
i7 
N704 
i7 
N705 
i7 
N706 
i7 
N707 
i7 
N708 
i7 
N709 
i7 
N710 
i7 
N711 
i7 
N712 
i5 
S503 
i7 
N701 
i7 
N702 
i7 
N703 
i7 
N704 
i7 
N705 
i7 
N706 
i7 
N707 
     
 
Tagmented samples were clean-up post PCR using AMPure XP beads according to the 
manufacturers’ protocol (Beckman Coulter - Kloof, South Africa).   
Library pooling was performed by transferring 5 µl of each to a clean 1.5 ml Eppendorf tube, 
and mixed by pipetting.  A 1: 24 dilution of the library was prepared by transferring 24µl of 
the pooled library to a clean 1.5 ml Eppendorf tube containing 576µ of HT1.  As a positive 
control, the diluted library was spiked by supplementing 180µl of it with 120µl of 10pmol 
PhiX.  The diluted library was loaded onto a thawed MiSeq reagent cartridge into the ‘Load 
Samples’ reservoir and sequenced according to the Illumina MiSeq System User Guide 
instructions.  The sample sheet required for sequencing was setup to allow for paired-end 
sequencing with 2 X 250 reads.  Amplicon sequencing methodology was selected and 
amplicon manifolds were created for the 5 target genes relative to Homo Sapiens UCSC 
Hg19 reference sequence.  Upon completion of the run, the MiSeq Reporter Software 
automatically aligns the amplified sequences for the specified target genes to the UCSC Hg19 
reference sequence using the Burrows-Wheeler Aligner (BWA) (Li and Durbin, 2009).  
Genome Analysis Toolkit (GATK) (Broad Institute) was used for variant calling.  GATK 
calls raw variants for each sample read, analyzes them against known variants (online 
databases such as NCBI and Ensembl), and applies a calibration procedure to compute false 
discovery rates for each variant.  Details of the algorithms used for these calibrations can be 
found at http://www.broadinstitute.org/gatk.  
Due to the possibility of identifying a large number of polymorphisms within the individuals 
screened using the aforementioned tNGS platform; the identified polymorphisms were 
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prioritized based on their possibility to be informative with regards to an anxiety disorder 
diagnosis.  Considering the preliminary nature of tNGS in this study (novelty of this kind of 
approach within anxiety disorders) and absence of available comparative datasets, further 
analyses was limited to those polymorphisms identified in either the cases or control 
individuals only. 
 
2.8. Genotyping 
 
Genotyping for the BDNF and MMP9 TagSNPs identified was performed using TaqMan
®
 
Probe assays (Applied Biosystems) according the manufacturers’ instructions.  Genotyping of 
the polymorphisms identified using tNGS (ARC, ERG2, EGR4, GRM2 and NTF4) was 
performed by KBiosciences (Herts, UK) using KASP
TM
 genotyping technology.  TagSNP 
analysis was utilized in order to maximize informative output and minimize cost considering 
the cost of genotyping analyses and the financial constraints associated with this study.  tNGS 
was also only carried out in subset of the cohort due to the cost associated with this kind of 
analyses.  Ideally a much larger, if not the entire cohort, would have been the preferred target 
for polymorphism assessment using tNGS.  
 
2.9. Statistics / data analysis 
 
2.9.1. Behavioural data 
 
Experimental rat groups (i.e. MS, RS and MS+RS) were compared in terms of their 
behaviour, relative to unstressed controls.  Statistical analyses were performed with 
assistance from Prof Martin Kidd (Head of the Statistical Consultation Center at Stellenbosch 
University) using Statistica 10 (StatSoft Inc., 2011).  MS, RS and MS+RS groups were 
compared to controls in order to assess deviation in terms of distance travelled (OFT), time 
spent within open arms (EPM) and immobility times (FST).  Statistical correlation of groups 
with regards to a time effect were evaluated by means of mixed model repeated measures 
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ANOVA and group assessment by one-way ANOVA.  In all cases Fisher LSD post hoc tests 
were performed. 
 
2.9.2. Clinical data, genotyping and association testing 
 
One of the aims of the present study was to assess whether the human homologues to genes 
that were differentially expressed in anxious rats could be associated with a diagnosis of 
OCD, SAD or PD in humans. 
Hardy Weinberg Equilibrium was assessed in case and control individuals using RStudio 
(Version 0.97) in conjunction with the R Genetics package.  The same package was also 
utilized to assess for significant association between SNPs identified and anxiety in a case-
control association fashion, adjusting for age and gender.  The additive, dominant and 
recessive genetics models were evaluated and the best fit selected.  p-values were ascertained 
using the effect size displayed for the most appropriate model by running ANOVA general 
linear models, adjusting for the aforementioned covariates.  To test for an interaction between 
CTQ total score and a SNP in anxiety disorders, an interaction term for CTQ total score and 
the polymorphism in question (CTQtot*SNP) was included in the generalized linear model 
(still adjusting for gender).  The results of this glm (including a SNP-CTQ total score 
interaction consideration) was assessed using ANOVA to identify significant variation 
between cases and controls.  Odds ratios (ORs) and confidence intervals (CIs) were 
calculated in R Genetics based on the anova.glm testing performed and calculated by 
imputing the anova.glm effect size generated for the significant p-values observed. 
 
Haplotype analyses were performed using Haploview 4.2, where D’ was assessed based on 
the methodology described by Gabriel et al., 2002 for block selection.  Haploblocks were 
designated based on 95% confidence bounds on D’ indicting strong linkage disequilibrium 
(LD).  This method ignores markers with MAF < 0.05.  This criteria was adjusted for genes 
in which 95% confidence bounds were not met due to SNPs interrupting LD within a gene, 
but for which LD appeared maintained by high D’ beyond the relevant SNP(s) inclusion.  LD 
obtained in Haploview was validated using the LD function from the R statistical genetics 
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package in RStudio (Version 0.97).  Identified haplotypes were confirmed using the 
Haplostats statistical package in RStudio (Version 0.97), which was also used to calculate 
ORs.  To assess for possible environmental - haplotype associated contributions to affection 
status, cases were subdivided into the top 33
rd
 (high CTQ total score) and bottom 33
rd
 
percentile (low CTQ total score) for comparison against controls.  This was performed in 
Haploview 4.2 according to the same methodology discussed above.  All statistically 
significant haplotypes identified were analyzed in RStudio using the Haplo.stats and Genetics 
library packages and implementation of a haplotype generalized linear model (haplo.glm).  
Gender was considered as a covariate during glm fitment.  ORs and confidence intervals 
(CIs) were calculated in R Genetics based on the haplo.glm testing performed and calculated 
by imputing the haplo.glm effect size generated for the significant p-values observed. 
Student’s t-test in GraphPad Prism Version 5.00 was used to assess for a significant 
difference in the distribution of CTQ total scores between cases and controls, as well as for 
the individual subcomponents of the CTQ scale (emotional abuse, emotional neglect, 
physical abuse, physical neglect and sexual abuse).  The subcomponents of the CTQ, 
although assessed for significance, were not used in conjunction with the RStudio R Genetics 
package to assess for a gene – environment interaction with the identified polymorphisms.  
This was considered to control for problems associated with multiple testing, increasing the 
chance for possible Type I error with the inclusion of multiple variables (the 5 sub-
components of the CTQ scale) between a two-group (case-control) comparisons.  
Considering CTQ total score is an additive representation of its subcomponents, only CTQ 
total score was considered for gene – environment interaction assessments within RStudio.  
To test for this aforementioned interaction, i.e. the severity of childhood trauma (as measured 
by the CTQ total score) with a particular SNP, interaction assessments were incorporated in 
the additive, dominant or recessive models utilized in the Genetics program of RStudio 
(Version 0.97) (as discussed above).  Generalized linear models (glms) were fit considering 
affection status (case or control), gender, CTQ total score, the relevant polymorphism and the 
interaction of that polymorphism with the CTQ total score in relation to affection status.  A 
binomial family object was applied for glm testing.  The analyses of deviance produced by 
the applied glms were assessed for a significant p-value using the ANOVA for glm in R 
Genetics.  The resulting output generated p-value associations before adjusting for the 
specified covariates, as well as when adjusted for gender.  Statistical representation of the 
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interaction of CTQ total score between cases and controls while considering the presence of a 
bi-allelic SNP were also produced based on ANOVA analyses of the best fit glm.  ORs and 
CIs were calculated in R Genetics based on the glm genotype testing performed and 
calculated by imputing the glm effective size generated for the significant p-value observed.  
ORs were considered to be representative of increased (>1) or decreased (<1) susceptibility to 
present with anxiety disorder with CIs indicative of the possible range of this prediction 
based on the data utilized. 
 
Stellenbosch University  http://scholar.sun.ac.za
Chapter 3: Results 
55 
 
 
 
 
 
 
 
Chapter 3 
 
Results 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
Chapter 3: Results 
56 
 
3. Results  
 
3.1. Animal work 
 
3.1.1. Behavioural data 
 
Behavioural data was assessed using the EthoVision video tracking software platform and 
data was statistically assessed (Statistica 10) using time-bin interval outputs for each group 
(MS, RS, RS-MS) relative to the controls (nRS nMS) as discussed in Chapter 2 (Section 
2.9.1).  As noted previously, 8 (instead of 13) rats per an experimental group were used for 
the RT
2
 Profiler
TM
 array due to budgetary constraints. The same statistical approach (as 
described in 2.7.1), however, was performed for the full cohort of each experimental group (n 
= 13) as well as the 8 utilized for the RT
2
 Profiler
TM
 Array to ensure the trend observed 
remains constant. 
 
3.1.1.1. Forced Swimming Test (FST) 
 
Levene’s test for homogeneity of variances yielded a significant p-value of 0.043 for 
immobility times. This indicates that any differences in immobility observed between the 
stressed groups relative to the controls was not due to chance alone.  Rats subjected to 
restraint stress alone showed the lowest immobility times, when compared to the three other 
cohorts (Figures 3.1 and 3.2), suggesting lowest anxiety (p < 0.001 in all cases).  Rats 
exposed to maternal separation showed the highest immobility times, assumed to be 
indicative of highest anxiety, comparatively.  A higher observable level of immobility (and 
therefore anxiety) was expected for the combination MS+RS cohort compared to the MS 
cohort, however, their times were not significantly different from that of the MS group (p = 
0.73 for all rats and p = 0.53 for those rats used in the RT
2
 Profiler Array) (Figures 3.1 and 
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3.2).  Considering the different stress-groups in their entirety (for observable trend, RS  
MS  MS+RS) for a better statistical power, significantly different immobility times were 
observed between the RS group and controls (p = 0.004) and MS and MS+RS groups and the 
controls (p < 0.001 and p = 0.001, respectively), but not between MS and MS+RS groups 
(Table 3.1). The MS and MS+RS groups also differed significantly from the rats exposed to 
restraint stress only (Table 3.1). 
 
Table 3.1: Fisher’s LSD test for variability in immobility times between stressor-groups 
for the forced swimming (FST) test 
GROUP 
Immobility 
mean 
(sec) 
+-SD 
(sec) 
nRS nMS 
(p-value) 
RS nMS 
(p-value) 
nRS MS 
(p-value) 
RS MS 
(p-value) 
nRS nMS 116.750 9.981 - 0.005 0.001 0.002 
RS nMS 91.923 24.700 0.005 - 0.000 0.000 
nRS MS 147.250 19.377 0.001 0.000 - 0.735 
RS MS 144.384 25.382 0.002 0.000 0.735 - 
*nRS nMS = controls; RS nMS = RS; nRS MS = MS; RS MS = RS-MS; SD = standard 
deviation
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Figure 3.1: Least squares (LS) mean immobility values 
for restraint-stress (RS nMS), maternal-separation (nRS 
MS), combination restraint-maternal separation (RS MS) 
and controls (nRS nMS).  Statistically significant 
differences are indicated by letters a, b and c with 
differing letters showing significant differences between 
those groups. 
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Figure 3.2: Least square (LS) mean immobility values 
for restraint-stress (RS nMS), maternal-separation (nRS 
MS), combination restraint-maternal separation (RS MS) 
and controls (nRS nMS).  Statistical significances are 
indicated by letters a, b and c with differing letters 
showing significant differences between those groups.  
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3.1.1.2. Open-Field Test (OFT) 
 
In the OFT test, a greater distance travelled can be indicative of an increased level of anxiety; 
as a greater distance needs to be travelled for rats to remain within the periphery of the 
experimental area (George et al., 2010).  The periphery represents a more controlled space 
and time spent within the periphery is associated with increased stress and a reluctance to 
explore (move within the center zone with all sides exposed).  The control group showed the 
lowest mean values for total distance travelled, indicative of a less anxious phenotype than 
rats exposed to an environmental stressor (Figure 3.3). Significant p values were found when 
comparing RS nMS rats to controls (p < 0.001) as well as combination RS MS (p = 0.007) 
(Table 3.2).  nRS MS and RS MS rats were not statistically different from one another with 
regards to the total distance travelled (p = 0.112) but were shown to be significantly different 
from the controls and restraint stress groups in this regard (Table 3.2).  As seen with the FST, 
profiler rats showed a similar trend for total distance travelled when compared to statistics 
representative of all rats used (Figure 3.3).  In summary, from observations in the OFT, nRS 
MS and RS MS rats therefore showed the highest levels of anxiety-like behaviours (as 
measured by total distance travelled values), but were not found to be significantly different 
from each other.  RS nMS showed the least anxious phenotype, however, this was still found 
to be significantly higher than the control group. 
 
Table 3.2: Fisher’s LSD test for variability in total distance travelled between stressor-
groups for the open field test (OFT) 
GROUP 
TDT 
mean 
(cm) 
+-SD 
(cm) 
nRS nMS 
(p-value) 
RS nMS 
(p-value) 
nRS MS 
(p-value) 
RS MS 
(p-value) 
nRS nMS 545.743 17.147  0.000 0.226 0.007 
RS nMS 575.468 17.147 0.000  0.001 0.073 
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nRS MS 660.126 17.847 0.226 0.001  0.112 
RS MS 614.722 17.147 0.007 0.073 0.112  
*nRS nMS = controls; RS nMS = RS; nRS MS = MS; RS MS = RS-MS; TDT = total distance 
travelled 
 
Assessment of the duration spent within the center zone indicated that the control group spent 
the most time in this area, compared to stress-applied groups and this was used as base-line 
anxiety (low anxiety) (Figure 3.5), and observed to be the lowest compared to the other 
groups.  RS nMS rats showed the lowest mean time spent within the center zone compared to 
controls (p = 0.028) followed closely by the maternally separated rats.   
 
 
 
Figure 3.3: Least square (LS) mean total distance 
travelled values for restraint-stress (RS nMS), maternal-
separation (nRS MS), combination restraint-maternal 
separation (RS MS) and controls (nRS nMS).  Statistical 
significances are indicated by letters a, b and c  with 
differing letters showing significant differences between 
those groups. 
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Figure 3.5: Duration within the center zone for restraint -
stress (RS nMS), maternal-separation (nRS MS), 
combination restraint-maternal separation (RS MS) and 
controls (nRS nMS). Statistical significances are 
indicated by letters a and b, with differing letters 
showing significant differences between those groups.  
 *LS = least squares 
 
Group; LS Means (Profiler Rats)
nRS nMS nRS MS RS nMS RS MS
Group
48.0
48.2
48.4
48.6
48.8
49.0
49.2
49.4
49.6
49.8
50.0
50.2
D
u
ra
ti
o
n
 i
n
 Z
o
n
e
 (
s
e
c
)
Duration within center zone for Open Field Test (OFT) 
b
b 
a 
Figure 3.4: Least square (LS) mean total distance 
travelled values for restraint-stress (RS nMS), maternal-
separation (nRS MS), combination restraint-maternal 
separation (RS MS) and controls (nRS nMS).  Statistical 
significances are indicated by letters a, b and c with 
differing letters showing significant differences between 
those groups. 
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3.1.1.3. Elevated-Plus Maze (EPM) 
 
In the EPM test, increased time spent within the closed-arms is indicative of anxiety.  When 
considering stressor groups and control rats together, there was an overall increase in 
preference for the closed arms (Figure 3.6) (p < 0.001).   
Figure 3.6: Least squares (LS) mean duration within 
closed and open arms for all rats.  
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3.2. RNA quantification and qualification 
 
RNA was quantified and the integrity assessed using the Experion RNA StdSens RNA 
Analysis kit and Experion automated electrophoresis system (Biorad - Parklands, 
Johannesburg).  An example of the digital RNA images indicating RNA quality can be seen 
below (Figure 3.7).  RNA Quality Indicator (RQI) values of 7 or above were considered 
adequate for subsequent cDNA conversion (Appendix II) (Denisov et al., 2008). 
   
 
 
 
 
Figure 3.7: Digital gel image obtained using Experion machine (Biorad – 
Parklands, Johannesburg) indicating the quality of RNA extracted from rat 
striatal tissue samples. Experion RNA ladder used.  “S(n)” refers to striatal 
sample and sample number. 
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3.3. RT2 ProfilerTM Array, Synaptic Plasticity Pathway 
 
cDNA synthesis was performed using the RT
2 
First Strand Kit (Qiagen) to ensure optimal 
results when using the RT
2 
Profiler Array.  cDNA quality was assessed using the RT
2
 QC 
Array according to the manufacturer’s instructions.  All samples passed quality control. 
The expression of 84 genes involved in the synaptic plasticity pathway was assessed using 
the Rat Synaptic Plasticity PCR Array, PARN – 126Z (SABiosciences, Germany).  A total of 
8 rats for each group (i.e. RS nMS, nRS MS, RS MS and controls) were utilized in the PCR 
array analysis based on a combination of the best behavioural data assessment (i.e. rats that 
showed the highest immobility, total distance travelled and duration within closed arm scores 
in FST, OFT and EPM, respectively, relative to controls), RQI assessment values, and QC 
array scores (according the manufacturer’s recommendations).  Analysis was performed 
online at http://www.sabiosciences.com/pcrarraydataanalysis.php according to the 
manufacturer’s instructions. 
Several genes were found to be differentially expressed in the stress-exposed rats compared 
to the control rat group.  Candidate susceptibility genes were subsequently selected on a basis 
of differential expression values greater than or equal to 1.7-fold (Table 3.3 and Figure 3.8) 
(Wurmbach et al., 2002; Pfaffl et al., 2003).  These were Bdnf, Mmp9, Arc, Grm2, Egr4, Egr2 
and Ntf4. 
 
Table 3.3: Fold-regulation representing differential expression of 1.7-fold or greater for 
RS nMS, nRS MS and RS MS rats, compared to controls 
EXPERIMENT GENE FOLD +/- 
nRS MS vs. nRS nMS 
Mmp9 + 1.80 
Bdnf + 1.97 
Egr4 + 2.20 
Arc + 1.80 
RS nMS vs. nRS nMS Bdnf + 3.22 
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Egr4 + 2.15 
Arc + 1.90 
Ntf4 + 2.19 
MS RS vs. nRS nMS 
Bdnf + 3.33 
Egr2 + 2.04 
Egr4 + 2.14 
Arc + 2.12 
Ntf4 + 2.65 
Grm2 - 1.80 
*(+) = up-regulation; (-) = down-regulation relative to the control (nRS nMS) group 
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Figure 3.8: Graphical representation of fold-regulation increases and decreases 
in gene expression from the synaptic plasticity pathway, normalized to 1 
(relative to control rats) (as depicted in Table 3.3).  Fold-regulation values 
>1.7-fold were considered and are depicted.  
 
Stellenbosch University  http://scholar.sun.ac.za
Chapter 3: Results 
66 
 
 
3.4. Human Work 
 
3.4.1. Clinical data 
 
The human cohort comprised 92 cases (52 with a primary diagnosis of OCD, 18 with PD and 
22 with SAD) and 194 healthy controls for which information regarding age, sex, 
comorbidity and childhood trauma was available.  Ages at interview, as well as the ages of 
males and females, were similar between cases and control groups (Table 3.4).  The mean 
total CTQ score (CTQtot) for patients (43.84 +/- 16.97) was significantly higher than controls 
(34.60 +/- 11.64) (p < 0.001, unpaired t-test; Welch’s correction), suggesting that patients 
reported significantly higher levels of childhood trauma compared to controls (Table 3.4 and 
Figure 3.9).  The control cohort was not interviewed and is representative of the general 
population (and matched with patients in terms of ethnicity), but as a convenience cohort.  As 
an assumed representative of the general population, they were taken as a gross 
approximation of the general population with regards to the investigated conditions (OCD, 
SAD and PD).  Comorbidity with major depressive disorder (MDD) was assessed within the 
patient group, but not controls.  The same assumptions where therefore made for MDD 
amongst the control cohort, i.e. similar rates of MDD as the average population. 
 
Table 3.4: Demographic and clinical characteristics of patient and control cohorts 
Variable Patients Controls p-value 
 
92 194 - 
Male (n) (%) 33 (36) 83 (43) - 
Female (n) (%) 58 (64) 111 (57) - 
Age (yrs. +/- SD) 36.82 +- 13.37 36.60 +- 13.49 - 
Comorbid MDD (n) (%) 65 (70) NA - 
CTQea mean (SD) 10.31 +- 5.54 7.38 +- 3.32 < 0.001  
CTQpa  mean ( SD) 7.73 +- 3.90 6.68 +- 2.83 0.014  
CTQsa  mean (SD) 7.63 +- 5.06 5.78 +- 2.60 < 0.001  
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*CTQea = emotional abuse; CTQen = emotional neglect; CTQpa = physical abuse; CTQpn 
= physical neglect; CTQsa = sexual abuse; CTQtot = total CTQ score; MDD: =major 
depressive disorder; n = number of; NA = not assessed; SD = standard deviation; p-values 
indicated statistically significant differences between patients and controls for the 
components of the CTQ scale 
 
 
3.4.1.1. CTQ scale interaction 
 
CTQ scores of patients and controls were compared using Student’s t-test. The groups 
differed significantly on all subscales except for physical neglect (Table 3.4).  As noted 
above, total severity of childhood trauma was significantly worse in patients compared to 
controls (p < 0.001).  Table 3.4 indicates variables considered as possible covariates for 
inclusion in subsequent statistical analyses (gene-environment correlation and interaction).  
As indicated, CTQ total score (a cumulative representation of the sub-components to be used 
CTQen  mean (SD) 11.39 +- 5.14 8.2 +- 3.76 < 0.001  
CTQpn mean (SD) 6.77 +- 2.87 6.55 +- 2.78 0.539 
CTQtot  mean (SD) 43.84 +- 16.97 34.60 +- 11.64 < 0.001  
Figure 3.9: Box-plot representation of CTQtot score differences between cases 
and control cohorts.  CTQtot scores were significantly different between cases 
and controls (p < 0.001) 
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for consideration in further analyses) meets criteria for covariate inclusion (statistically 
significance in cases compared to controls).  
 
3.4.2. TagSNP identification 
 
Genes identified to be differentially expressed via the RT
2
 Profiler Array were assessed using 
a TaqSNP approach.  The HapMap project online database (www.hapmap.org), using 
HapMap genome browser release #27 (Phase II & III – merged genotypes and frequencies) 
on Feb09, on NCBI B36 assembly, dbSNP b126 was utilized to identify tagSNPs (MAFs of ≥ 
0.2 and R
2
 ≥ 0.8 used at cut-offs) in the human homologues of Bdnf and Mmp9 (Table 3.5), 
BDNF and MMP9.  The CEU (Utah residents with ancestry from Northern and Western 
Europe) population was used in TagSNP identification and all the identified TagSNPs were 
selected for inclusion in this study.  The HapMap database did not possess sufficient 
population-specific genotyping information for the remaining 5 gene homologues (NTF4, 
ARC, GRM2, EGR2 and EGR4).   
 
Table 3.5: TagSNPs selected for BDNF and MMP9 screening based on CEU 
GENE TagSNPs Other alleles Captured 
BDNF 
rs6265 None 
rs925948 None 
rs7103411 rs6484320 
rs11030104 rs16917237 
rs2049045 None 
rs1401635 
rs11030108 
rs1013402 
rs7124442 
rs7127507 
rs10835210 
rs7103873 
rs11030101 
rs11030107 rs10835211 
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rs11030102 
rs11030109 None 
rs28383487 n/a 
MMP9 
rs2274755 None 
rs2236416 
rs2274756 
rs3918261 
rs17576 rs3918249 
rs3918253 rs3918256 
rs1805088 None 
rs3787268 None 
rs3918242 n/a 
rs17577 n/a 
rs13925 n/a 
* MAFs of ≥ 0.2 and R2 ≥ 0.8 used at cut-offs; CEU: Utah residents with Northern and 
Western European decent according to the HapMap database. 
 
3.4.3. SMART assessment and inter-species conservation 
 
The remaining 5 genes were subjected to SMART assessment to identify core domain regions 
in the proteins for which they encode.  Core domains were identified in 4 of the 5 candidate 
proteins.  The ARC gene was subjected to an inter-species conservation assessment after no 
core domains were identified for the ARC protein. A 301 bp (mouse) and 326 bp (rat) region 
involving the immediate 3’UTR promoter region, as well as the first exon, was found to be 
highly conserved when related to the Homo sapiens species (Table 3.6). 
 
Table 3.6: Core domains and inter-species conservation sites in EGR2, EGR4, NTF4, 
GRM2 and ARC 
Gene Domain Amino acid bp Polymorphisms Type 
EGR2 Zn_C2H2 340 - 364 72 CM993142 coding unknown 
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rs104894161 nonsynonymous 
rs147417827 nonsynonymous 
rs45602133 synonymous 
Zn_C2H2 370 - 392 66 
CM004043 coding unknown 
rs104894160 nonsynonymous 
Zn_C2H2 398 - 420 66 
rs104894159 nonsynonymous 
rs121434563 nonsynonymous 
EGR4 
Zn_C2H2 380 - 404 72 
rs145518054 synonymous 
rs147950764 synonymous 
rs7558708 synonymous 
rs139071376 synonymous 
rs146218927 nonsynonymous 
Zn_C2H2 410 -  432 66 rs146026377 synonymous 
Zn_C2H2 438 - 460 66 
rs149141742 nonsynonymous 
rs141733943 nonsynonymous 
NTF4 NGF 89 - 202 339 
rs149008630 synonymous coding 
rs145846156 nonsynonymous 
rs144842220 nonsynonymous 
rs62127897 synonymous 
rs34922845 frameshift 
rs140946623 nonsynonymous 
rs147294437 synonymous 
rs144346396 nonsynonymous 
GRM2 
Transmembrane 567 - 589 66 rs1054625 synonymous 
Transmembrane 602 - 624 66 None - 
Transmembrane 634 - 651 51 rs150657954 synonymous 
Transmembrane 678 - 700 66 
rs61729081 nonsynonymous 
rs138903693 nonsynonymous 
rs61729078 synonymous 
Transmembrane 728 - 747 57 
rs144440968 synonymous 
rs148405091 synonymous 
rs149954328 synonymous 
rs145802255 nonsynonymous 
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Transmembrane 760 - 782 66 rs143499566 synonymous 
Transmembrane 797 - 819 66 rs149853208 nonsynonymous 
Inter-species conservation analysis 
Gene Species Location bp 
ARC 
Conserved Region 
Mouse (mm9) - exon & UTR 
chr8: 143692410 - 
143692710 
 (80.1%  Identity) 
301 
 
Conserved Region 
Rat (rn4) – exon and UTR 
chr8: 143692410 – 
143692735 
(77.9% Identify) 
326 
*chr8 = chromosome 8; Zn_C2H2 = Zinc-finger binding domain; NGF = nerve growth 
factor; UTR = un-translated region 
 
A graphical representation of the conserved regions identified for the ARC specified genomic 
region (chr8: 143692410 – 143695833) can be seen in Figure 3.10 (ECRbrowser V 2.0) 
(Ovcharenko et al., 2004).  The figure highlights both core evolutionary conserved regions 
(core ECRs) (A), which comprised UTR and coding exonic regions; as well as the full ECR 
annotation for the gene (B). 
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3.5. Next-generation sequencing (NGS) 
 
Next-generation sequencing yielded 6.4 gigabases (G) total data, more than 75% of which 
had a Q-Score greater than 30 (error rate of 1 in 1000) (Table 3.8).  Initial alignment of PhiX 
spike was at ~ 30% meaning the remaining ~70% of data pertained to the pooled library 
samples. 
 
3.5.1. Variation 
 
Variant calling was performed according to the default settings of the MiSeq Reporter 2.1 
software (Illumina).  MiSeq Reporter software v 2.1 utilizes algorithms which transform 
Phred-scaled [Phil Green’s PHRED base-calling software where PhredScore = -10log (10Є)] 
genotype likelihoods into variation scores that GATK (Genome Analysis Toolkit) can use 
A 
B 
Figure 3.10: Graphical representation of sequencing conservation between 
human, rat and mouse species for ARC using rVista and ECRbrowser 
(http://rvista.dcode.org and http://ecrbrower.dcode.org). The X-axis 
represents the genomic region and Y-axis the percentage sequence 
conservation for the right-margin indicated species, relative to Homo 
sapiens.  A: core evolutionary conserved regions (ECRs) only. B: all ECRs. 
*Blue: coding exons; Yellow: UTRs; Red: intergenic regions; Green: 
transposons and simple repeats; Pink: ECRs 
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internally.  This allows for reliable and accurate quality  (Q) scores (Quail et al., 2012).  A 
total of 300 SNPs and 76 insertions/ deletions (indels) were identified across the five 
amplicons amongst the 12 patients and 19 controls (see Section 2.7.4) subjected to NGS.  Of 
these, 103 SNPs and 9 indels passed all default filter criteria set by the MiSeq Reporter 
software (according to the manufacturer’s recommendations and a minimum of 10X read 
depth per included SNP).  The quality control and yields are presented in Table 3.7.  
Furthermore, 38 SNPs and 4 indels were found to be unique to either patient or control 
individuals only.  These variants can be seen in Table 3.8 below.  The frequency listed refers 
to the frequency of that variant at that particular coverage depth (referred to as ‘Depth’ in 
Table 3.8).  Only 7 of the 42 (16.67%) variations identified were classified on the dbSNP 
and/ or alternative databases (Ensembl and 1000 Genomes).  The remaining 83.33% of 
unique pass variation identified was therefore novel. 
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Table 3.7: MiSeq Analysis Software NGS paired-end run summary indicated total yield data and quality (Q30) of data produced 
Lane 
Yield 
Total 
(G) 
Projected Total 
Yield (G) 
Yield 
Perfect 
(G) 
Yield <= 3 
errors (G) 
Aligned 
(%) 
% Perfect 
[Num Cycles] 
% <= 3 errors 
[Num Cycles] 
Error 
Rate (%) 
Intensity 
Cycle 1 
% Intensity 
Cycle 20 
% >= 
Q30 
Read 
1 
3.1 3.1 0.6 0.9 29.98 67.2 [250] 91.7 [250] 1.17 121 140.1 75.3 
Read 
2 
0.1 0.1 0.0 0.0 0.00 0.0 [7] 0.0 [7] 0.00 339 0.0 64.1 
Read 
3 
0.1 0.1 0.0 0.0 0.00 0.0 [7] 0.0 [7] 0.00 93 0.0 66.7 
Read 
4 
3.1 3.1 0.5 0.8 28.94 53.2 [250] 84.3 [250] 1.51 117 130.2 59.9 
Total 6.4 6.4 1.1 1.6 29.46 60.3 88.1 1.34 168 135.1 67.5 
*G = gigabases; Num = number 
 
 
Table 3.8: Variation identified with NGS unique to either patient or control individuals only 
 Sample Chromosome Location Type Variation Frequency Depth dbSNP MAF 
current/dbSNP 
Gene Intron/ Exon/ UTR 
 Patient chr19 49563625 SNP T>G 0.22 54 novel  NTF4 3' UTR 
 Patient chr19 49565418 SNP G>A 0.52 250 rs77113200 0.04/0.12 NTF4 Intron 1 
 Patient chr19 49565472 SNP C>T 0.24 58 novel  NTF4 Intron 1 
 Patient chr19 49565762 SNP C>T 0.46 249 novel  NTF4 Intron 1 
 Patient chr3 51741114 SNP C>G 0.25 16 novel  GRM2 Exon 1 (NonCoding) 
 Patient chr3 51741512 SNP T>G 0.41 245 novel  GRM2 Intron 1 
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 Patient chr3 51743789 SNP G>A 0.22 88 novel  GRM2 Intron 2 
 Patient chr3 51743972 SNP G>A 0.27 15 novel  GRM2 Intron 2 
 Patient chr3 51744568 SNP G>T 0.48 182 novel  GRM2 Intron 2 
 Patient chr3 51745321 SNP C>T 0.47 249 rs149905463 0.02/0.0006 GRM2 Intron 2 
 Patient chr3 51746173 SNP C>T 0.23 26 novel  GRM2 Intron 2 
 Patient chr3 51746239 SNP G>A 0.41 157 rs113426529 0.05/0.011 GRM2 Intron 2 
 Patient chr3 51744609 Indel AG>-- 0.36 159 rs140701867  GRM2 Intron 2 
 Patient chr3 51748891 Indel TT>-- 0.26 249 novel  GRM2 Intron 3 
 Control chr19 49563243 SNP C>A 0.33 21 novel  NTF4 3' UTR 
 Control chr19 49563812 SNP C>G 0.26 35 novel  NTF4 3' UTR 
 Control chr19 49564944 SNP A>C 0.32 247 novel  NTF4 Exon2 
 Control chr19 49565936 SNP G>T 0.24 21 novel  NTF4 Intron 1 
 Control chr19 49566491 SNP C>T 0.21 33 novel  NTF4 Exon 1 
 Control chr19 49566492 SNP A>G 0.21 33 novel  NTF4 Exon 1 
 Control chr19 49566727 SNP A>C 0.23 248 novel  NTF4 Exon 1 
 Control chr19 49567376 SNP G>A 0.65 250 rs34619524  NTF4 3' UTR 
 Control chr3 51741138 SNP C>T 0.42 166 rs149387441 0.06/0.019 GRM2 Exon 1 (NonCoding) 
 Control chr3 51745540 SNP C>T 0.59 250 novel  GRM2 Intron 2 
 Control chr3 51747245 SNP A>C 0.26 248 novel  GRM2 Exon 3 
 Control chr3 51747288 SNP G>A 0.45 227 rs116567227 0.02/0.01 GRM2 Exon 3 
 Control chr3 51749957 SNP A>C 0.29 245 novel  GRM2 Exon 4 
 Control chr3 51750091 SNP A>C 0.26 247 novel  GRM2 Exon 4 
 Control chr3 51751642 SNP A>C 0.23 247 novel  GRM2 Intron 4 
 Control chr3 51751994 SNP A>C 0.29 245 novel  GRM2 Intron 5 
 Control chr10 64575010 SNP T>C 0.39 247 novel  EGR2 Intron 1 
 Control chr10 64575034 SNP A>C 0.29 248 novel  EGR2 Intron 1 
 Control chr10 64575357 SNP A>C 0.24 247 novel  EGR2 Intron 1 
 Control chr10 64575417 SNP T>C 0.64 250 rs7893472 0.04/0.14 EGR2 Intron 1 
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 Control chr10 64576915 SNP A>C 0.3 244 novel  EGR2 5' UTR 
 Control chr10 64577757 SNP A>G 0.48 247 novel  EGR2 5' UTR 
 Control chr10 64577870 SNP G>A 0.45 62 novel  EGR2 5' UTR 
 Control chr10 64577871 SNP C>A 0.41 63 novel  EGR2 5' UTR 
 Control chr10 64577986 SNP A>G 0.21 19 novel  EGR2 5' UTR 
 Control chr2 73519479 SNP A>G 0.46 11 novel  EGR4 Exon 2 
 Control chr19 49566045 Indel -- >GT 0.29 17 novel  NTF4 Intron 1 
 Control chr19 49568047 Indel - >C 0.47 209 novel  NTF4 5' UTR 
*chr3/19/10/2 = chromosome 3/ 19 /10/2; Indel = insertion or deletion; SNP = single nucleotide polymorphism; UTR = un-translated region; 
MAF = minor alleles frequency (dbSNP) 
*’Frequency’ refers to that of the variant allele and ‘Depth’ refers to the read depth coverage for that particular variant 
* Variant is underlined in ‘Variation’ column
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3.5.2. Genotyping 
 
Genotyping was performed for the 92 patients and 194 controls for which CTQ score data 
was available as well as in an expanded sample of 626 patients and 638 controls (without 
CTQ data).  As noted previously, there were significantly higher numbers of females in both 
the patient and control cohorts; gender was thus entered as covariate into the analyses.   
In the following sections, I will firstly report on the bi-allelic loci association testing, and 
then GxE correlations and GxE interactions.  
 
3.5.2.1. Bi-allelic loci association testing 
 
Table 3.9 depicts the results of case-control association analyses for unadjusted, adjusted and 
interaction with CTQ total score for TaqSNPs and NGS SNPs considered, and genotyped in 
the extended genotyping cohort.  Of the 42 polymorphisms identified using NGS and the 19 
SNPs using a TagSNP approach, 26 were found to be informative and were considered for 
further analyses (Table 3.9). Statistically significant associations were observed for 5 SNPs 
(MMP9: rs3918242, rs1805088; BDNF: rs6265 (Val66Met), rs10835210; and GRM2: 
rs116567227).  Deviation from Hardy Weinberg Equilibrium (HWE) was observed for SNPs 
rs1805088 and could not be calculated for rs116567227 due to its low frequency within the 
screened cohort.  It is generally accepted that HWE deviation in cases (where HWE is met 
within controls), points to possible association of that polymorphism with the specific 
disorder under investigation.  This was observed for SNP rs2049045 in BDNF only.  For 
MMP9’s rs17576 and BDNF’s rs925948 HWE was found to be met within the cases cohort, 
but deviated in controls.  MMP9’s rs1805088 presented with HWE deviation in both the case 
and control groups.  The increased frequency for the CC genotype (ancestral) within both 
cases and controls appears responsible for the skew. 
 
Stellenbosch University  http://scholar.sun.ac.za
Chapter 3: Results 
78 
 
Table 3.9: Genotype, allele frequencies and significant associations for polymorphisms 
in anxiety disorder cases vs. healthy controls, as well as CTQ total score interaction with 
designated polymorphisms on anxiety disorders diagnosis  
 Controls HWE Anxiety Cases HWE Association P-Val 
Count
a
 Freq
b
 P-Val Count
a
 Freq
b
 P-Val Unadjusted
c 
Adjusted
d 
CTQtot 
Interaction
e 
MMP9 
rs3918242 210 
 
1 279 
 
0.24 
   
C/C 201 0.96   231 0.83   0 0 0.179 
C/T 9 0.04   48 0.17         
C 411 0.98   510 0.91   0 0 0.179 
T 9 0.02   48 0.09         
 rs17577 183   0.170 331   0.352       
G/G 142 0.78   249 0.75   0.766 0.775 0.127 
G/A 36 0.2   74 0.22         
A/A 5 0.03   8 0.02         
G 320 0.87   572 0.86   0.651 0.651 0.894 
A 46 0.13   90 0.14         
 rs2274755 170   0.312 313   0.439       
G/G 131 0.77   242 0.77   0.95 0.96 0.134 
G/T 35 0.21   65 0.21         
T/T 4 0.02   6 0.02         
G 297 0.87   549 0.88   0.879 0.906 0.73 
T 43 0.13   77 0.12         
rs2236416 186   0.314 332   0.619       
A/A 145 0.78   255 0.77   0.896 0.902 0.104 
A/G 37 0.2   71 0.21         
G/G 4 0.02   6 0.02         
A 327 0.88   581 0.88   0.852 0.835 0.541 
G 45 0.12   83 0.12         
rs17576 187   0.017 325   0.713       
A/A 84 0.45   137 0.42   0.081 0.072 0.235 
A/G 71 0.38   151 0.46         
G/G 32 0.17   37 0.11         
A 239 0.64   425 0.65   0.641 0.671 0.453 
G 135 0.36   225 0.35         
 rs3918253 183   0.066 326   0.427       
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T/T 70 0.38   107 0.33   0.121 0.145 0.695 
T/C 76 0.42   166 0.51         
C/C 37 0.2   53 0.16         
T 216 0.59   380 0.58   0.821 0.725 0.914 
C 150 0.41   272 0.42         
 rs1805088 201   0 362   0       
C/C 166 0.83   325 0.9   0.002 0.002 0.309 
C/T 23 0.11   13 0.04         
T/T 12 0.06   24 0.07         
C 355 0.88   663 0.92   0.168 0.164 0.158 
T 47 0.12   61 0.08         
 rs3787268 172   0.097 308   0.316       
G/G 103 0.6   191 0.62   0.628 0.634 0.309 
G/A 55 0.32   99 0.32         
A/A 14 0.08   18 0.06         
G 261 0.76   481 0.78   0.453 0.476 0.925 
A 83 0.24   135 0.22         
 rs13925 177   0.180 331   0.33       
G/G 136 0.77   252 0.76   0.928 0.934 0.102 
G/A 36 0.2   71 0.21         
A/A 5 0.03   8 0.02         
G 308 0.87   575 0.87   0.949 0.959 0.644 
A 46 0.13   87 0.13         
BDNF 
 rs6265 210   0.236 370   0.109       
G/G 145 0.69   173 0.47   0 0 0.007 
G/A 56 0.27   170 0.46         
A/A 9 0.04   27 0.07         
G 346 0.82   516 0.7   0 0 0.034 
A 74 0.18   224 0.3         
 rs925948 125   0.012 346   1       
G/G 123 0.98   344 0.99   0.255 0.258 NA 
G/A 1 0.01   2 0.01         
A/A 1 0.01   0 0         
G 247 0.99   690 1   0.182 0.175 NA 
A 3 0.01   2 0         
 rs7103411 180   0.826 330   1       
T/T 111 0.62   227 0.69   0.181 0.162 0.924 
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T/C 60 0.33   94 0.28         
C/C 9 0.05   9 0.03         
T 282 0.78   548 0.83   0.068 0.06 0.589 
C 78 0.22   112 0.17         
 rs11030104 150   0.795 252   0.831       
A/A 98 0.65   170 0.67   0.774 0.758 0.402 
A/G 46 0.31   75 0.3         
G/G 6 0.04   7 0.03         
A 242 0.81   415 0.82   0.552 0.524 0.67 
G 58 0.19   89 0.18         
rs2049045 162   0.051 306   0.02       
G/G 117 0.72   236 0.77   0.244 0.239 0.023 
G/C 45 0.28   70 0.23         
G 279 0.86   542 0.89   0.244 0.239 0.023 
C 45 0.14   70 0.11         
rs1401635 164   0.144 306   0.509       
G/G 82 0.5   146 0.48   0.716 0.633 0.149 
G/C 62 0.38   127 0.42         
C/C 20 0.12   33 0.11         
G 226 0.69   419 0.68   0.894 0.834 0.099 
C 102 0.31   193 0.32         
rs10835210 164   0.52 292   0.641       
C/C 52 0.32   73 0.25   0.036 0.043 0.009 
C/A 85 0.52   142 0.49         
A/A 27 0.16   77 0.26         
C 189 0.58   288 0.49   0.016 0.02 0.067 
A 139 0.42   296 0.51         
rs11030107 114   0.157 220   0.075       
A/A 63 0.55   128 0.58   0.811 0.783 0.036 
A/G 39 0.34   73 0.33         
G/G 12 0.11   19 0.09         
A 165 0.72   329 0.75   0.529 0.492 0.19 
G 63 0.28   111 0.25         
rs11030109 146   1 313   1       
G/G 137 0.94   295 0.94   0.861 0.852 0.58 
G/A 9 0.06   18 0.06         
G 283 0.97   608 0.97   0.861 0.852 0.58 
A 9 0.03   18 0.03         
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rs28383487 172   1 287   1       
G/G 163 0.95   271 0.94   0.875 0.879 0.873 
G/T 9 0.05   16 0.06         
G 335 0.97   558 0.97   0.875 0.879 0.873 
T 9 0.03   16 0.03         
NTF4 
rs77113200 104   1 81   1       
G/G 100 0.96   77 0.95   0.718 0.749 1 
G/A 4 0.04   4 0.05         
G 204 0.98   158 0.98   0.718 0.749 1 
A 4 0.02   4 0.02         
GRM2 
SNP_06_GRM2 103   1 79   1       
T/T 100 0.97   77 0.97   0.876 0.887 0.101 
T/G 3 0.03   2 0.03         
T 203 0.99   156 0.99   0.876 0.887 0.101 
G 3 0.01   2 0.01         
rs149905463 104   1 80   1       
C/C 101 0.97   78 0.98   0.873 0.882 0.097 
C/T 3 0.03   2 0.02         
C 205 0.99   158 0.99   0.873 0.882 0.097 
T 3 0.01   2 0.01         
rs113426529 101   1 77   1       
G/G 95 0.94   74 0.96   0.532 0.495 0.042 
G/A 6 0.06   3 0.04         
G 196 0.97   151 0.98   0.532 0.495 0.042 
A 6 0.03   3 0.02         
rs149387441 102   1 79   1       
C/C 95 0.93   75 0.95   0.613 0.646 0.302 
C/T 7 0.07   4 0.05         
C 197 0.97   154 0.97   0.613 0.646 0.302 
T 7 0.03   4 0.03         
rs116567227 105   1 81   -999       
G/G 100 0.95   81 1   0.016 0.016 1 
G/A 5 0.05   0 0         
G 205 0.98   162 1   0.016 0.016 1 
A 5 0.02   0 0         
EGR2 
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rs7893472  103   1 81   1       
T/T 98 0.95   78 0.96   0.702 0.736 1 
T/C 5 0.05   3 0.04         
T 201 0.98   159 0.98   0.702 0.736 1 
C 5 0.02   3 0.02         
 a
Genotype and allelic counts; 
b
Genotype and allelic frequency; 
c
P-value for association 
between polymorphism and anxiety disorder status, unadjusted. An additive model was used 
for the allelic effect; 
d
P-value for association between polymorphism and anxiety disorder 
status, adjusted for gender and age. An additive model was used for the allelic effect.  
e
P-
value for interaction between CTQtot with relevant SNP, adjusted for gender and age.   
*-999: HWE could not be calculated due to exceedingly small sample numbers for that 
particular scenario. **NA: implies insufficient genotyping information available to perform 
analysis.  ***Blue: indicates trends towards significance or borderline significant values.  
****Red: significant values. 
 
3.5.2.2. Gene-environment correlation 
 
Genetic risk, as identified by polymorphisms within a gene, may be inferred by the 
observation of the increased likelihood that an individual be exposed to a particular 
environment, and that that individual may be at increased likelihood to develop a disorder.  In 
the case of anxiety disorders, genetic risk may be identified by investigating variation within 
an anxiety disorders cohort for which higher severity of childhood trauma has been reported.  
Genetic risk can therefore be expressed by investigating variation in individuals with greater 
exposure towards environmental stressors such as childhood trauma (gene-environment 
correlation) and then subsequently the increased susceptibility to develop anxiety disorders 
(gene-environment interaction), by looking at the interaction these variables may have with 
environmental influence (Lau and Eley, 2008).   
Significant case-control associations for the presence of anxiety disorders diagnoses were 
observed for MMP9 (rs3918242 and rs1805088), BDNF (rs6265 and rs10835210) and GRM2 
(rs116567227). Upon further statistical evaluation the rs3918242 SNP identified with an OR 
value much higher than 1 (4.674) (Table 3.10) for the CT genotype, suggesting that this 
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genotype is associated with > 4X increased susceptibility risk to develop anxiety disorders.  
Considering allelic contribution, a significant p-value was identified for the T allele as well; 
however, no homozygous TT genotypes were identified within the current study.  This 
scenario has been previously reported in the evaluation of this SNP (Holliday et al., 2007).  
SNPs rs1805088 (MMP9) and rs6265 (BDNF) presented with OR values less than 1 for the 
significantly identified homozygous CC (OR = 0.287) and AG (OR = 0.001) genotypes, 
respectively, suggesting the presence of these genotypes to be associated with a protective 
effect for the presence of anxiety disorders.  Similarly, the rs10835210 (BDNF) 
polymorphism presented with ORs less than 1 for both AC (OR = 0.586) and CC (OR = 
0.504) genotypes.  This polymorphism was therefore also associated with the decreased 
susceptibility risk for anxiety disorders, and this decreased susceptibility was associated with 
the presence of the C allele.  In this case, however, although the presence of the homozygous 
C allele indicated a decreased susceptibility risk, the heterozygous genotype presented with a 
similar OR, indicated that the C allele was not associated with a logarithmic decreased 
susceptibility advantage.  Considering GRM2, although significant association was found for 
rs116567227, due to the absence of the A allele from the case group (only present in 
controls), subsequent analyses could not be performed and further investigation in a larger 
cohort is warranted. 
These polymorphisms were assessed in a cases cohort with a significantly higher severity of 
childhood trauma (p < 0.001), than the controls.  This is suggestive of anxiety diagnosed 
patients being more likely to find themselves in traumatic situations during early 
developmental years, and that the polymorphisms identified and statistically described here 
could be correlated with the development and/ or progression of anxiety disorders.  
 
Table 3.10: Association analysis of polymorphisms investigating genotype distributions 
between cases and controls indicating genes, SNPs, p-values and OR ratios 
Gene SNP Genotype p-Val OR 
CI 
2.50% 97.50% 
MMP9 rs3918242 CT < 0.001 4.674 2.340 10.40 
rs1805088 CC < 0.001 0.287 0.138 0.575 
BDNF rs6265 AG < 0.001 0.001 <0.001 1.317 
rs10835210 AC 0.042 0.586 0.346 0.971 
  CC 0.018 0.504 0.284 0.883 
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OR: Odds ratio where OR < 1 implies a decreased risk for anxiety disorders and OR > 1 
implies an increased risk for anxiety disorders; CI: confidence interval 
 
3.5.2.3. Gene-environment interaction 
 
Gene-environment interaction in the context of this study refers to the phenotypic effect of 
interactions between genes and the environment, whereby a particular genotype (or allele) 
can be associated with altered susceptibility risk to developing anxiety disorders within a 
particular environment.  This was investigated by assessing a genotype-by-CTQ interaction 
term in the R Genetics package of RStudio.  Whilst assessing for gene-environment 
correlation above, it was seen that individuals with a genetic risk for anxiety disorders present 
with increased exposure to childhood trauma, and the following results indicate that this 
exposure influences susceptibility risk to anxiety disorders, demonstrated here by changes in 
odds ratios associated with a particular genotype. 
The interaction of the severity of childhood trauma (as represented by the CTQ total score) 
with the presence of a particular polymorphism was assessed in a case-control fashion.  This 
was to ascertain whether the association between the severity of childhood trauma and the 
presence of anxiety disorders was modified by the presence of a genetic polymorphism 
(Table 3.11). The p-values for polymorphism-by-CTQ total score interaction are depicted in 
the last column of Table 3.9 above.  Significant interaction statistics were identified for four 
SNPs (rs6265, rs2049045, rs10835210, and rs11030107) all found to be located within the 
BDNF gene.  A significant interaction was also identified for the rs113426529 polymorphism 
in the GRM2 gene, however, due to the low frequency of the minor allele this was not 
considered for further statistical analyses.  
Focusing on BDNF, the rs2049045 and rs11030107 polymorphisms did not show significant 
gene-environment correlation (Table 3.11), however presented with p-values of 0.047 and 
0.037, respectively for polymorphisms-CTQ total score interaction assessment (Table 3.11).  
Evaluation of the ORs associated with these polymorphisms within the current dataset 
indicated the rs2049045 variant to be associated with a slight decreased susceptibility risk for 
anxiety disorders (OR = 0.916), whereas the rs11030107 presented with a possible increased 
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susceptibility risk (OR = 1.081) (Table 3.11).  The remaining two variants (rs6265 and 
rs10835210) also presented as possible increased susceptibility risk for anxiety disorders 
upon interaction with CTQ total score; however, these polymorphisms were also previously 
identified to be significant in the gene-environment correlation assessments above.  When 
including the CTQ total score interaction statistic the rs6265 polymorphism previously 
predicted protective effect (OR = 0.001) is completely abolished, OR = 1.132) (Table 3.11).  
The rs10835210 polymorphism falls into the same category as rs6265, where the 
consideration of childhood trauma interaction with this polymorphism negates the predicted 
protective advantage associated with it previously (rs10835210 gene-environment 
correlation: AC, OR = 0.586; CC OR = 0.504 and rs10835210 gene-environment interaction: 
AC, OR = 1.084) (Table 3.11).    
 
Table 3.11: Gene, SNP, p-values and OR ratios for significant interaction of CTQ total 
score (CTQtot) and polymorphisms in anxiety cases vs. controls 
Gene SNP Genotype p-Val OR 
CI 
2.50% 97.50% 
BDNF 
rs2049045 GG 0.047 0.916 0.83 0.99 
rs10835210 AC 0.004 1.084 1.02 1.15 
rs11030107 AG 0.037 1.081 1.01 1.17 
rs6265 AG < 0.001 1.132 0.93 1.33 
OR: Odds ratio where an OR < 1 implies a decreased susceptibility risk for anxiety disorders 
and OR > 1 implies an increased susceptibility risk for anxiety disorders; CI: confidence 
interval 
  
Stellenbosch University  http://scholar.sun.ac.za
Chapter 3: Results 
86 
 
Figure 3.11: LD plots (indicating D’ values) generated using polymorphisms 
genotyped for (A) MMP9 and (B) BDNF.  Haplotype blocks were identified based on 
criteria outlined in Gabriel et al., 2002 (if 95% of informative comparisons are 
strong LD). 
A B 
3.5.3. Haplotype analyses 
 
Here, again, I report on GxE correlations and subsequently on GxE interactions.  
 
3.5.3.1. Gene-environment correlation 
 
As previously mentioned, gene-environment correlation refers to the ability of genetic risk to 
be expressed through anxiety cases presenting with a greater exposure to environmental 
stressors, specifically childhood trauma.  Cases have been shown to be associated with a 
significantly higher severity of childhood trauma, relative to controls (p < 0.001) and they are 
therefore assessed here for haplotype analyses.  
Haplotype analyses was performed for the identified polymorphisms using Haploview and 
confirmed using the LD genetics package in RStudio V 0.97.  Linkage disequilibrium (LD) 
plots with D’ values according to Gabriel et al., 2002’s recommended CI criteria (default 
setting in Haploview) can be seen in Figure 3.11.  Haplotype blocks pertain to 
polymorphisms identified in MMP9 and BDNF genes. 
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Figure 3.12: LD plots (indicating D’ values) generated using polymorphisms 
genotyped for (A) MMP9 and (B) BDNF.  Haplotype blocks were identified based on 
criteria outlined in Gabriel et al., 2002 (if 95% of informative comparisons are 
strong LD) for BDNF, but modified to include rs3918242 and exclude rs3787268 for 
MMP9.  
A B 
No significant haplotype associations were found for the MMP9 gene, however one (BDNF 
*rs11030104-rs1401635-rs10835210-rs7103411: AGAT) in the BDNF gene was found to 
trend towards significance, with increased frequency of the haplotype amongst cases (Table 
3.12). 
 Table 3.12: Haplotype frequencies, χ2 and P-value associations (Gabriel et al., 2002) 
*rs3918253-rs2274755-rs17576-rs2236416-rs3787268-rs17577 (MMP9) 
*rs11030104-rs1401635-rs10835210-rs7103411 (BDNF) 
Block Haplotype Freq. 
Case, Control 
Ratios 
Case, Control  
Frequencies 
χ2 p-value 
MMP9 
TGAAGG 0.582 
362.8:265.2, 201.0:141.0 
0.578, 0.588 0.081 0.776 
CGGAAG 0.215 
129.8:498.2, 80.0:262.0 
0.205, 0.234 1.105 0.293 
CTGGGA 0.123 
78.8:549.2, 40.0:302.0 
0.126, 0.117 0.179 0.672 
CGAAGG 0.061 
43.1:584.9, 16.0:326.0 
0.069, 0.047 1.919 0.166 
 BDNF 
AGAT 0.461 
303.1:320.9, 142.3:197.7 
0.484, 0.419 3.814 0.050 
ACCT 0.291 
174.0:450.0, 105.2:234.8 
0.281, 0.310 0.893 0.345 
GGCC 0.168 
96.0:528.0, 66.3:273.7 
0.153, 0.195 2.76 0.097 
AGCT 0.057 
35.1:588.9, 20.0:320.0 
0.056, 0.059 0.02 0.886 
Freq.: frequency of cases and control haplotypes respectively; χ2: chi-squared 
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Expansion of the haplotype block for MMP9 to include rs3918242 for which significant D’ 
values were obtained and exclude rs3787268 which resulted in a break in LD revealed 
significant associations of two haplotypes in this gene with possible anxiety disorder 
susceptibility (Figure 3.12 and Table 3.13). 
     
Table 3.13: Haplotype frequencies, χ2 and P-value associations, modified Block 
*rs3918242-rs3918253-rs2274755-rs17576-rs2236416-rs17577-rs13925(MMP9) 
*rs11030104-rs1401635-rs10835210-rs7103411 (BDNF) 
Block Haplotype Freq. 
Case, Control 
Ratios 
Case, Control  
Frequencies 
χ2 p-value 
 
MMP9 
CTGAAGG 0.581 
363.1:264.9, 199.9:142.1 
0.579, 0.585 0.031 0.860 
CCGGAGG 0.218 
130.9:497.1, 82.0:260.0 
0.207, 0.240 1.413 0.235 
CCTGGAA 0.063 
30.0:598.0, 31.0:311.0 
0.048, 0.091 6.791 0.009 
CCGAAGG 0.059 
40.7:587.3, 16.0:326.0 
0.065, 0.047 1.357 0.244 
TCTGGAA 0.054 
42.9:585.1, 8.9:333.1 
0.069, 0.026 7.892 0.005 
 
BDNF 
AGAT 0.461 303.1:320.9, 142.3:197.7 0.484, 0.419 3.814 0.050 
ACCT 0.291 174.0 : 450.0, 105.2:234.8 0.281, 0.310 0.893 0.345 
GGCC 0.168 96.0:528.0, 66.3:273.7 0.153, 0.195 2.76 0.097 
AGCT 0.057 35.1:588.9, 20.0:320.0 0.056, 0.059 0.02 0.887 
Freq.: frequency of cases and control haplotypes respectively; χ2: chi-squared 
 
Two haplotypes within the MMP9 gene (rs-3918242-rs3918253-rs2274755-rs17576-
rs2236416-rs3787268-rs17577-rs13925: CCTGGAA and TCTGGAA) were found to be 
statistically significant for susceptibility to anxiety disorders (Table 3.13).  CCTGGAA was 
found to be present at lower frequency within cases compared to controls whereas 
TCTGGAA was higher in cases compared to controls. 
Considering the observation of significant haplotype frequency between cases and controls 
identified (Table 3.13), the MMP9 CCTGGAA haplotype demonstrated a predicted reduced 
susceptibility risk for the development of anxiety disorders with an OR of 0.469 (Table 3.14).  
The other significant haplotype frequency observation in MMP9, TCTGGAA, presented with 
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a predicted 4.6-fold increased susceptibility risk to develop anxiety disorders (OR = 4.608).  
This coincides with the inclusion of the T allele for rs3918242 which presented with a > 4-
fold increased risk in gene-environment correlation bi-allelic association testing in section 
3.4.1.2 (Table 3.10).  One haplotype was identified for the BDNF gene, AGAT.  This 
haplotype was associated with a 2.5-fold increased susceptibility genes to develop anxiety 
disorders (OR = 2.519), and can appropriately be found at higher frequency amongst the 
cases (Table 3.14).   
 
Table 3.14: Significant p-values and OR ratios for significantly identified haplotype 
effects associated with anxiety disorder susceptibility in bottom 33
rd
 percentile (lower 
CTQ total scores) cases vs. control 
*rs3918242-rs3918253-rs2274755-rs17576-rs2236416-rs17577-rs13925(MMP9) 
*rs11030104-rs1401635-rs10835210-rs7103411 (BDNF) 
Gene Haplotype p-Val OR 
CI 
2.50% 97.50% 
MMP9 
CCTGGAA 0.009 0.469 0.429 0.514 
TCTGGAA 0.005 4.608 2.641 8.039 
BDNF AGAT 0.050 2.519 1.990 3.190 
OR: Odds ratio where an OR < 1 implies a decreased susceptibility risk for anxiety disorders 
and OR > 1 implies an increased susceptibility risk for anxiety disorders; CI: confidence 
interval 
 
3.5.3.2. Possible gene-environment interaction? 
 
The statistical assessment of haplotype association in a case-control fashion for a 
polymorphism-CTQ total score interaction component was not possible using the employed 
statistical programming.  To evaluate a possible interaction of the influence that the severity 
of childhood trauma may have on the presentation of haplotype associations between cases 
and controls, analyses were performed for the top 33
rd
 percentile (30 cases, highest CTQ total 
score; mean = 64.36, median = 60.50) and bottom 33
rd
 percentile (30 cases, lowest CTQ total 
scores, mean = 28.9, median = 29) for cases, relative to controls (194 controls representative 
of the general population, mean CTQ total score = 34.60, median CTQ total score = 30.50).  
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Analyses were performed using Haploview.  Linkage disequilibrium (LD) plots with D’ 
values according to Gabriel et al., 2002’s recommended CI criteria (default setting in 
Haploview) can be seen in Figures 3.13 and 3.14.  Haplotype blocks pertain to 
polymorphisms identified in the MMP9 and BDNF genes. 
 
Considering the bottom 33
rd
 percentile of cases, representative of lower CTQ total scores, 
two haplotype blocks were identified (Figure 3.13), one for MMP9 and one for BDNF.  When 
looking at the haplotype analyses performed for the entire cohort in section 3.4.2.1 above, the 
haplotype block for MMP9 was similar (Figure 3.12), except here the rs13925 polymorphism 
is included.  The BDNF haplotype block presented was quite different to that seen in Figure 
3.11 and includes rs6265 and rs11030104, whilst excluding rs7103411 (Figure 3.14).  
Although different haplotype blocks were obtained using this strategy, there were no 
haplotype associations found to be significantly associated with anxiety disorders 
susceptibility for the MMP9 or BDNF genes (Table 3.15), when considering a group of low 
incidence severity for childhood trauma (CTQ total score below 30).  
 
Figure 3.13: LD plots (indicating D’ values) generated using polymorphisms 
genotyped for (A) MMP9 and (B) BDNF comparing the bottom 33
rd
 percentile (low 
CTQ total score) cases to controls.  Haplotype blocks were identified based on 
criteria outlined in Gabriel et al., 2002. 
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Table 3.15: Haplotype frequencies, χ2 and P-value associations for bottom 33rd 
percentile (low CTQ total score) cases vs. controls 
*rs3918253-rs2274755-rs17576-rs2236416-rs3787268-rs17577-13925 (MMP9) 
*rs6265-rs11030104-1401635-rs2049045-rs10835210 (BDNF) 
Block Haplotype Freq. 
Case, Control 
Ratios 
Case, Control  
Frequencies 
χ2 p-value 
MMP9 
TGAAGGG 0.589 18.0:12.0, 201.0:141.0 0.600, 0.588 0.017 0.896 
CGGAAGG 0.239 9.0:21.0, 80.0:262.0 0.300, 0.234 0.664 0.415 
CTGGGAA 0.113 2.0:28.0, 40.0:302.0 0.067, 0.117 0.697 0.404 
CGAAGGG 0.043 0.0:30.0, 16.0:326.0 0.000, 0.047 1.467 0.226 
 
BDNF 
GAGGA 0.42 12.6:17.4, 143.0:197.0 0.419, 0.421 0.000 0.991 
GACGC 0.301 6.2:23.8, 105.3:234.7 0.208, 0.310 1.352 0.245 
AGGCC 0.168 3.9:26.1, 58.4:281.6 0.131, 0.172 0.332 0.565 
GAGGC 0.071 1.9:28.1, 24.3:315.7 0.065, 0.071 0.020 0.888 
GGGGC 0.018 1.2:28.8, 5.5:334.5 0.041, 0.016 0.989 0.320 
Freq.: frequency of cases and control haplotypes respectively; χ2: chi-squared 
 
 
Figure 3.14: LD plots (indicating D’ values) generated using polymorphisms 
genotyped for (A) MMP9 and (B) BDNF comparing the top 33
rd
 percentile (high 
CTQ total score) cases to controls.  Haplotype blocks were identified based on 
criteria outlined in Gabriel et al., 2002.  
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The top 33
rd
 percentile of cases, representative of higher CTQ total scores, also maintained a 
single haplotype block per gene presentation pattern (Figure 3.14).  Considering the 
haplotype analyses performed for the bottom 33
rd
 percentile CTQ total scores individuals 
above, the haplotype block for MMP9 was identical to that seen in Figure 3.13. The BDNF 
haplotype block  for the top 33
rd
 percentile presented with a block identical to that reported in 
section 3.4.2.1 above for haplotype analyses of the entire cohort (Figure 3.12). Although an 
identical haplotype block was obtained for MMP9 here: where there were no significant 
associations identified in the bottom 33
rd
 percentile – here two significant haplotype 
associations were found (MMP9: *rs3918253-rs2274755-rs17576-rs2236416-rs3787268-
rs17577-13925: CGGAAGG and CGAAGGG) (Table 3.16). The CGGAAGG haplotype 
presented with a higher frequency in cases (suggestive of increased susceptibility risk for 
anxiety disorders), whereas CGAAGGG presented with a higher frequency in controls 
(suggestive on decreased susceptibility risk for anxiety disorders).  No significant haplotype 
associations for anxiety disorders were identified for the BDNF gene in the context of the top 
33
rd
 percentile CTQ total score cases relative to controls (Table 3.16), but this may be 
attributed to sample cohort sizes considering the trend towards significance identified for the 
gene-environment correlation analyses above (section 3.4.2.1). 
 
Table 3.16: Haplotype frequencies, χ2 and P-value associations for top 33rd percentile 
(high CTQ total score) cases vs. controls 
*rs3918253-rs2274755-rs17576-rs2236416-rs3787268-rs17577-13925 (MMP9) 
*rs11030104-1401635-rs2049045-rs10835210-rs7103411 (BDNF) 
Block Haplotype Freq. 
Case, Control 
Ratios 
Case, Control  
Frequencies 
χ2 p-value 
 
MMP9 
TGAAGGG 0.595 24.0:12.0, 201.0:141.0 0.667, 0.588 0.843 0.359 
CGGAAGG 0.217 2.0:34.0, 80.0:262.0 0.056, 0.234 6.096 0.014 
CTGGGAA 0.116 4.0:32.0, 40.0:302.0 0.111, 0.117 0.011 0.917 
CGAAGGG 0.056 5.0:31.0, 16.0:326.0 0.139, 0.047 5.266 0.022 
 
BDNF 
AGGAT 0.432 19.8:16.2, 142.5:197.5 0.549, 0.419 2.251 0.134 
ACGCT 0.304 8.9:27.1, 105.6:234.4 0.246, 0.311 0.645 0.422 
GGCCC 0.16 4.0:32.0, 56.2:283.8 0.111, 0.165 0.713 0.398 
AGGCT 0.053 0.4:35.6, 19.7:320.3 0.010, 0.058 1.462 0.227 
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GGGCC 0.033 2.0:34.0, 10.2:329.8 0.056, 0.030 0.672 0.412 
AGGCC 0.012 0.0:36.0, 4.7:335.3 0.000, 0.014 0.499 0.480 
Freq.: frequency of cases and control haplotypes respectively; χ2: chi-squared 
 
Two MMP9 haplotype associations were identified when considering the top 33
rd
 percentile 
CTQ total score cases (representative of the higher CTQ total scores) (Table 3.16).   The 
MMP9 CGGAAGG demonstrated a predicted reduced susceptibility risk for the development 
of anxiety disorders with an OR of 0.890 (Table 3.17).  A second haplotype, CGAAGGG, was 
associated with a 1.7-fold increased susceptibility risk (OR = 1.721).  In this case the 
haplotype did not contain the rs3918242 polymorphism associated with the > 4-fold risk for 
developing anxiety disorders, inferring that alternate polymorphisms may exist within the 
MMP9 gene that could negatively influence susceptibility risk. 
 
Table 3.17: Significant p-values and OR ratios for significantly identified haplotype 
effects associated with anxiety disorder susceptibility in top 33
rd
 percentile (higher CTQ 
total scores) cases vs. control 
*rs3918253-rs2274755-rs17576-rs2236416-rs3787268-rs17577-13925 (MMP9) 
Gene Haplotype p-Val OR 
CI 
2.50% 97.50% 
MMP9 
CGGAAGG 0.014 0.890 0.865 0.916 
CGAAGGG 0.022 1.721 1.548 1.913 
OR: Odds ratio where and OR < 1 implies a decreased susceptibility risk for anxiety 
disorders and OR > 1 implies an increased susceptibility risk for anxiety disorders; CI: 
confidence interval 
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4. Discussion 
 
Chapter 4 presents a detailed discussion of the findings and summarized descriptions of the 
results presented in Chapter 3. The relevance and relatedness of the novel susceptibility genes 
that were identified are addressed and an account of the genotyping findings after 
extrapolation onto a human cohort is provided. 
 
4.1. Animal Work 
 
4.1.1. Environmental intervention animal model 
 
The Sprague Dawley rats used in this study comprised an outbred model.  This allowed for a 
better representation of the molecular genetics involved than an inbred model considering the 
genetic heterogeneity that would be observed in an unrelated human study cohort.  The 
environmental stressors implemented in the present study (i.e. maternal separation and 
restraint stress) are well established models for eliciting anxiety-like behaviours in rodents 
(Section 2.4), and although alternative models for eliciting anxiety-like behaviours (such as 
strain differences, bi-directional breeding or various combinations thereof) might prove to be 
better models upon implementation (Schmidt and Müller, 2006; Egan et al., 2010) – the 
candidate genes identified here allude to environmental intervention alone as also being 
effective.  The use of alternative models such as strain differences and bi-directional 
breeding, in conjunction with environmental interventions, may be helpful in validating the 
data produced here.  
The results of the rat model and interventions used in this study are discussed in some detail 
below. 
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4.1.2. Behavioural data 
 
Maternal separation in mice and rats is believed to represent early-life trauma and is expected 
to result in increased anxiety amongst exposed subjects (George et al., 2010).  It may be 
argued that our MS rats experienced significantly increased anxiety, as indicated by the 
increased immobility times (during the FST task) observed relative to control rats (p < 
0.0001) (Figure 3.1 and 3.2).  Maternal separation has been previously reported to result in 
increased anxiety-like behaviour in rats (Kuhn and Schanberg, 1998; Romeo et al., 2003; 
George et al., 2010; Uchida et al., 2010) and increased immobility time as an indirect 
measure of this (Mineur et al., 2013).  We further hypothesized that rats exposed to an early-
life stressor (i.e. maternal separation), and subsequently exposed to a mild adulthood stressor 
(i.e. restraint stress), would show increased anxiety-like behaviours compared to healthy 
controls due to a possible additive mechanism of perpetuation (Uchida et al., 2010).  
However, this was not confirmed in the present study.  Although significantly higher 
immobility times (suggesting higher anxiety) were observed in the MS+RS and MS groups 
compared to the control group, no significant differences were observed between MS+RS and 
MS groups in this regard.  This is not consistent with a recent study (Uchida et al, 2010), 
which reported that early developmental trauma with subsequent stressors resulted in 
increased anxiety in adulthood.  An alternative explanation to our findings may be that 
synaptic preconditioning (referring to the ability of neurons to regulate their overall action 
potential firing rate - (Turrigiano, 2007, 2008) may have occurred, i.e. when exposed to a 
major-life trauma, changes in gene expression occurs, causing synaptic remodeling, 
subsequently altering the phenotypic response to further stressors (Figure 3.1 and 3.2).  In the 
present study, rats exposed to restraint stress only showed lower immobility times (FST) than 
the control group, reflecting greater activity and indicative of hypervigilance, i.e. more 
anxious behaviour compared to controls.  So, in summary, MS and MS+RS rats showed 
behaviours indicative of higher anxiety levels compared to controls.  The RS group, in 
contrast, had lower anxiety than MS and MS+RS groups, contrary to expectation.  The RS 
group showed “inconsistent” behaviour, i.e. lower anxiety than the other experimental groups 
in one task (FST), but higher anxiety in the 2 other tasks (OFT and EPM).  It may be 
hypothesized that this unexpected finding resulted from the rats exhibiting panic due to the 
lack of preconditioning to trauma during early life.  Considering the inconsistent RS findings, 
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it is important to note that the core focus here was early developmental trauma perpetuating 
observable increased anxiety-like behaviours in adulthood, which was seen in the MS and 
MS+RS groups.  This is in line with current literature regarding childhood trauma and 
anxiety disorders in humans  (Heim and Binder, 2012; Chu et al., 2012). 
In the OFT, increased total distance moved is indicative of increased time spent within the 
outer-zone of the maze (as with time kept constant, the rat would need to travel to the outer-
zone to yield higher total distance travelled times), and this is subsequently associated with 
increased anxiety levels amongst subjects (Hulshof et al., 2011).  The distance travelled by 
the control group was lowest, suggesting lowest levels of anxiety in this group.  The MS 
group travelled furthest i.e. showed the most anxiety-related behaviour, suggesting that this 
group experienced the most anxiety.  Again, there was no statistically significant difference 
between the MS and MS+RS groups in terms of the level of anxiety-like behaviour observed. 
Given these findings, it is plausible to assume that early trauma exposure allows for gene 
expression facilitating synaptic modeling that is less responsive to subsequent traumatic 
events.  As mentioned earlier, this contradicts previous work (Uchida et al., 2010) stipulating 
that early-life trauma predisposes to increased anxiety response in adulthood upon subsequent 
stress application.  The methodology employed by Uchida et al. differed slightly to that used 
in this study, which could possibly account for deviation in observed results.  Uchida and co-
workers, for example, used a female rat cohort, whereas only male rats were used in the 
present study.  A precedent for synaptic scaling has been established in literature before (Citri 
and Malenka, 2008; Schmidt et al., 2013) and therefore replication of this study in female rat 
populations, or rats of a different breed, to establish whether the trend observed here is 
maintained, may be warranted.  Nonetheless, to reiterate, the focus of the present study was 
the observation of anxiety-like behaviours after the application of an early-life stressor, and 
this was observed in the MS and MS+RS groups, relative to controls. 
In summary, our findings suggest that rats exposed to maternal separation during early-
development exhibit significantly increased anxiety-like behaviours in adulthood.  It was 
hypothesized that rats exposed to MS and subsequent adulthood stress (i.e. MS + RS) would 
have even higher anxiety than those exposed to MS only, but this was not confirmed.  A 
preconditioning effect arguably allowed for less anxiety-like behaviour in the combination 
RS + MS rat group, relative to the MS rats.  The behavioural differences observed between 
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rats exposed to an early-life stressor (maternal separation) and controls, could be (at least 
partially) explained by differential expression in genes responsible for synaptic plasticity.   
The synaptic plasticity pathway was subsequently investigated for differential expression in 
the rat striatum.  The striatum is an area of high synaptic plasticity, and the primary input 
nucleus receiving excitatory impulses from the cortex and thalamus – previously implicated 
in anxiety disorders literature (Citri and Malenka, 2008; Greer and Capecchi, 2002; Welch et 
al., 2007). 
 
4.1.3. RT2 Profiler Array, Synaptic Plasticity 
 
Several genes were found to be differentially expressed between the four experimental groups 
of rats, namely Mmp9, Bdnf, Ntf4, Arc, Egr2, Egr4 and Grm2.  The human homologues 
(MMP9, BDNF, NTF4, ARC, EGR2, EGR4 and GRM2) for these genes and their plausible 
candidacy as susceptibility genes for increased risk for anxiety disorders are discussed below: 
 
4.1.3.1. Matrix metallopeptidase 9 (MMP9) 
 
Matrix metalloproteinases (MMPs) comprise of a family of over 25 distinct zinc-dependent 
members with a primary role comprising the degradation and alteration of the intrasynaptic 
extracellular matrix (ECM) structure and function (Matrisian, 1992; Bauvois, 2012).  The 
elucidation of the role of MMPs in nervous system function remains relatively recent; 
however, initial studies have implicated MMP2, MMP3 and MMP9 in cognitive impairment 
related to multiple nervous system disorders, such as autoimmune demyelinating disease and 
nervous system lymphoma (Gold et al., 2009; Yong, 2010; Hottinger et al., 2011).   MMP’s 
brain involvement has, however, not been limited to neurodegenerative diseases but also to 
the areas of neural development and response to injury.  MMP9 specifically, is required for 
oligodendrocyte process extension and myelination (Oh et al., 1999; Kim et al., 2012) and 
has increased expression during postnatal cerebellar development (Vaillant et al., 1999).  In 
the hippocampus, increased levels of MMP9 can be observed in response to kainic acid and 
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bicuculline-induced seizures, correlating with subsequent synapse formation (Matrisian, 
1992; Huntley, 2012).  Literature indicates the role of MMPs to be vital in synaptic 
remodeling and therefore possibly vital for synaptic plasticity (Phillips and Reeves, 2001; 
Reeves et al., 2003; Huntley, 2012). 
Activity-dependent changes in synaptic adhesion, reflected in structural molecule 
modifications within synaptic elements, could underlie the functional and morphological 
plasticity of synapses during learning (Agnihotri et al., 1998; Lynch, 1998; Lynch et al., 
2007; Caroni et al., 2012). The ECM contains components which regulate the activity of 
multiple cell adhesion molecules (CAMs), and it is believed that changes in the ECM could 
alter synaptic architecture in ways that could change the efficiency of synaptic transmission.  
In addition to CAM regulation, the ECM also houses a number of neurotransmitters and 
growth factors which can be utilized accordingly in response to ECM changes (Meighan et 
al., 2006).  ECM modulation is therefore paramount in the modification of synaptic plasticity 
and learning. 
Molecules that play a role in the process of synaptic plasticity need to be able to conform to a 
system that is under constant, necessary revision, and the molecules of the ECM appear to 
meet this criterion.  Matrisian et al. (1992) have shown that MMPs (specifically MMP 3 and 
9) are required for spatial learning and that MMP modulation is governed by NMDA and/ or 
glutamate receptor function (Matrisian, 1992; Bauvois, 2012).  This is interesting within the 
context of the results presented here, as the only significantly down-regulated gene was Grm2 
(a glutamate receptor), in the RS MS rats, relative to controls.  MMP9 has previously been 
reported to work indirectly on glutamate receptors through the cleavage of β-dystroglycan 
(Michaluk et al., 2007).  The role of MMP9 in glutamate receptor trafficking, in particular 
GluR2, is observed by its over-expression allowing for a neurotoxic role.  MMP9 may be 
responsible (if only partially) for the Grm2 down-regulation seen in this study (Michaluk et 
al., 2009).  Over- and constant stimulation of glutamate receptors resulting in their damage 
allows for MMP9 over-expression to play a role in mediating excitotoxic neuronal loss.  
MMP9 is found at higher levels in response to higher levels of plasticity response post 
neuronal damage, aiding in the formation of new synapses in response to damage (Michaluk 
et al., 2009; Szklarczyk et al., 2002).  It is therefore noteworthy that Mmp9, was not flagged 
as significantly altered in this MS+RS group, but was significant in the MS group.  The 
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double-edged nature of the Mmp9 protein characterized within the literature just described 
could allude to different Mmp9 function (plasticity-promoting or excitotic) depending on the 
application of adulthood stress in MS+RS group vs. MS only. Further studies, such as protein 
quantification and interaction experiments, are warranted to determine when MMP9 is acting 
in a plasticity-promoting, excitotoxic or dual manner relating to a specific stressor group.  
The exact interaction that may be at play in this particular instance therefore requires further 
investigation.  It is important to note, however, that different neurotransmitters or receptors 
and their intracellular signaling mechanisms appear to be responsible for regulating specific 
subsets of MMPs (Schroen and Brinckerhoff, 1996; Mott and Werb, 2004; Michaluk et al., 
2007, 2009). 
An alternative mechanism of MMP function includes the modification of the ECM and 
synaptic plasticity through cadherins, neural CAMs and integrins.  These are highly 
expressed within synaptic structures and are vital for synaptic plasticity.  Recent studies have 
shown that the neuronal cadherin, Cdh2, was associated with OCD-like behaviour in a dog 
model (Dodman et al., 2010), strengthening hypotheses for MMP9 involvement in the 
pathogenesis of anxiety disorders.  Previous work shows direct MMP interaction with 
cadherin regarding synaptic remodeling and the formation of new synaptic pathways post 
traumatic brain injury (Warren et al., 2012).  This, the aforementioned work implicating 
Cdh2 in OCD within a dog model, and the identification of Mmp9 as aberrantly expressed in 
rats exposed to environmental stressors in this study makes strong supporting evidence for its 
consideration as a target susceptibility gene for anxiety disorders in humans. 
MMP9 has therefore been associated with synaptic plasticity within literature before, but to 
the best of our knowledge this is the first study to implicate the gene specifically within an 
anxiety disorders setting.  The identification of Mmp9 as a susceptibility candidate using a rat 
model and subsequent identification of polymorphisms within MMP9 in a gene-environment 
correlation and interaction approach makes for the first molecular evidence for the 
involvement of MMP9 in the underlying molecular etiology of anxiety disorders, as 
represented by OCD, SAD and PD in this study.   
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4.1.3.2. Brain-derived neurotrophic factor (BDNF) 
 
Brain-derived neurotrophic factor (BDNF), a member of the neurotrophin super-family, is 
synthesized as pro-forms, which are cleaved intracellularly to release mature, secreted 
ligands.  Mature neurotrophins are then able to selectively bind to tyrosine kinase receptors 
(Trk) which promote Trk-mediated differentiation and survival of neural circuitry (Hall et al., 
2003).  With BDNF belonging to the neurotrophin family, the neurotrophin hypothesis 
stipulates that neuronal activity is able to enhance the synthesis, secretion and signaling of 
neurotrophins (Fig 4.1), enabling the modification of synaptic transmission.  This ultimately 
provides a connection between neuronal activity and synaptic plasticity (Schinder and Poo, 
2000).  Neurotransmitters are able to portray an instructive role, whereby they act at the 
synapse to directly modify presynaptic transmitter release, synaptic morphology and 
postsynaptic sensitivity to allow for a persistent synaptic modification (Kotaleski and 
Blackwell, 2010; Mayford et al., 2012).   
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Neurotrophins permit rapid morphological change allowing for axonal and dendritic 
sprouting, and ultimately persistent synaptic modifications (Mcallister et al., 1995; Boulanger 
and Poo, 1999; van Ooyen, 2011; Maya-Vetencourt and Caleo, 2013).  In the present study 
we observed over-expression of Bdnf and another neurotrophin gene, Ntf4, in rats exhibiting 
increased anxiety-like behaviours relative to controls, and considering the aforementioned 
literature, this is most likely for effective synaptic modification.  The persistent presence of 
neurotrophins throughout the adult nervous system suggests multi-functional roles throughout 
the lifespan of the organism (Rothman and Mattson, 2012).  The over-expression of Bdnf and 
Ntf4 observed in adult rats exposed to restraint stress, an adulthood stressor, supports this 
Figure 4.1: The neurotrophin hypothesis for plasticity of synaptic 
transmission.  Neuronal activity regulates neurotrophins at three different 
levels: synthesis, secretion and signaling.  Synaptic transmission and 
connectivity are modified as a consequence of specific changes in the pre- and 
postsynaptic neurons.  There is experimental evidence to support the existence 
of all three levels of regulation (figure adapted from Schinder and Poo, 2000). 
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finding, assuming its literature specified involvement in synaptic plasticity and the 
assumption that synaptic plasticity changes are involved in stress response adaptions.   
Whether neurotrophins play a permissive or instructive role most likely depends on a number 
of factors including, but not limited to, the type of synapse, the stage of neuronal 
development and ultimately the pattern of neuronal activity controlling its expression 
(Schinder and Poo, 2000).   
BDNF has been linked to serotonin, with studies indicating that neurochemical and 
behavioural analysis of heterozygous Bdnf
+/-
 mice with partial impairment of Bdnf expression 
show physiological disturbances in central serotonergic neurons in early adulthood and that 
this leads to structural deterioration with advancing age (Hall et al., 2003).  BDNF has further 
been specified to promote neuronal proliferation, regeneration and connectivity during 
development and maintenance of plasticity during adulthood (Bramham and Messaoudi, 
2005). This is strengthened by the findings in this study with Bdnf being highlighted as a 
candidate in all stress-application rat groups, relative to controls (Alonso et al., 2008).  BDNF 
may therefore be involved in the pathogenicity of anxiety conditions via serotonergic neurons 
specifically, but also via alternative pathways by altering or modifying synapses. 
Multiple lines of evidence exists associating BDNF polymorphism with anxiety disorders. 
Hall et al. (2003) identified two haplotypes [*rs988748-rs2049046-rs6265-a20: CTGC, P = 
0.007; GAAG, P = 0.002 (Sklar et al., 2002)] associated with OCD in a probands cohort of 
164 American Caucasian individuals for both over- and under-transmission, respectively.  
BDNF and OCD association was further concreted by Alonso and co-workers (2008) who 
employed a tagSNP approach to generate haplotype data in a Spanish Caucasian cohort of 
OCD patients and controls.  The research allowed for haplotype generation similar (although 
not identical) to that of Hall et al. (2003), but containing the rs6265 polymorphism defining 
the same protective haplotype against OCD.  The protective nature associated with the rs6265 
polymorphism has been previously investigated, and confirmed, within our group as well 
(Hemmings et al., 2008; Katerberg et al., 2009).  The most recent study by our group has 
identified the rs6265 (BDNF Val66Met) polymorphism to specifically interact with the 
presence of childhood trauma, and that the A allele (met-allele) specifically results in 
increased risk to develop OCD in the presence of emotional abuse (Hemmings et al. 2013).  
This coincides with the modifying interactive effects observed in this study discussed in the 
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human work later on (Section 4.2)  BDNF has also been investigated in SAD and PD 
(Gorman, 2000; Morreale et al., 2009; Schumacher et al., 2011; Goes, 2012), with findings 
suggesting varied contribution of BDNF to anxiety disorders etiology.  There are however, 
still relatively few studies that focused on PD and SAD specifically and therefore it may be 
entirely plausible that different genetic contributions within the BDNF gene may contribute to 
these disorders differently.  The current study, which encompassed an anxiety disorders 
cohort, i.e. a cohort that expanded beyond individual phenotypic classifications, alludes to an 
underlying mechanism of involvement for BDNF in the etiology of anxiety disorders.  
Focusing specifically on plasticity, BDNF signaling at synapses has been shown in enhance 
long-term potentiation (LTP) (a process of synaptic strengthening associated with learning 
and memory) and this is mediated by cAMP (Mattson et al., 2004).  The mechanisms 
underlying LTP were evaluated in the hippocampus, and therefore striatal application 
warrants further investigation.  This strengthens the plausibility of the identification of Bdnf 
(in rats) as a susceptibility candidate in our synaptic plasticity assays and as a subsequent 
plausible susceptibility candidate for anxiety pathogenesis involving the striatum and 
plasticity in humans. 
 
4.1.3.3. Neurotrophin 4 (NTF4) 
 
Neurotrophin 4 (NTF4) is also known as neurotrophin 5 (NTF5).  As mentioned (Section 
4.1.2.2), neurotrophins exert their effect through two main receptor subunits, namely Trk and 
p75 (Mcallister et al., 1995; Schinder and Poo, 2000; Huang and Krimm, 2010).  Tyrosine 
kinase receptor B (trkB) is the main receptor of NTF4 and is shared by BDNF (Mattson et al., 
2004; Huang and Krimm, 2010.  The trkA receptors are expressed mainly on large 
cholinergic interneurons, whereas trkB (the receptor for NTF4) is expressed mainly on 
striatal projection neurons and some interneurons (Ardelt et al., 1994), tying into a possible 
explanation for  Ntf4 differential expression in this study.   
There is evidence to suggest that NTF4 is involved in the modulation of synaptic efficacy 
(Machado Dias, 2011; Runge et al., 2012).  Furthermore, hippocampal cell induction in cell 
culture with BDNF, NTF3 and NTF4 has been shown to result in rapid potentiation of 
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glutamate-mediated synaptic transmission (Lessmann et al., 1994; Schinder and Poo, 2000).  
Ntf4 and Bdnf may therefore be involved in anxiety-like behaviour manifestation by 
facilitating for Grm2-mediated synaptic transmission (glutamate receptor excitation).  
Experimental data has shown that NTF4 is a requirement for neuronal survival and was 
observed to be essential for the survival of striatal neurons in an organotypic slice culture 
(Ardelt et al., 1994; Huang and Krimm, 2010; Harrington and Ginty, 2013).  This was shown 
again in subsequent investigations (Huang and Krimm, 2010; Harrington and Ginty, 2013).  
NTF4-treated cultures indicated an increase in the number of neurons, which may have been 
as a result of stimulated proliferations and/ or differentiation of neural precursor cells, or the 
rescuing of cells that were undergoing apoptotic death.  The role of this gene in reshaping 
synaptic circuitry and synaptic plasticity processes is therefore important, and its involvement 
most likely paramount for inclusion in anxiety pathogenicity considering synaptic reshaping 
in response to early-life stress.  The literature described above indicates Bdnf and Grm2 
interact or influence Ntf4 function and this supports the candidacy of these genes as 
susceptibility targets for investigation in human anxiety pathogenicity.   
The application of neurotrophins at developing and mature synapses acutely stimulates 
neurotransmitter release (Kang and Schuman, 1996; Wang and Poo, 1997).  Neuromuscular 
cell culture work shows both pre- and postsynaptic effects of neurotrophins, increasing the 
spontaneous and evoked release of synaptic vesicles and changing the kinetics of 
acetylcholine receptors (Wang and Poo, 1997).  Low levels of neurotrophins act 
synergistically with synaptic terminal depolarization, and to be effective, depolarization must 
take place during the time of neurotrophin exposure.  cAMP synergizes with BDNF to 
potentiate both spontaneous and action potential based evoked neurotransmitter release 
(Boulanger and Poo, 1999).  Literature therefore clearly outlines an important and 
multifaceted role for BDNF in neuronal circuitry shaping and plasticity, again in conjunction 
with NTF4. 
Literature reports that adverse life events during early developmental stages can produce long 
lasting changes in the hypothalamic-pituitary-adrenal (HPA) axis, increasing susceptibility to 
stress and placing one at an increased risk to develop mental disorders (Roceri et al., 2004).  
Neurotrophins may be an important factor or downstream target of stress considering their 
regulation integrates changes in response to hormones and neurotransmitters (Runge et al., 
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2012; Harrington and Ginty, 2013).  Literature indicates that traumatic life experiences (such 
as those replicated by maternal separation rat model employed in this study) can affect the 
levels of neurotrophins, namely BDNF.  This is exactly what has been found in the present 
study, where we observed increased levels of BDNF and NTF4 in stress application rat 
groups, relative to controls.  Roceri and co-workers (2004) showed that in a maternal 
separation rat model, a significant reduction in BDNF expression was observed within the 
prefrontal cortex and striatal brain regions, and speculated that this may render these brain 
regions less plastic and more vulnerable under challenging conditions (increase susceptibility 
to psychiatric disorders associated with these brain regions).  In this study we find that both 
Ntf4 and Bdnf were up-regulated relative to controls (Bdnf in all stress-application groups) 
contradicting Roceri (2004).  We hypothesize that this may be necessary for neuronal 
survival and for allowing for a higher level of plasticity in response to environmental 
stressors.  This may contribute to the synaptic scaling observed in the RS MS group, which 
was not observed in Roceri and co-workers (2004).   BDNF is a regulator of ARC (the 
protein product of another gene identified to be differentially expressed relative to controls), 
and this may support the contradictory increase in Bdnf expression identified in this study 
compared to Roceri and co-workers (2004). Regardless of the contradiction stated here, the 
identification of neurotrophins, specifically BDNF and NTF4 as susceptibility candidates in 
the development of anxiety disorders, warrants further investigation within a human anxiety 
disorders cohort.   
Although neurotrophins have been shown to be involved in striatal neuronal survival, 
synaptic plasticity, neuronal differentiation and neuronal cell rescue (as described above), 
there is no data regarding the specific involvement of NTF4 via the aforementioned 
mechanism in OCD, SAD, PD or any of the other anxiety disorders.  This is therefore, to the 
best of our knowledge, the first study implicating NTF4 in the molecular etiology of anxiety 
disorders, and considering the more present (although still yet not fully understood) BDNF 
involvement stated above, NTF4 is another novel susceptibility gene for investigation in 
anxiety disorders.   
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4.1.3.4. Activity-regulated cytoskeleton-associated protein (ARC) 
 
ARC, also known as the activity-regulated gene 3.1 (ARG3.1), produces mRNA which is 
immediately and rapidly transported to dendrites and specifically accumulates at sites of 
synaptic activity (Link et al., 1995; Steward et al., 1998).  ARC accumulates within dendritic 
cells at the site of local synaptic activity, suggesting a local synthesis (Steward et al., 1998; 
Rodriguez-Murillo and Greenberg, 2008; Whalley, 2012).  The ARC gene produces a single 
protein, whose sequence is highly conserved amongst vertebrate species (Plath et al., 2006; 
Whalley, 2012).  It was initially predicted to be a cytosolic protein (Lyford et al., 1995).  
Subsequent studies using yeast two-hybrid systems revealed interaction with two proteins, 
namely dynamin and endophilin, known to play an endocytotic role (Chowdhury et al., 
2006).  When co-expressed in neurons, ARC and endophilin associate with vesicles that 
selectively traffic AMPARs (AMPA-type glutamate receptors).  The rate of surface AMPAR 
endocytosis is increased and the level of surface AMPAR therefore reduced.  The protein 
similarly reduces the level of synaptic AMPAR responses, as evidenced in experiments using 
spontaneous miniature excitatory synaptic currents.  During these processes the ARC protein 
also appears to be the rate limiting molecule, as endophilin over-expression did not alter the 
AMPAR trafficking (Whalley, 2012).  Models using ARC knockouts show synaptic AMPAR 
levels to be at steady-state, with reduced endocytosis, and also shows increased amplitude of 
spontaneously evoked miniature excitatory synaptic currents (Bramham et al., 2008).  The 
identification of Arc as a susceptibility candidate in our synaptic plasticity assays is therefore 
well routed within the literature, considering its active role in synaptic activity and 
glutamatergic regulation.  It can also be hypothesized that the reduction in Grm2 (an 
AMPAR) may be as a result of Arc up-regulation resulting in receptor endocytosis and 
degradation. 
Excitatory synaptic strength and ARC expression suggest the role of ARC in homeostatic 
plasticity (Rial Verde et al., 2006).  This could explain the differential expression of Arc seen 
in nRS MS and RS nMS groups, relative to controls where Grm2 expression was not 
significantly different to controls.  ARC expression blocks homeostatic increases in AMPAR 
function as a result of chronic neuronal activity (Hayashi et al., 2012; Whalley, 2012).  ARC 
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therefore evokes continuous and precise control over synaptic strength and cellular 
excitability (Bramham et al., 2008).  It was initially thought that ARC action would be 
limited to late-phase plasticity events, however considering the rapid local translation of ARC 
mRNA, studies revealed it is able to act in an NMDA receptor-independent form of Hebbian 
plasticity (referring to basic synaptic plasticity in which an increase in synaptic efficacy 
arises from the presynaptic cell’s persistent stimulation of the postsynaptic cell (Park et al., 
2008; Waung et al., 2008; Ljaschenko et al., 2013).  This form of plasticity requires rapid, de 
novo protein synthesis in dendrites, and it was observed that ARC is translationally induced 
within 5 min of group 1 metabotropic glutamate receptors (mGluR). This is essential for 
mGluR-dependent long-term depression (LTD) and once again ties into the susceptibility 
candidates identified in the RS MS rat group as seen by the down-regulation of Grm2.  This 
is characteristic of LTD (Kanhema et al., 2006; Park et al., 2008).    
ARC has been shown to be involved in early-phase LTP enhancement and the blockage of 
late-phase LTP (Plath et al., 2006).  Early ARC synthesis is necessary for LTP expression, 
whilst late expression is involved in LTP consolidation.  LTP consolidation is modulated by 
signaling events initiated post LTP induction, and one of the major regulators of this process 
is BDNF (Bramham and Messaoudi, 2005; Lynch et al., 2007), further strengthening our 
plausible susceptibility targets identified.  The highlighting of BDNF as a regulator of ARC, 
acts as support for the contradictory increase in Bdnf expression identified in this study 
compared to Roceri and co-workers (2004).  This may support a theory of pathway-based 
approach for complex trait disorders, such as the anxiety disorders.  This means that a single 
gene may have varied observable effects due to the involvement of entire pathways in 
disorder pathogenicity.   
ARC is therefore capable of neural activity pattern translation at many different levels of 
protein synthesis-dependent synaptic plasticity.  It serves a critical role in AMPAR 
endocytosis underlying LTD and homeostatic plasticity. Its regulation by BDNF ties it in 
with Bdnf and Grm2 in the hypothesis of synaptic plasticity  and gene expression changes 
therein being associated with the manifestation of anxiety-like behaviours in rats and supports 
our the hypothesis for it as a plausible susceptibility gene for anxiety disorders pathogenicity 
in humans.  Again, although ARC has been studied with regards to plasticity; it has not been 
investigated specifically in relation to OCD, PD or SAD.  This makes for the first molecular 
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evidence for the involvement of ARC in anxiety disorders pathogenicity and makes for the 
identification of a novel gene for susceptibility thereto. 
 
4.1.3.5. Early-Growth Response 2, 4 (EGR2, EGR4) 
 
EGRs are members of a family of transcription-regulatory factors with a defining 
characteristic, namely the highly conserved DNA-binding domain composed of three zinc-
finger motifs  (Gashler and Sukhatme, 1995; O’Donovan et al., 1999).  Due to the highly 
conserved DNA-binding domains and zinc-finger motifs amongst the individual EGR 
molecules, it is plausible to assume that they might have similar or related functions in the 
brain (Gashler and Sukhatme, 1995; O’Donovan et al., 1999; Gashler and Sukhatme, 1995).  
The EGR family has been extensively implicated in the gene expression changes required for 
synaptic or neuronal plasticity, learning and memory (Milbrandt, 1988; O’Donovan et al., 
1999; Li et al., 2005; Poirier et al., 2007). Little is known about the function of the EGR2 
protein in the adult brain but it has been associated with peripheral nerve myelination 
(Topilko et al., 1994), hindbrain segmentation (Giudicelli et al., 2003) and endochondreal 
bone formation (Levi et al., 1996).  Due to the incompatibility of Egr2 knock-out mice with 
life, EGR2 studies have been limited to those examining regulated expression after a 
pharmacological input or, as in this study, environmental stressor (maternal separation and 
restraint stress).  Studies by Poirier et al. (2007) using conditional mutant mice showed that, 
contradictory to the current model of similar function based on EGR1 and EGR3,  Egr2-
deficiency may facilitate learning and memory function (Poirier et al., 2007).  This implies 
that Egr2 may be involved in antagonistic mechanisms toward brain function, whereby 
deficient regulation could hamper memory and learning.  In the current study, the up-
regulation of Egr2 expression might therefore be advantageous to mechanisms of synaptic 
remodeling (supporting memory and learning) required in response to early-developmental 
trauma. 
To date, no functional work regarding EGR4 functionality in cognitive and behavioural 
phenotypic manifestation has been performed and very little is known about the role of the 
protein in synaptic plasticity (Poirier et al., 2007).  This specific member of the EGR family 
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has been previously associated with male infertility and autonomous germ-cell defects 
(O’Donovan et al., 1999; Cooke and Saunders, 2002), however no work has been performed 
in OCD, SAD, PD or any of the other anxiety disorders.  The up-regulation of this gene in all 
stress application groups is therefore an interesting finding and warrants further investigation 
with regards to functionality in regulation concerning plastic remodeling and homeostasis.  
Its marked up-regulation in all three stress groups alludes to a possible functional role in 
synapse modification in response to a stressor in both early-developmental and adulthood 
stress (although the exact nature of this role has not been elucidated in literature before).  
This data therefore suggest a role for this gene in manifestations of anxiety in rats.  This 
warrants its consideration in the etiology of anxiety disorder in humans. 
 
4.1.3.6. Glutamate receptor 2 (GRM2) 
 
Glutamate is a major excitatory neurotransmitter in the central nervous system (Iihara et al., 
2001).  The metabotropic glutamate receptors (mGluRs) are members of a class of GTP-
binding protein coupled receptors comprising eight subtypes.  GRM2 belongs to glutamate 
receptors subtype 2 and has been previously associated with mental health disorders such as 
schizophrenia (Joo et al., 2001; Tamandani et al., 2012), which may have phenotypic overlap 
with anxiety and stress disorders (Watson and Naragon-Gainey, 2010; Achim et al., 2011; 
Wakabayashi et al., 2012).  The significant identification of this gene in the synaptic 
plasticity pathway of rats exhibiting anxiety-like behaviours suggests that it could prove 
pivotal to synaptic modeling that may be involved in anxiety disorders (Achim et al., 2011).  
GRM2 is involved in adenylyl cyclase inhibition thereby suppressing the production of 
cAMP, and has been involved in pathways such as excitatory neuronal transmission, synaptic 
plasticity, neural cell death and learning and memory (Joo et al., 2001).  The Grm2 gene was 
the only gene to show down-regulation relative to the control rats, and only in the 
combination stressor group (MS+RS).  We hypothesized that the down-regulation of this 
gene in rats exposed to adulthood stress, post early-life trauma, is involved in synaptic 
preconditioning, allowing neural pathways involved in stress-response to better adapt to a 
stressful environment.  The down-regulation observed for Grm2 could therefore be the reason 
for the plateau seen in the behavioural results between MS rats and MS+RS, when we 
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initially expected to find an increase in anxiety-like behaviour with combination stressors.  
The possible involvement of GRM2 in synaptic scaling in response to early-life trauma seems 
paramount to the understanding of gene-environment interaction and warrants the 
investigation of this gene in the pathogenicity of anxiety disorders.  The glutamate receptors 
have become quite popular with regards to the involvement in anxiety disorder pathogenicity 
considering their potential as drug targets for anxiety disorders and schizophrenia treatment 
strategies (Swanson et al., 2005; Conn and Jones, 2009).  The glutamate receptors and 
glutamatergic-associated plasticity is a hot topic regarding anxiety etiology to date and it has 
been associated with OCD, SAD and PD pathogenicity (Schoepp et al., 2003; Swanson et al., 
2005; Ting and Feng, 2008; Conn and Jones, 2009; Nasca et al., 2013).  The elucidation of 
GRM2 as a susceptibility candidate in this study is therefore in accordance with the literature 
and in its identification, adds confidence to the completely novel genes identified alongside it 
in this study with regards to anxiety disorders.  
 
4.2. Work in Humans 
 
4.2.1. Childhood trauma as a susceptibility risk 
 
Traumatic events occurring during early developmental years have been associated with 
increased risk for anxiety disorders (Gunnar and Quevedo, 2007; Danese et al., 2009; Irish et 
al., 2010; Nugent et al., 2011).  Results obtained in this study provide further evidence for 
this hypothesis; patients had significantly increased childhood trauma compared to controls. 
Patients reported increased exposure to childhood trauma with regard to all the abuse and 
neglect subscales of the CTQ, except for physical neglect.  Compared to controls, emotional 
neglect amongst patients demonstrated the highest level of significance (p < 0.0001) followed 
closely by emotional abuse (p < 0.001) and sexual abuse (p < 0.001).  Physical abuse yielded 
a significant p-value of p = 0.014, representing significantly higher levels of physical abuse 
amongst cases, relative to controls.  Although various emotional and physical forms of 
trauma during childhood appear to be associated with increased susceptibility to develop one 
or more anxiety disorders, our data suggest that the emotional forms (i.e. emotional abuse and 
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emotional neglect) bear the most weight for this increased risk.  Of the physical forms of 
trauma, sexual abuse carried the most weight for increased susceptibility risk.  Interestingly, 
physical neglect did not yield significant findings in this study; however, this was also 
previously demonstrated in specifically SAD and anxiety in general (Wessel et al., 2001; Kuo 
et al., 2011).  It is possible that physical neglect is not as weighted as the other components of 
the CTQ scale, or that based on the presence of a possible support system, physical neglect 
may be of the variables to nullify more easily.   
In summary, our data is consistent with literature that supports a role for childhood trauma as 
a susceptibility risk factor for the development of anxiety disorders.  The role that the 
selected polymorphisms and haplotypes may have in the susceptibility risk for anxiety 
disorders will be discussed in the following sections of this chapter. 
 
4.2.2. tNGS 
 
Amplicon-based targeted next generation sequencing (tNGS) was performed on a subset (12 
patients and 19 controls) of the research cohort, as described in the methodology.  103 SNPs 
and 9 indels were identified for both patients and controls.  Of these 112 variants, 30 (27 
SNPs and 3 indels) were found to be previously identified. This means that 73% of the 
variation identified was novel to this study (Table 4.1).  Considering the 112 variants again, 
38 SNPs and 4 indels were unique to either patient or control individuals.  Many of these 
variants are found within the 5’ or 3’ UTR region and could account for transcriptional 
regulation changes.  These could be especially relevant in considering the role of early life 
trauma in the pathogenesis of anxiety disorders – a core gene-environment interactive 
component of this study as well. When focusing on the exome-related data generated: a 
number of novel exonic variants were found, as well as intronic variants that may disrupt 
splicing (Table 4.1). 
 
Table 4.1: Summary of the variation identified with NGS 
  SNPs Indels 
Total 103 9 
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Previously Identified (%) 26.21 33.33 
This study (%) 73.79 66.66 
Patients (%)  49.51 77.78 
Controls (%) 50.49 22.22 
Unique to Patients (%) 11.65 50.00 
Unique to Controls (%) 88.35 50.00 
UTR (%) 26.21 11.11 
Intron (%) 43.70 77.77 
Exon (%) 30.09 11.11 
*SNP = single nucleotide polymorphism; Indel = insertion/ deletion; UTR = untranslated 
region 
The large number of novel polymorphisms identified (in these already novel anxiety-related 
susceptibility genes) attests to the alluded unique nature of the South African population 
(specifically Caucasian individuals in this study) (Wright et al., 2011).  Genotyping of the 
aforementioned polymorphisms in the extended cohort provided valuable insight into 
polymorphism frequencies specifically in the South African Caucasian population. 
Determining the genetic architecture of susceptibility for complex neuropsychiatric disorders, 
like the anxiety disorders, continues to be a challenge.  Initial strategies suggested that the 
advent of genome-wide association studies (GWAS) would result in the elucidation of 
multiple new targets for further research under the assumption that a number of common 
genetic variants are most likely the culprits in complex disorders, and not rare mutations 
(Kricka and Di Resta, 2012; Ripke et al., 2013).  What has been found however, is that 
common variants represent a rather small effect size and that the genetic architecture of some 
of the more complex disorders are most likely the result of a combination of common and 
rare variation (Ezewudo and Zwick, 2013).  A number of research articles have indicated that 
with the advent of NGS, de novo, rare and novel population-specific variations in the genetic 
code could be identified and could present with  a better association with disorder etiology in 
complex disorders like schizophrenia and autism (O’Roak et al., 2011; Xu et al., 2011).  The 
same is most likely true for the anxiety disorders and the large quantity of novel 
polymorphisms identified here (in only five susceptibility genes) supports this assumption. 
Although no significant differences were found in terms of case-control association analyses 
when considering the SNPs identified using tNGS, substantially larger or smaller MAFs were 
observed compared to previously described data (Table 3.8).  The non-significance finding 
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may be due to small sample sizes despite large discrepancies reported relative to database 
entries (Evans and Purcell, 2012).  In complex disorders, such as the anxiety disorders, the 
genetic components may be spread across several loci and therefore large sample sizes are 
necessary to assess a (most likely) small contribution of multiple genes and/ or 
polymorphisms to disorder pathogenesis.  To achieve an 80% power assuming a significance 
level of 0.05 (α = 0.05; β = 0.20) with an OR of 1.2 or greater for small effects for rare and/ 
or common alleles,  population cohorts much larger than that used here would be necessary 
(Evans and Purcell, 2012; Pfeiffer and Gail, 2003). Considering the cohort size in this study 
and assuming a 30.1% life-time prevalence rate for anxiety disorders in the South African 
population (Kessler et al., 2007), a 83% power can be reached assuming a false-positive 
maximum of 3 for the polymorphisms investigated for a relative genotype risk of 1.5.  This 
refers to common polymorphisms of a MAF of at least 0.2 (Center for Statistical Genetics, 
University of Michigan, http://www.sph.umich.edu/csg/abecasis/CaTS/tour1.html) (Skol et 
al., 2007).  For polymorphisms with MAF less than 0.2, the power is greatly reduced and 
findings need to be replicated and validated in a much larger cohort (such as the 
polymorphisms identified using tNGS). 
In summary, the application of tNGS sequencing of five potential susceptibility genes in 
anxiety disorders yielded 112 polymorphisms (109 SNPs and 3 Indels).  Of these the 83%  
found to be novel (considering the 42 polymorphisms unique to either cases or controls only) 
suggests that a combination of de novo, rare and common population-specific genetic 
mutations may contribute to disorder susceptibility, and that these may be a result of recent, 
sudden and immense population expansion rates (Ezewudo and Zwick, 2013; Tennessen et 
al., 2012).  The large discrepancies in MAFs reported for the 7 previously reported tNGS 
SNPs identified (Table 3.8) in this study further merit the aforementioned statement, and 
although no significant p-values were obtained, due to small sample and effect sizes these 
non-significant results can best be described as inconclusive until replicated with greater 
power.  As previously mentioned, 112 passed all filter criteria, however only the 42 unique to 
either cases or controls only were considered for further analyses to minimize SNPs for 
investigation to those that were most likely to be informative for increased or decreased 
susceptibility risk, respectively.  The remaining 70 polymorphisms were not included for 
further genotyping in an expanded cohort due to budget constraints, this does not negate their 
possible association with disorder pathogenesis, and they too should be considered for further 
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analysis in studies with greater power.  The results represented here warrant, at the very least, 
further consideration for NGS application in the anxiety disorders, in a population specific 
fashion. 
 
4.2.3. Hardy-Weinberg Equilibrium (HWE) 
 
The Hardy-Weinberg Equilibrium principle states that in the absence of migration, mutation, 
natural selection and assortative mating, genotype frequencies at any locus are a simple 
function of allele frequencies (Wigginton et al., 2005; Wittke-Thompson et al., 2005).  
Deviation in the aforementioned principles could therefore result in an absence of agreement 
for a HWE model and it is generally deemed that the absence could be associated with the 
model of disease or disorder being investigated.  It is generally accepted that the presence of 
a variant increasing risk for the development of a particular disease/ disorder could result in 
deviation from HWE and subsequently that this variant may therefore be a disease-causing or 
affiliated mutation.  A HWE deviation is therefore generally accepted to be found within the 
cases for variant associated with disease, whilst HWE is met within the controls; however 
this is not always the case.  The reverse may also be possible where deviation from HWE is 
found within the controls but met within the patients, as is the case with rs17576, and 
rs925948 in this study.  The assumption that can be made in these cases is that deviation from 
HWE in the control group is possibly associated with disorder pathogenicity and if so in a 
protective capacity i.e. the controls are adapting whereas the cases are not and this is making 
cases more susceptible to disease (as discussed by Wigginton et al., 2005; Wittke-Thompson 
et al., 2005).  This may be the case in this study considering the rs925948 polymorphism in 
BDNF and rs17576 polymorphism in MMP9; however no statistically significant associations 
were found for either of these variants.  This can therefore best be described as inconclusive 
and requires validation in a larger cohort.   
Focusing on the SNP rs1805088, HWE deviation was observed in both the case and control 
populations.  When evaluating the allelic distribution, HWE was met.  The establishment of 
common trends of HWE and deviation from there in complex disorders (such as the anxiety 
disorders) is not as well characterized as that of common models of disease (Wittke-
Thompson et al., 2005).  Additional confounders to HWE deviation in complex disorders 
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include (but are not limited to) gene-gene interactions, gene-gene-environment, as well as 
age, gender and population stratification.  It is true that deviation from HWE can be a result 
of genotyping error (Wigginton et al., 2005), however in this study SNPs genotyped using 
TaqMan probe assays were repeated for randomized selected samples to confirm results. 
Genotyping performed using assays by LGC Genomics/ KBiosciences using KASP
®
 
technology were wet-benched tested prior to mass genotyping and quality controlled to 
ensure accurate typing.  Thus it may be argued that genotyping error was not the reason for 
HWE deviation here.  Considering the novelty of the South African Caucasian population 
(i.e. that fact that it has never been utilized for the screening of the variant before), as well as 
this polymorphism not having been characterized in a cohort of collective anxiety disorders 
patients (OCD, SAD and PD), deviation from HWE could be expected due to a number of 
variables (e.g. population stratification, the combination of different anxiety disorders 
grouped into a single cohort, and/ or environmental interaction), some of which were not 
considered here or are unknown.  The reason for deviation, however, is not known and before 
results can be considered sound for this variant, screening in larger cohorts to ascertain 
whether the genotype and allelic frequencies observed here are maintained, is necessary. 
 
4.2.4. Genotyping, significant associations and interactions 
 
As noted previously, severity of childhood trauma rates were significantly higher in anxiety 
disorder patients than controls.  The following genes and polymorphisms were found to be 
significantly associated with anxiety disorder pathology, considering childhood trauma as a 
correlating variable: BDNF: rs6265, rs10835210, MMP9: rs3918242, rs1805088 and GRM2: 
rs116567227. 
 
4.2.4.1. BDNF 
 
The rs6265 (also known as Val66Met) polymorphism has been well studied in anxiety, as 
well as other psychiatric disorders (depression, attention deficit hyperactivity disorder and 
Alzheimer’s) (Huang et al., 2007; Krishnan et al., 2007; Sánchez-Mora et al., 2010).  The G 
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allele (Val-allele) has previously been reported to be protective against the development of 
anxiety disorders in American and Spanish Caucasian cohorts, whereas the A allele (Met-
allele) affects the intracellular processing of the pro-BDNF polypeptide preventing or 
hampering its release from active neuronal cells.  This protective allelic attribute described 
was investigated in OCD (Hall et al., 2003) and the intracellular polypeptide mechanism in 
schizophrenia (Egan et al., 2003) cases.  The significant association of rs6265 with anxiety 
disorders pathogenesis in this study is therefore in line with that reported previously (Chen et 
al., 2006; Sánchez-Mora et al., 2010, 66), and the OR of < 0.001 in favor of the AG genotype 
validates the G allele predicting a protective role for this variant.  Whereas the significance of 
this polymorphism in OCD and other psychiatric disorders has been studied (Egan et al., 
2003; Hall et al., 2003), this is the first study highlighting its involvement in the underlying 
etiology of anxiety disorders in an anxiety disorders cohort extended beyond disorder based 
classifications, as the cases cohort comprised a combination of three anxiety disorders main 
diagnoses (OCD, SAD and PD). 
The rs10835210 has previously been associated with phobic disorders (Xie et al., 2011), as 
well as associated with a 1.761 X increased likelihood to develop internalizing disorders 
(Meng et al., 2011).  In the present study rs10835210 AC and CC genotypes were found to be 
significantly correlated with anxiety disorders in protective capacity with ORs of 0.586 and 
0.504, respectively suggesting a ~50% reduced susceptibility risk to anxiety disorders.  
Contradictory to recent reports regarding phobic and internalizing disorders implicating the C 
allele to result in increased occurrence for internalizing disorders, the presence of the C allele 
here coincides with an apparent protective effect.  This is further validated by the presence of 
the A allele in the identified BDNF AGGAAT haplotype found with increased frequency 
amongst anxiety disorders cases in this study. 
Focusing on a gene-environment interaction, four genetic variants (BDNF: rs6265, 
rs2049045, rs10835210, and rs11030107) were found to significantly interact with the 
severity of childhood trauma (as measured by CTQ total score) to modify the predicted 
susceptibility risk to anxiety disorders (as indicated by OR).  A single variant was also found 
to approach significance (BDNF: rs1401635).  The only variants also found to be statistically 
significant under gene-environment correlation assessment were rs6265 and rs10835210.  
Looking at the CTQ total score, although highly significant (at least two tier) p-values were 
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obtained [rs6265: p = 0.007 (genotype), 0.034 (allele) and rs10835210: p = 0.009 (genotype) 
and 0.067 (allele)], ORs deviating only slightly from 1 were identified when looking at gene-
environment interaction.  This would generally be inconclusive at best, however, considering 
the rs10835210 polymorphism, a decreased risk for anxiety disorders was predicted when 
assessing gene-environment correlation (OR = 0.287) for this variant. When considering an 
interaction with childhood trauma (as indicated by CTQ total score), this predicted risk is not 
observed and the presence of this polymorphism interacting with childhood trauma trends 
towards increased susceptibility to anxiety disorders (OR = 1.084, CI = 1.02 – 1.15).  The 
rs6265 variant demonstrates this environmental interaction with even more clarity.  Gene-
environment correlation with childhood trauma indicated the A allele of the heterozygous AG 
genotype for the rs6265 polymorphism to present with the reduced risk to develop anxiety 
disorders within this study with an OR of < 0.001.  Considering a gene-environment 
interaction with the severity of childhood trauma this reduced risk is no longer observed and 
the presence of the A allele is associated with an up to 1.33-fold increased susceptibility to 
develop anxiety disorders (OR = 1.132, CI = 0.93 – 1.33).  Previous work performed by our 
group has demonstrated an interaction of the severity of childhood trauma and A allele of the 
rs6265 polymorphism with increased susceptibility to OCD (Hemmings et al.2013).  
Validating these findings in larger cohorts for anxiety disorders in general is necessary to 
confirm results, as well as investigating whether these findings hold true for the individual 
anxiety disorders.  
The rs2049045 (BDNF) has been previously reported to be associated with the progression of 
bipolar disorder with psychiatric comorbidities (Neves et al., 2011).  It was found that the 
presence of this variant in heterozygous or homozygous mutant states was not associated with 
bipolar disorder itself, but with increased risk for smoking, drinking and alcoholism in these 
patients.  That is a representation of genetic risk by gene-environment correlation.  A number 
of other studies also support the association of rs2049045 with smoking and substance abuse 
tendencies in psychiatric conditions (Li et al., 2008; Novak et al., 2010), and therefore makes 
the interaction of this variant with increased severity of childhood trauma to influence anxiety 
disorder phenotype an interesting finding.  The interaction of rs2049045 with CTQ total score 
in this study yielded an OR of 0.916 (CI: 0.83 – 0.99) suggesting reduced susceptibility risk 
to having anxiety disorders with the presence of this polymorphism in an individual with 
early developmental trauma.   The final polymorphism within the BDNF gene associated with 
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childhood trauma severity interaction, rs11030107, had a heterozygous genotype presenting 
with an OR of 1.081 (CI: 1.01 1.17), suggesting that presence of this genotype is associated 
with increased risk for having an anxiety disorder, when there is a history of childhood 
trauma to interact with.  This same risk, however, was not seen for the homozygous mutant 
genotype and this could be explained by heterozygous advantage.  Heterozygous advantage is 
where there is a selective preference for the heterozygous genotype of higher fitness as the 
phenotype of the heterozygote lies outside the phenotype range of both homozygotes (Penn et 
al., 2002; Charlesworth and Willis, 2009).   
The aforementioned gene-environment interactions attest to a definite effect of the severity of 
childhood trauma in the development and/ or progression of anxiety disorders.  These results 
support the consideration of early life trauma as an interacting co-variable in the underlying 
neurobiology of anxiety disorders. 
 
4.2.4.2. MMP9 
 
Polymorphisms found within the MMP9 gene have been well documented to date, but never 
within an anxiety disorders context.  The rs3918242 polymorphism has previously been 
associated with cardiovascular disease, cancer, and obesity to name a few (Wu et al., 2010; 
Zhou et al., 2011; Andrade et al., 2012).  The MMP proteins are able to degrade nearly all of 
the endogenous ECM ligands of adhesion molecules, and it is therefore plausible that 
variation found within the gene has been associated with a large number of disorders/ 
diseases.  Anxiety prognosis has been extensively characterized to be a comorbidity in 
cardiovascular disease and cancer afflicted patients (Martens EJ et al., 2010; Vahdaninia et 
al., 2010) where the MMP (and specifically MMP9) proteins have been found to be involved 
in disease progression.  The identification of MMP9 in this study and significant association 
of polymorphisms with increased susceptibility to anxiety disorders presents molecular 
evidence for the increased frequency of anxiety phenotypes in these diseases.  In this study 
rs3918242 was found to be significantly associated with anxiety disorders with a high 
prevalence for the heterozygous genotype containing the mutant T allele amongst patients.  
Further analyses revealed an OR of 4.674 for the CT genotype indicating a > 4-fold increased 
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likelihood to develop anxiety disorders.  Furthermore, no homozygous TT cases were found 
in this study, and this has been the case in previous studies (Holliday et al., 2007).  Although 
this is the first study reporting on this variant and gene in strictly an anxiety disorders setting, 
previous literature supports the increased susceptibility risk nature of this polymorphism and 
T allele with disease progression with a 9.1 OR in a breast cancer study (Hughes et al., 2007). 
The rs1805088 SNP indicated statistically significant association for gene-environment 
correlation analyses.  Further analyses indicated a predicted reduced susceptibility for anxiety 
disorders associated with CC genotype (OR = 0.287).  When focusing on the CT and TT 
genotypes for this variant, there appeared to be an increased prevalence for the CT 
heterozygous genotype amongst the cases, and increased frequency for the TT genotype 
amongst the controls.  This is rather an unusual phenomenon and is most likely responsible 
for the deviation in HWE identified for this polymorphism.  As previously mentioned, 
deviation in HWE is mostly likely an indicator of errors in genotyping; however this 
particular variant was typed using a TaqMan assay, with repeat samples typed at a different 
experimental time-point for quality control purposes. This polymorphisms has not been 
previously been screened in an anxiety disorders cohort, or the South African Caucasian 
population.  Considering the deviation from HWE associated with this polymorphism, 
validation of its frequency within a larger cohort as well as alternative South African 
population is necessary to expand on the uncertainty regarding this polymorphism, and 
subsequently validate results presented in this study.  
 
4.2.4.3. GRM2 
 
The GRM2 gene is of particular interest considering its presentation as the only down-
regulated gene found in the synaptic plasticity arrays performed on rats exhibiting anxiety-
like behaviour.  Polymorphisms identified in GRM2 were achieved by tNGS in a subset of the 
controls and anxiety cases and then extended to the remainder of the cohort via probe-based 
genotyping techniques (KASP
®
 genotyping).  The results revealed very low genotypic and 
allele frequencies for polymorphisms identified within the study cohort, however one 
previously identified polymorphism, rs116567227, was found to be significant.  Literature 
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regarding the specifics of this polymorphism with regards to function and/ or effect is lacking 
except for its identification in the 1000 Genomes project, making its elucidation here a novel 
one within the context of anxiety disorders and synaptic plasticity.  SIFT and PolyPhen are 
online programmes designed to detect whether the presence of a variant will result in an 
amino acid change that could affect normal protein function.  SIFT and PolyPhen predictions 
(Ensembl database) indicated low toleration scores and possibly damaging predications, 
respectively.  Due to the low frequency of this polymorphism, ORs predicting decreased or 
increased susceptibility risk effects were not calculated.  Further analyses in larger sample 
cohorts are necessary to investigate and validate the significance identified here. 
Considering gene-environment interaction, the rs113426529 in GRM2 showed statistical 
significance for CTQ total score interaction; however, larger cohorts are needed to effectively 
discern how the presence of childhood trauma affects the phenotypic outcome in the presence 
of this SNP.  It is also noteworthy to mention that BDNF’s rs1401635 approached 
significance for interaction with increased severity of childhood trauma.  This variant should 
be considered for possible significance in larger cohort studies or meta-analysis.   
 
4.2.5. Haplotype Analyses 
 
 
4.2.5.1. Gene-environment correlation 
 
The ability of genetic risk to be expressed through anxiety cases presenting with a greater 
exposure to environmental stressors, specifically childhood trauma for haplotype associations 
was assessed for the polymorphisms identified.  Cases have been shown to be associated with 
a significantly higher severity of childhood trauma, relative to controls (p < 0.001) and they 
are therefore assessed considering this, relative to controls for haplotype associations. 
LD analyses were performed on candidate genes for the polymorphisms identified.  The 
majority of the analyses were conducted using the default algorithm designed by Gabriel et 
al., 2002 in which 95% confidence bounds on D’ were generated for each comparison.  That 
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is, if 95% of informative comparisons are in strong LD, a haplotype block is created.  Under 
the confidence intervals analyses, haplotype blocks were identified for polymorphisms in 
MMP9 BDNF genes.  Under the standard confidence interval settings no significant 
haplotype associations between cases and controls were identified in the MMP9 gene.  
BDNF, however, yielded one significant haplotype, * rs11030104-rs1401635-rs10835210-
rs7103411 AGAT which was associated with a higher frequency within cases, compared to 
controls, and indicated a 2.5-fold increased susceptibility risk to developing anxiety disorders 
(OR = 2.519).  The rs10835210 polymorphism was previously implicated in the aetiology of 
phobic disorders (including SAD and PD) (Xie et al., 2011), providing further evidence for 
increased susceptibility risk with this haplotype.   
The rs3918242 polymorphism demonstrated high LD, although its inclusion within a 
haploblock was impeded by the rs3787268 polymorphism which broke LD.  Modification of 
the MMP9 haplotype block to include rs3918242 for which considerable D’ was seen, and to 
exclude the rs3787268 polymorphism which broke LD from rs3918242, yielded two 
significant haplotypes for the MMP9 gene (MMP9 *rs3918242-rs3918253-rs2274755-
rs17576-rs2236416-rs17577-rs13925 CCTGGAA and TCTGGAA).  The CCTGGAA 
haplotype was found with higher frequency in cases compared to controls, yet found to be  
associated with a decreased susceptibility risk to develop anxiety disorders (OR = 0.469).  
This is an unusual finding but, and it is possibly attributed to the presence of the C allele of 
the rs3918242 polymorphism in this haplotype, protective over its T allele counterpart.  
TCTGGAA, however, was found to be present predominantly amongst cases and a > 4.6-fold 
increased susceptibility risk (OR = 4.608).  This haplotype contains the rs3918242 
polymorphism previously associated with cardiovascular disease, cancer, and obesity to name 
a few (Wu et al., 2010; Zhou et al., 2011; Andrade et al., 2012) and 9-fold increased risk for 
breast cancer (Hughes et al., 2007); conditions known to be associated with high rates of 
comorbid anxiety prognosis (section 4.2.4.2) (Martens EJ et al., 2010; Vahdaninia et al., 
2010).  This data, however, represents the first haplotype data that supports association of 
variation within MMP9 gene with anxiety aetiology in specifically an anxiety disorders 
cohort.  This therefore poses the questions: should cancer and cardiac compromised patients 
who carry the associated alleles be monitored (and possibly pre-treated) for anxiety 
disorders?  And also should patients being treated for anxiety disorders who test positive for 
these polymorphisms be considered at increased risk for heart disease and cancer?  These 
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questions have large clinically, economic and administrative complications when it comes to 
treatment strategies.  The results presented here need to be validated in larger, and alternative 
cohorts to evaluate whether the considerations the proposed questions imply outweigh the 
complications mentioned. 
 
4.2.5.2. Possible gene-environment interaction? 
 
To assess gene-environment interaction with regards to haplotype associations, the top (30 
cases, highest CTQ total score; mean = 64.36, median = 60.50) and bottom (30 cases, lowest 
CTQ total scores, mean = 28.9, median = 29) 33
rd
 percentile of patients were tested for 
association.  A direct haplotype-CTQ total score interaction was not able to be assessed 
within Haploview.  Separation of the anxiety disorders cases into high and low CTQ total 
score sub-groups was therefore performed to assess for differences in the haplotype 
associations identified.  LD analyses were conducted using the same default algorithm 
designed by Gabriel et al., 2002 in which 95% confidence bounds on D’ were generated for 
each comparison.  Under these confidence intervals analyses, two haplotypes were identified 
within the MMP9 gene, however only within the top 33
rd
 percentile comparisons (MMP9 
*rs3918253-rs2274755-rs17576-rs2236416-rs3787268-rs17577-13925, CGGAAGG and 
CGAAGGG) (Table 3.18).  The CGGAAGG haplotype presented with an OR of 0.890 and 
was associated with decreased susceptibility risk towards developing anxiety disorders.  The 
remaining significantly identified haplotype association, CGAAGGG, was found to be present 
in higher frequency within the cases and was appropriately found to be associated with a 1.7-
fold increased susceptibility risk (OR = 1.721). 
From the gene-environment correlation and gene-environment interaction analyses it is clear 
that haplotypes within the MMP9 gene are significantly associated with the pathogenicity of 
anxiety disorders, and predominantly with substantial increased risk.  This association also 
appears to be influenced by the severity of childhood trauma, observed by the absence of 
haplotype associations in the bottom 33
rd
 percentile cases (associated with low severity of 
childhood trauma in patients – relatable to that seen in controls) but with the identification of 
two within the top 33
rd
 cases sub-group (associated with high severity of childhood trauma).  
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The validation of these results using statistical consultation to allow for direct haplotype-
childhood trauma interaction analyses is necessary to more concretely ascertain the 
involvement of haplotype interaction with the severity of childhood trauma.  The 
identification of a ‘severity of childhood trauma-single polymorphism’ interaction earlier 
provides some foundation for this assumption being perpetuated on a haplotype level as well.  
The identification of haplotype associations considering high severity of childhood trauma, 
but not low severity childhood trauma in a case-control association fashion further merits the 
further consideration of haplotype associations in a gene-environment interactive setting. 
 
4.3. Limitations 
 
4.3.1. Animal models of anxiety 
 
For an animal model to be optimal in mimicking a particular condition or disorder, it needs to 
mimic said condition with regards to etiology, symptomatology and treatment (Bloom and 
Kupfer, 1995).  In complex psychiatric conditions, however, many of the cardinal features are 
based on subjective verbal report – making the ‘ideal’ animal model somewhat infeasible. 
This means that when looking at an animal model for human anxiety disorders it is important 
to redefine the usual requirements and to focus on approaches relying on the mimicking of 
specific signs, symptoms, behaviours or responses as opposed to trying to replicate the entire 
condition (Müller and Holsboer, 2006; Schmidt and Müller, 2006).  Rodents are the most 
widely used animals of choice in animal research.  In particular, mice and rats are the most 
commonly used animals in models used for mimicking anxiety disorder traits.   
Subjecting rats to maternal separation and restraint stress yielded anxiety-like behaviours as 
well as changes in gene expression.  Significance was maintained for some of the identified 
genes when extrapolated onto a human cohort suggesting the utilized animal model was 
effective for this study.   
In this study, there were 13 stressor (referring per stressor group) and 13 control rats.  This 
number was found to be acceptable based on literature guidelines (Guidelines for the Care 
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and Use of Mammals in Neuroscience and Behavioral Research, 2003) and consistent with 
recent literature pertaining to anxiety disorders (Slattery and Neumann, 2010; Molander et 
al., 2011).  These studies, as well as the present one, comprised of only male rats (to control 
for any possible sex-linked and hormonal effects in candidate identification) and made use of 
only environmental interventions.   
 
4.3.2. Cohort size and power 
 
Interrelated variables such as effect size, the type of genetic model used, agreement between 
susceptibility and marker allele frequency and LD all contribute to the power of an 
association study.  In etiologically complex disorders, such as the anxiety disorders, often 
very large sample sizes are required to obtain significance since a number of common and 
rare variants spread across several loci may all make a contribution to the phenotype.   
To achieve an 80% power at α = 0.05 with an odds ratio of 1.2 or greater in a case-control 
association study assuming variants with small effects, cohorts in the tens of thousands are 
needed.  Therefore in this study, findings should be considered as preliminary, requiring 
validation in a much larger sample.  Specifically, in situations where statistical significance 
was not obtained, it can best be described as inconclusive, until validated in a larger study or 
subjected to meta-analyses.  And where statistical significance was obtained, replication is 
required for validation.   
To maximize statistical power within this study, association testing was not performed on the 
population stratifying for the individual main diagnoses (OCD, SAD and PD).  This warrants 
further investigation in a larger study cohort to ascertain whether significance is maintained, 
enhanced or lost when stratified. 
 
4.3.3. OCD as an anxiety disorder 
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OCD has been classified as an anxiety disorder in DSM-II through to DSM-IV; however, 
recent developments and new knowledge have brought this categorization under scrutiny.  
Notably, in ICD-10, OCD is classified separately to the other anxiety disorders under the 
category of “Neurotic, stress-related, and somatoform disorders” (Stein et al., 2010; Bienvenu 
et al., 2012).  Changing its classification would not change which individuals would receive a 
particular diagnosis, however, it would bare influence on disorder conceptualization and 
ultimately treatment regime (Stein et al., 2010).  There are many overlapping features 
between OCD and the other anxiety disorders (e.g. frequent comorbidity with depression, 
avoidance behaviours, response to SSRIs, etc.).  However, over time, research and clinical 
evidence suggested that OCD may be more closely related to other conditions characterized 
by driven, non-functional, repetitive nature (e.g. body-focused repetitive behaviour disorder, 
hair-pulling disorder (trichotillomania) and skin-picking disorder).  Nevertheless, there is 
considerable overlap between OCD and the anxiety disorders and this project rests on these.  
Considering a neuronal circuitry perspective, for example, there is evidence to suggest 
similarities in neuronal circuitry between OCD and the anxiety disorders (e.g. OCD, PD, 
SAD and PTSD share dopaminergic and serotonergic neuronal pathway involvement 
considering SSRI effectivity in treatment) (Stein et al., 2010).  Family studies have also 
linked OCD to anxiety disorders, particularly general anxiety disorder (GAD), (Stein et al., 
2010).  Reviews of the current literature have led to recommendations that DSM-5 change the 
section of anxiety disorders to include OC-spectrum disorder (Phillips et al., 2010; Stein et 
al., 2010) and be called “ Anxiety and Obsessive Compulsive-Spectrum Disorders”.   
Drawing on evidence from the above literature, the inclusion of OCD in this study of some of 
the anxiety disorders thus seems warranted.  Although the reclassification of OCD in DSM-5 
may be clinically relevant, it may be argued that the significant overlap with other anxiety 
disorders warrants its inclusion in a study to elucidate the molecular etiology of anxiety 
disorders.  
 
4.3.4. The absence of other DSM-IV anxiety disorders: PTSD, GAD and specific 
phobia 
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PTSD is an anxiety disorder in the DSM-IV and also believed to be associated with early-
developmental trauma, although characteristically manifesting after an immediate life 
threatening event (Perry, 1994; Yehuda et al., 2001; Shavitt et al., 2010).  A GAD diagnosis 
requires an uncontrollable, unrealistic worry about multiple topics as well as an 
accompanying physiological symptom, over a long period of time (Stein, 2004).  
Development of GAD has also been associated with childhood trauma (Afifi et al., 2010; 
Nugent et al., 2011; Weems and Varela, 2011).  Specific phobia is characterized by severe 
anxiety in response to, and subsequent avoidance of, a specific stimulus, and often develops 
after a particular traumatic event (First and Gibbon, 2004).  Specific phobia has also 
previously been associated with childhood trauma resulting in increased susceptibility for the 
disorder (Briggs-Gowan et al., 2010).  Arguably, it would have been useful to include 
individuals with a primary diagnosis of PTSD, GAD or specific phobia, in addition to the 
current population.  Unfortunately we did not have access to large enough numbers of 
samples with these diagnoses.  Repeating this work in such cohorts is warranted. 
 
4.3.5. Use of the dorsal striatum 
 
Another limitation is the use of the rat striatum only. There are several other brain regions 
associated with anxiety disorder pathology (e.g. the hippocampus and amygdala).  Using the 
methods presented here on these other brain structures may provide further insight into the 
pathogenicity of anxiety disorders. 
 
4.4. Future research directions 
 
The present study forms part of a larger collaborative research effort to investigate and 
identify the molecular etiology of anxiety disorders.  The aim here was to identify novel 
genes that may be involved in the pathogenesis of anxiety and also to ascertain gene-
environment interaction effects in disorder pathogenicity.   
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The use of rats exhibiting anxiety-like behaviours to identify novel susceptibility genes for 
anxiety disorders in humans was successfully demonstrated in this study, with the 
identification of several genes that have previously been reported to be involved in synaptic 
plasticity and other neuronal pathways, but not directly in an anxiety disorders disorder 
cohort. 
The identification of more than 100 polymorphisms within five genes of which 80% were 
novel, attests to the unique nature of the South African population from a genetic perspective 
(Wright et al., 2011).  With NGS becoming more affordable and easily accessible, the 
application of targeted deep sequencing for known anxiety-associated genes within a South 
African context (or other geographical delineations) could yield many new polymorphisms.  
Novel polymorphisms may be working in an epistatic fashion with already characterized 
polymorphisms (such as the rs6265 polymorphism in BDNF), with each other or with 
environmental influences (such as childhood trauma), and identifying these may allow for a 
more complete picture of the genetic architecture of anxiety disorders. 
A further consideration is the statistically significant association between childhood trauma 
and the presence of an anxiety disorder.  Gene-environment interactions were identified 
between certain polymorphisms and the severity of childhood trauma.  Childhood trauma is 
but one of the environmental variables that can play a role in the pathology of anxiety 
disorders and further gene-environment interplay (and combinations thereof) (e.g. 
pharmacotherapy and nutrition) should be investigated in future studies. 
 
4.5. Conclusion 
 
In this study a Sprague Dawley rat model subjected to environmental stressors was 
implemented to determine the effect of developmental stress on gene expression.  The 
objectives of this study were to determine if there are differentially expressed genes in rats 
with a trauma history vs. those without, to determine whether the identified differentially 
expressed genes are potential susceptibility genes for anxiety disorders in humans, using 
case-control association studies, and to determine whether genes that are differentially 
expressed in rats with a trauma history and with consequent anxiety-like behaviours point to 
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susceptibility genes for anxiety disorders in humans for which childhood trauma severity 
scores are known. 
Firstly, study findings confirmed that rats exposed to environmental stressors were observed 
to exhibit significantly increased anxiety-like behaviours compared to unexposed controls.  
When differences in gene expression were assessed comparing rat groups exhibiting anxiety-
like behaviours to controls, several genes (i.e. Bdnf, Mmp9, Arc, Ntf4, Grm2, Egr2, and Egr4) 
were found to be differentially expressed in the synaptic plasticity pathway of striatal tissue.  
This provides evidence for the usefulness of an environmental intervention rat model 
displaying subsequent anxiety-like behaviours in evaluating the molecular underpinnings 
regarding a gene-environment interaction in anxiety disorders.  Secondly, considering the 
human homologues for the susceptibility candidates identified, BDNF was the only gene to 
be well characterized within the anxiety disorder literature.  The remaining candidates, 
although prominent in synaptic plasticity, have not been specifically investigated within 
anxiety disorder pathology.  This study, therefore, successfully produced novel candidate 
genes to act as susceptibility targets in anxiety disorders.  Moreover, in addition to identifying 
novel susceptibility candidates using a pathway specific approach, differentially expressed 
genes were associated with anxiety-like behaviours, making a strong argument for 
susceptibility candidacy in anxiety disorder pathology.  For example, the under-regulation of 
the GRM2 gene (involved in excitatory neuronal responsiveness) in the combination stressor 
groups points to an attenuating or scaling response to further stressors. 
And thirdly, the work presented here provides further validation for childhood trauma as a 
risk factor for susceptibility to anxiety disorders.  Candidate genes, assessed in a case-control 
association fashion, yielded significant variant associations with anxiety disorders in either a 
protective or increased susceptibility risk fashion.  Four significant SNP interactions with 
childhood trauma were also identified suggesting a gene – environment interaction with the 
presence of early life trauma in the manifestation of anxiety disorders.  The rs10835210 
polymorphism presented with protective attributes associated with the AC genotype; 
however, this seemed to skew to an increased susceptibility in the presence of childhood 
trauma.  The same was true for Val66Met (rs6265) in BDNF, whose highly protective effect 
was eliminated when considering increased severity of childhood trauma.  This is the kind of 
gene – environment interaction observed that needs to be evaluated when considering the 
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etiology of the anxiety disorders, to allow for a better understanding, and ultimately better 
treatment of these conditions.  The rs2049045 polymorphism and it’s identification as a 
genetic risk factor by gene-environment correlation in substance abuse is interesting, 
considering substance abuse being a commonly associated comorbidity amongst anxiety 
disorders and its identification as a gene-environment interaction variable in this study.  
Substance abuse as an environmental contributor to the phenotypic manifestation of a 
disorder or disease as a result of gene – environment interaction has been documented 
previously (Douglas et al., 2010; Pani et al., 2010).  Validating its role as a gene – 
environment component in anxiety disorders in a cohort for which substance abuse 
information is available is warranted.  To summarize, there is a definite gene – environment 
interaction to be considered when there is an observable increased incidence in the severity of 
childhood trauma in cases, and in the presentation of anxiety disorders.  There are also 
grounds for the consideration of other environmental contributants (smoking, alcohol abuse 
etc.) in addition to the effect of childhood trauma in investigating and understanding the 
molecular etiology of anxiety disorders. 
This study represents one of the first to employ a tNGS approach to identify novel and 
previously characterized genetic variants associated with anxiety disorders.  In excess of 100 
polymorphisms (>100 SNPs and 4 Indels) were identified of which over 80% were novel, 
contributing valuable knowledge to current database capacities regarding anxiety disorder 
etiology.   
In conclusion, the work presented here yields important findings pertaining to the 
neurobiological underpinnings of anxiety disorders and has contributed novel susceptibility 
genes, SNP and haplotype associations for consideration in the molecular etiology of anxiety 
disorders.  These variants have been investigated in the context of gene-environment 
interaction and gene-environment correlation in the context of childhood trauma, and 
significant associations have been found.  The sample size remains to be one of the most 
important limitations warranting follow up in a larger sample for validation, as well as 
assessment in individual anxiety disorders to determine whether the significance identified 
here holds true.  The genetic heterogeneity of the anxiety disorders is challenging; however, 
the findings presented here contribute substantially to a better understanding of the etiology 
of anxiety disorders. 
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Appendix I 
Buffers and Solutions 
 
1. DNA extraction solutions 
 
Cell Lysis Buffer 
 Sucrose 0.32 M 
 Triton-X-100 1% 
 MgCl2 5 mM 
 Tris-HCl 10 mM 
 H2O 1 L 
3 M Sodium Acetate 
 Sodium Acetate 
 H2O 
 pH adjusted to 5.2 with glacial acetic acid (Merck) 
 ddH2O – brought to volume of 100 ml 
Na-EDTA solution 
 NaCl (Sigma) 18.75 ml of 4 M Stock 
 EDTA (Sigma) 250 ml of 100 mM stock solution 
Phenol/Chloroform 
 Phenol 50 ml 
 Chloroform 48 ml 
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 8-yhydroxyquinone 2 ml 
 Mix and store at 4°C 
Chloroform/ octanol (24:1) 
 Chloroform 96 ml 
 Octanol 4 ml 
 Store at 4°C 
TE-Buffer (10X stock) 
 Tris OH 108 g 
 EDTA (pH 8.0) 0.01 M 
 H2O 150 ml 
 
2. Electrophoresis Solutions 
 
 
TBE-Buffer (10X Stock) 
 Tris-HCl (Sigma) 108 g 
 Boric Acid (Sigma) 58 g 
 Na2EDTA (Sigma) 9.3 g 
 ddH2O to final volume of 1 L 
Ethidium Bromide 
 Ethidium Bromide 500 mg 
 ddH2O 50 ml 
Cresol loading dye 
 Cresol Red (Sigma) Solution 10 mg in 1 ml ddH2O 
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 Sucrose Solution 3.4 g sucrose in 9.8 ml ddH2O 
 Add 200 µl to 10 ml of sucrose solution 
2% Agarose Gel 
 Agarose (Sigma) 2 g 
 ddH2O bring to volume of 100 ml 
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Appendix II 
 
Experion output data for RNA quality and quantity assessment 
 
Sample 
Name 
RNA 
Area 
[RNA] 
(ng/µl) 
Ratio 
[28S:18S] 
RQI 
RQI 
Classification 
S1 328.28 96.05 1.47 9.2 Green 
S2 304.74 89.16 0.88 7.7 Green 
S3 370.52 133.66 1.78 9.7 Green 
S3 222.39 65.07 1.53 9.3 Green 
S4 250.13 73.18 1.18 8.9 Green 
S5 338.46 99.03 1.45 9.1 Green 
S6 321.65 94.11 1.57 9.4 Green 
S7 267.17 78.17 1.18 9.2 Green 
S8 254.61 74.5 1.02 8.9 Green 
S9 355.64 104.05 1.37 9.2 Green 
S10 272.13 79.62 1.6 9.5 Green 
S11 340.46 99.61 1.3 9.2 Green 
S12 411.69 148.51 1.71 9.5 Green 
S14 269.42 78.83 1.06 9 Green 
S15 377.24 136.09 1.46 9.4 Green 
S16 240.07 86.6 1.74 9.5 Green 
S17 19.08 6.88 1.35 N/A Red 
S18 181.15 98.14 1.06 8.9 Green 
S19 299.97 108.21 1.74 9.6 Green 
S20 277.02 99.93 1.61 9.5 Green 
S21 361.5 130.41 1.72 9.5 Green 
S22 221.96 80.07 1.35 9.2 Green 
S23 258.99 93.43 1.28 9.1 Green 
S24 244.64 88.25 1.32 9 Green 
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S25 235.11 84.81 1.35 9.1 Green 
S26 180.18 64.17 1.09 9 Green 
S27 64.55 22.99 1.59 9.2 Green 
S28 161.33 57.45 1.36 8.8 Green 
S30 84.83 45.95 1.27 8.8 Green 
S31 45.22 24.5 1.37 8.7 Green 
S32 18.95 10.26 1.25 7.2 Green 
S33 64.2 34.78 1.35 9 Green 
S34 75 40.63 1.65 8.9 Green 
S35 56.94 30.85 1.31 8.6 Green 
S36 89.17 48.31 1.71 9.1 Green 
S37 101.49 54.98 1.61 9 Green 
S38 55.19 19.65 1.85 9.2 Green 
S39 29.45 10.49 1.7 9.1 Green 
S40 35.63 12.69 1.83 9.6 Green 
S41 71.19 38.57 1.31 8.7 Green 
S42 46.03 24.94 1.24 8.8 Green 
S43 66.21 23.58 1.46 9.6 Green 
S44 37.74 13.44 1.23 9.2 Green 
S45 142.07 50.59 1.7 9.4 Green 
S46 118.32 42.14 1.43 9 Green 
S47 103.64 36.91 1.51 8.9 Green 
S48 112.19 39.95 1.61 9.2 Green 
S49 13.84 7.5 1.91 N/A Red 
*RQI = RNA quality indicator; RQI Classification: Red = failed, Green = passed; S refers to 
Striatal tissue 
**S50 and S51 were failed samples and are not represented here 
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Appendix III 
RT
2
 Profiler
TM
 Array gene list 
 
Type Unigene GeneBank Symbo
l 
Description Gene 
Name 
5, 6, 9 Rn.42924 XM_217197 Adam1
0 
ADAM metallopeptidase domain 10 MADM 
3 Rn.21414
5 
XM_223616 Adcy1 Adenylate cyclase 1 (brain) Ac1 
3 Rn.10382 NM_017142 Adcy8 Adenylate cyclase 8 (brain) Ac8 
7 Rn.11422 NM_033230 Akt1 V-akt murine thymoma viral oncogene homolog 
1 
Akt 
1, 9 Rn.10086 NM_019361 Arc Activity-regulated cytoskeleton-associated 
protein 
rg3.1 
1, 3 Rn.11266 NM_012513 Bdnf Brain derived neurotrophic factor MGC10525
4 
3 Rn.10749
9 
NM_012920 Camk2
a 
Calcium/calmodulin-dependent protein kinase 
II alpha 
PK2CDD, 
PKCCD 
3, 7 Rn.10961 NM_133605 Camk2
g 
Calcium/calmodulin-dependent protein kinase 
II gamma 
- 
3, 5 Rn.23200 NM_031333 Cdh2 Cadherin 2 N-cadherin 
1 Rn.6479 NM_024125 Cebpb CCAAT/enhancer binding protein (C/EBP), 
beta 
Il6dbp, 
LAP, NF-
IL6, TCF5 
1 Rn.20262
0 
NM_013154 Cebpd CCAAT/enhancer binding protein (C/EBP), 
delta 
C, EBPd, 
CELF 
3 Rn.89774 NM_012784 Cnr1 Cannabinoid receptor 1 (brain) SKR6R 
1 Rn.90061 NM_031017 Creb1 CAMP responsive element binding protein 1 Creb 
1 Rn.10251 NM_013086 Crem CAMP responsive element modulator Icer 
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9 Rn.9765 NM_019621 Dlg4 Discs, large homolog 4 (Drosophila) Dlgh4, 
PSD95, 
Sap90 
1 Rn.9096 NM_012551 Egr1 Early growth response 1 Krox-24, 
NGFI-A, 
Ngf1, Ngfi, 
zif-268 
1 Rn.89235 NM_053633 Egr2 Early growth response 2 Krox20 
1 Rn.44371 NM_017086 Egr3 Early growth response 3 - 
1 Rn.31998 NM_019137 Egr4 Early growth response 4 Egr4l1, 
NGFI-C 
8 Rn.27233 XM_233574 Ephb2 Eph receptor B2 RGD15642
32 
1 Rn.10375
0 
NM_022197 Fos FBJ osteosarcoma oncogene c-fos 
3 Rn.10368 NM_017295 Gabra5 Gamma-aminobutyric acid (GABA) A receptor, 
alpha 5 
- 
3, 4, 8 Rn.11391 NM_013145 Gnai1 Guanine nucleotide binding protein (G protein), 
alpha inhibiting 1 
BPGTPB 
3, 4, 8, 9 Rn.29971 NM_031608 Gria1 Glutamate receptor, ionotropic, AMPA 1 gluR-A 
3, 4, 8 Rn.91361 NM_017261 Gria2 Glutamate receptor, ionotropic, AMPA 2 GluR-K2, 
GluR2, 
gluR-B 
4, 8, 9 Rn.74049 NM_032990 Gria3 Glutamate receptor, ionotrophic, AMPA 3 GLUR3, 
GluR-3, 
GluR-C, 
GluR-K3 
4, 8, 9 Rn.10938 NM_017263 Gria4 Glutamate receptor, ionotropic, AMPA4 GluR-D, 
GluR4 
3, 7, 8, 9 Rn.9840 NM_017010 Grin1 Glutamate receptor, ionotropic, N-methyl D-
aspartate 1 
NMDAR1, 
NR1 
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3, 5, 7, 
8, 9 
Rn.9710 NM_012573 Grin2a Glutamate receptor, ionotropic, N-methyl D-
aspartate 2A 
NMDAR2A, 
NR2A 
3, 5, 7, 
8, 9 
Rn.9711 NM_012574 Grin2b Glutamate receptor, ionotropic, N-methyl D-
aspartate 2B 
- 
3, 7, 8, 9 Rn.9709 NM_012575 Grin2c Glutamate receptor, ionotropic, N-methyl D-
aspartate 2C 
NR2C 
3, 7, 8 Rn.91209 NM_022797 Grin2d Glutamate receptor, ionotropic, N-methyl D-
aspartate 2D 
- 
4 Rn.74240 NM_032069 Grip1 Glutamate receptor interacting protein 1 - 
4, 8, 9 Rn.87787 NM_017011 Grm1 Glutamate receptor, metabotropic 1 Gprc1a 
4, 8 Rn.9681 XM_343470 Grm2 Glutamate receptor, metabotropic 2 - 
8, 9 Rn.41715 XM_001062
001 
Grm3 Glutamate receptor, metabotropic 3 mGluR3 
8 Rn.89046 NM_022666 Grm4 Glutamate receptor, metabotropic 4 - 
8 Rn.29972 NM_017012 Grm5 Glutamate receptor, metabotropic 5 mGluR5, 
mGlur5 
8 Rn.10409 NM_031040 Grm7 Glutamate receptor, metabotropic 7 - 
8 Rn.44420 NM_022202 Grm8 Glutamate receptor, metabotropic 8 Glur8, 
Gprc1h, 
Mglur8, 
mGluR8b, 
mGlur 
1, 9 Rn.37500 NM_031707 Homer
1 
Homer homolog 1 (Drosophila) HOMER1F, 
Vesl-1 
4 Rn.6282 NM_178866 Igf1 Insulin-like growth factor 1 - 
2 Rn.9874 NM_017128 Inhba Inhibin beta-A - 
1 Rn.93714 NM_021835 Jun Jun oncogene - 
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1 Rn.15806 NM_021836 Junb Jun B proto-oncogene - 
1 Rn.2398 NM_031135 Klf10 Kruppel-like factor 10 Tieg 
3, 4, 7 Rn.34914 NM_053842 Mapk1 Mitogen activated protein kinase 1 Erk2 
1, 3, 6 Rn.10209 NM_031055 Mmp9 Matrix metallopeptidase 9 - 
5 Rn.11283 NM_031521 Ncam1 Neural cell adhesion molecule 1 Cd56, 
MGC12460
1, N-CAM, 
NCAM-C, 
Ncam 
1 Rn.2411 XM_342346 Nfkb1 Nuclear factor of kappa light polypeptide gene 
enhancer in B-cells 1 
NF-kB 
1 Rn.8395 NM_030867 Nfkbib Nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, beta 
MGC93398 
1 Rn.22168 XM_227525 Ngf Nerve growth factor (beta polypeptide) Ngfb 
4 Rn.10980 NM_012610 Ngfr Nerve growth factor receptor (TNFR 
superfamily, member 16) 
LNGFR, 
RNNGFRR, 
p75, 
p75NTR 
4 Rn.10573 NM_052799 Nos1 Nitric oxide synthase 1, neuronal bNOS 
1 Rn.16210
1 
NM_001034
199 
Nptx2 Neuronal pentraxin 2 Narp 
1 Rn.10000 NM_024388 Nr4a1 Nuclear receptor subfamily 4, group A, 
member 1 
HMR, Ngfi-
b, Nur77 
1 Rn.9715 NM_031073 Ntf3 Neurotrophin 3 - 
3 Rn.44225 NM_013184 Ntf4 Neurotrophin 4 NT4P, Ntf5 
3, 8 Rn.11246 NM_012731 Ntrk2 Neurotrophic tyrosine kinase, receptor, type 2 RATTRKB1
, TRKB1, 
Tkrb 
1, 5 Rn.23337 NM_022868 Pcdh8 Protocadherin 8 - 
4, 9 Rn.24750 NM_053460 Pick1 Protein interacting with PRKCA 1 Prkcabp 
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1 Rn.34888 NM_017034 Pim1 Pim-1 oncogene - 
1, 4, 6 Rn.10710
2 
NM_013151 Plat Plasminogen activator, tissue PATISS, 
tPA 
3 Rn.11243 NM_013187 Plcg1 Phospholipase C, gamma 1 PPLCA 
3, 4, 7 Rn.2024 NM_031527 Ppp1ca Protein phosphatase 1, catalytic subunit, alpha 
isoform 
- 
3, 4, 7 
 
Rn.1495 NM_022498 Ppp1cc Protein phosphatase 1, catalytic subunit, 
gamma isoform 
Ppp1cc1 
4 Rn.73852 NM_130403 Ppp1r1
4a 
Protein phosphatase 1, regulatory (inhibitor) 
subunit 14A 
Cpi17 
4, 5 Rn.1271 NM_017039 Ppp2ca Protein phosphatase 2 (formerly 2A), catalytic 
subunit, alpha isoform 
Pp2a1 
3, 4 Rn.6866 NM_017041 Ppp3ca Protein phosphatase 3 (formerly 2B), catalytic 
subunit, alpha isoform 
Calna1 
3, 4 Rn.20790
8 
XM_343975 Prkca Protein kinase C, alpha Pkca 
3 Rn.9747 NM_012628 Prkcg Protein kinase C, gamma MGC10548
7, PKC, 
PKCI, Prkc, 
Prkcc, 
RATPKCI 
4 Rn.20472
4 
XM_219805 Prkg1 Protein kinase, cGMP-dependent, type 1 Pkgi, cGk1 
3 Rn.44409 NM_013018 Rab3a RAB3A, member RAS oncogene family RAB3 
1 Rn.19480 NM_199267 Rela V-rel reticuloendotheliosis viral oncogene 
homolog A (avian) 
NFkB 
5, 6 Rn.98353 NM_080394 Reln Reelin Reelen, Rl, 
reeler 
10 Rn.12325
1 
XR_008709 RGD15
62511 
Similar to MmKIF17 - 
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1 Rn.1892 NM_053453 Rgs2 Regulator of G-protein signaling 2 - 
1 Rn.859 NM_013216 Rheb Ras homolog enriched in brain - 
10 Rn.21997
6 
XM_228146 Sirt1 Sirtuin (silent mating type information 
regulation 2 homolog) 1 (S. cerevisiae) 
Sir2 
1 Rn.1501 NM_001109
302 
Srf Serum response factor (c-fos serum response 
element-binding transcription factor) 
RGD15597
87 
2, 9 Rn.42910 NM_021695 Synpo Synaptopodin - 
6 Rn.25754 NM_053819 Timp1 TIMP metallopeptidase inhibitor 1 TIMP-1, 
Timp 
1, 5 Rn.2275 NM_012675 Tnf Tumor necrosis factor (TNF superfamily, 
member 2) 
MGC12463
0, RATTNF, 
TNF-alpha, 
Tnfa 
3 Rn.2502 NM_013053 Ywhaq Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, theta 
polypeptide 
14-3-3t 
11 Rn.973 NM_001007
604 
Rplp1 Ribosomal protein, large, P1 MGC72935 
11 Rn.47 NM_012583 Hprt1 Hypoxanthine phosphoribosyltransferase 1 Hgprtase, 
Hprt, 
MGC11255
4 
11 Rn.92211 NM_173340 Rpl13a Ribosomal protein L13A - 
11 Rn.10789
6 
NM_017025 Ldha Lactate dehydrogenase A Ldh1 
11 Rn.94978 NM_031144 Actb Actin, beta Actx 
*1: immediate-early response (IEGs), 2: late response, 3: long term potentiation (LTP), 4: long term depression 
(LTP), 5: cell adhesion, 6: extracellular matrix and proteolytic processing, 7: CREB factors, 8: neuronal 
receptors, 9: postsynaptic density, 10: other, 11: housekeeping genes 
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Appendix IV 
Patient Information and Informed Consent 
 
UCT/ US MRC UNIT ON ANXIETY AND STRESS DISORDERS 
 
PATIENT INFORMATION AND INFORMED CONSENT 
Genetics of Anxiety Disorders 
 
PURPOSE: 
 
This study is part of a research project we are conducting to learn more about the genetic 
causes and symptoms of anxiety disorders (including obsessive-compulsive and spectrum 
disorders such as trichotillomania (TTM), panic or social anxiety disorder).  We would like to 
discuss your life experiences and those of your other family members with you.  Doctors and 
scientists at the MRC Unit on Anxiety and Stress Disorders and the University of 
Stellenbosch, in collaboration with qualified researchers from other research institutions 
worldwide, hope to identify the genes that may increase susceptibility to these disorders. 
This is not a treatment study.  Information is being collected for research purposes only. 
 
STUDY PROCEDURE: 
 
If you decide to participate, we shall ask you to attend an interview (which may be 
videotaped) with a researcher.  This interview will include neuropsychological tasks and a 
number of questions related to your current illness, comorbid conditions like depression, 
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family functioning, quality of life, your prior history of treatment for psychiatric conditions, 
and particular symptoms you may have experienced as part of your illness.  In addition, we 
may ask to take photographs of your face and hands.  This whole procedure will last about 4-
5 hours (two 2-hour sessions with a break in-between).   
 
You will also be asked to have your blood drawn.  Approximately 48 ml (3 tablespoons) of 
blood will be drawn from your arm.  We may need to contact you again to get another blood 
sample should we fail to get a DNA sample from your blood.  The blood sample you give 
may be used to create a cell line.  This is done by changing some of your blood cells so that 
they can grow forever.  The cell line is living tissue and it can be used to make more of your 
DNA at any time in the future.  This process will take place at the MRC Centre for Molecular 
and Cellular Biology and the Division of Medical Biochemistry, Faculty of Health Sciences, 
at the University of Stellenbosch.  The DNA will then be taken from the cell line and saved 
for scientific analyses which will be performed now, and possibly in the future.   
 
We may contact you later for further information, or request you to complete another 
interview at a later date, in order to obtain follow-up information that may be of use in our 
genetic analyses.  This may involve an assessment similar to the current assessment, 
including a series of interviews and/or another blood sample.  Your current participation is in 
no way binding to your future participation. 
 
We would like your permission to contact your relatives in order to get more information 
about any family history of mental illness, if need be.   
 
If you have been diagnosed with TTM, we hope to also interview one of your close (first-
degree) relatives.  You can still participate in the study even if your relatives do not.  If you 
are a relative (e.g. a parent) of a person diagnosed with TTM who have participated in this 
project, we will ask you to complete a number of self-report scales.  These scales will ask 
questions about your current psychiatric symptoms if any, depression, anxiety, family 
functioning and quality of life.  These scales will also ask you whether your child has tics, 
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OCD and other problems.  They will also ask about your child’s psychiatric condition and 
how you respond to it.  It can take up to 4 hours to complete these self-report scales – either 
at home or at our Unit. 
 
Personal information that could be used to identify you (such as your name, contact 
information, etc.) will not be given out.  Your data and DNA is likely to be made available to 
qualified scientists around the world to study your particular disorder.  Your cell line and 
DNA will be maintained permanently, unless you request to have it removed.  If at any time 
in the future you wish to have your DNA, cell lines or clinical data removed from the storage 
site, you may do so by contacting the researchers conducting this study (Christine Lochner at 
021 - 938 9179). 
 
The researchers who will have access to your DNA include those who work with private 
and/or for profit companies.  These researchers may be interested in eventually developing 
commercial medical products using the DNA from you and other participants.  They may sell 
or patent discoveries based on this research and thus benefit financially.  Please note that you 
or your heirs will not receive any compensation if this occurs.    
 
We do not expect to discover any information of direct benefit to your condition, or your 
treatment, during the next few years.  If later on, diagnostic tests or new ways to treat your 
condition are discovered, this information will have to be obtained from properly licensed 
clinical labs, clinics, or your physician, and will not be available from the research team. 
 
If you are hospitalized at a psychiatry facility or have received any treatment from a mental 
health professional, we would like your permission to review your treatment records, which 
will be obtained from your doctor. 
 
RISKS:     
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There are no more than minimal medical or psychological risks associated with this study.  If 
you feel fatigued, tired, uncomfortable, or in any way upset during any part of the session(s), 
you may ask to stop for a rest break or have the interview discontinued.  The research 
interview does not take the place of a full psychiatric evaluation.  You may experience some 
emotional discomfort when answering some questions.  If any particular question makes you 
feel uncomfortable, you may discuss its importance with the specially trained interviewer.  
You may choose not to answer any question which you are still uncomfortable with. 
 
You may feel some pain associated with having blood withdrawn from a vein.  You may 
experience discomfort, bruising and/or other bleeding at the site where the needle is inserted.  
Occasionally, some people experience fleeting dizziness or feel faint when their blood is 
drawn. 
 
Some insurance companies may mistakenly assume that your participation in this study is an 
indication that you are at higher risk of a genetic disease, and this could hurt your access to 
health or other insurance.  We will not share any information about you, or your family, with 
an insurance company.  However, if you discuss your participation in this study with your 
doctor, and he or she records it in your medical record, it is possible that an insurance 
company may access the information as part of a medical record review.  It is the opinion of 
the investigators that participation in this study does not constitute genetic testing.  Although 
one long-term goal of this research is the development of a genetic test for the anxiety 
disorders, at the current time, no information from your DNA sample that would be useful in 
the treatment of your disorder will be obtained.  Therefore, participation in this study should 
not be reported as genetic testing.   
 
Your unidentified DNA and cell line will be available to qualified researchers permanently.  
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BENEFITS:   
 
There are no direct benefits to you.  However, individuals who might develop one or more of 
these anxiety disorders in the future, their family members, and future generations may 
benefit if we can locate the genes that lead to such disorders.  That knowledge could then lead 
to the development of methods for prevention and new treatments for curing these diseases.   
 
CONFIDENTIALITY:    
 
If you consent to participate in this study, your identity will be kept confidential.  Your 
answers will not be shared with other family members or anyone else except for staff 
members involved in this study.  All data will be kept in locked file cabinets accessible only 
to the research staff.  All research information obtained will not be associated with your 
name; research staff will use only a coded number and/or your initials.  Blood samples will 
be safely stored and identified by code number and access will be limited to authorized 
scientific investigators.  Copies of treatment records from hospitals or mental health 
professionals are kept in locked files and are reviewed by members of the research team only.  
Any publications resulting from this study will not identify you by name.   
 
VOLUNTARY PARTICIPATION: 
 
Your participation in this study is voluntary and you may refuse to participate or withdraw 
from the study at any time without any loss of benefits to which you are otherwise entitled.  
Some members of the team of investigators conducting this study may be responsible for 
your clinical care.  Refusal to participate in this study will not change your clinical care. 
 
RESEARCH QUESTIONS AND CONTACTS: 
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If you are interested in genetic counseling, you will be given information about where you 
can receive such counseling and a new blood sample may be required at that time.  DNA 
information about a relative will be released only if the genetic counsellor confirms that the 
relative in question is deceased or cannot be found and that the information is essential for 
clinical counseling. 
 
The researchers will answer any questions you might have about the procedures described 
above, or about the results of the study.  If you have any questions, you may call Dr Christine 
Lochner at (021) 938 9179.   
 
The University of Stellenbosch Committee for Human Research has approved recruitment 
and participation of individuals for this study. 
 
You have been given a copy of this consent form to keep.   
 
INFORMED CONSENT/ASSENT TO TAKE PART AND AUTHORIZATION TO 
USE OR SHARE HEALTH INFORMATION FOR RESEARCH: 
 
I have read the above patient information, the research study has been explained to me, 
including risks and benefits (if any), all my questions have been answered, and I consent 
voluntarily to participate in this study. 
 
Print name:  __________________________ Signature:  ____________________________ 
(Adults or Minors younger than 18 years) 
Date: ________________________________ 
Stellenbosch University  http://scholar.sun.ac.za
Appendices 
148 
 
 
OR 
 
I understand the information that was given to me, and would like to give permission for my 
child/the person I am authorized to represent, to take part in this research study, and also 
agree to allow his/her health information to be used and shared as described above.  
 
Print name:  ___________________________Signature:  ____________________________ 
(Parent / Guardian of Minor) 
 
Date: ________________________________ 
 
OR 
 
Print name:  __________________________Signature:  ____________________________ 
(Family member / next of kin) 
 
Date: ________________________________ 
Relationship to patient: __________________________________ 
 
I have discussed the proposed research with this subject and, in my opinion, this patient 
understands the benefits, risks, and alternatives (including non-participation) and is capable 
of consenting to voluntary participation. 
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Print name:  __________________________Signature:  ____________________________ 
(Study Investigator or Designee) 
 
Date: ________________________________ 
 
 
Print name:  __________________________Signature:  ____________________________ 
(Witness (if applicable)) 
 
Date: ________________________________ 
Lochner et al, Approved Version 5, July 2007 
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